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ABSTRACT 
 
Estrogens greatly affect the activity and connectivity of serotonergic neural cell 
populations, which extend from clusters of nuclei in the brainstem, termed the raphe 
nuclei, where estrogen receptor β is the most abundantly expressed estrogen receptor 
subtype. Estrogenic effects on the raphe nuclei are primarily important for influencing 
various neuropsychological behaviors, including depression, mood swings and anxiety 
behaviors. Because of this connection, phases of intense hormone fluctuations for 
instance during menopause are often associated with several mood disturbances that 
often reduce the quality of life of menopausal women. Accordingly, long-term use of 
hormone replacement therapy appeared to be the method of choice for many 
menopausal women to help alleviate vasomotor symptoms, which may include 
neuropsychological changes such as depression. However, given the limitations and 
number of serious health risks attributed to hormone replacement therapy, natural 
compounds such as phytoestrogens are receiving widespread awareness due to their 
occurrence in medicinal plant extracts and a wide variety of food items including dietary 
supplements with respective health claims. Flavonoids, particularly the isoflavones and 
the naringenin-type flavanones, belong to a group of polyphenolic plant-derived 
secondary metabolites known to possess estrogen-like bioactivities. Nevertheless, little is 
known about their transactivational activity and their potential to regulate endogenous 
gene expression of estrogen responsive genes in the raphe nuclei due to the lack of 
suitable cellular models expressing sufficient amounts of functional estrogen receptor β. 
 
Hence, a raphe nuclei-derived cell line that expresses a functional estrogen receptor β 
was sought as a model to investigate effects of flavonoids in vitro. In this regard, 
RN46A-B14 cells derived from embryonic day 13 rat medullary raphe nuclei were 
primarily used in this study as the main cellular model. Nonetheless, expression of 
endogenous estrogen receptor β in these cells was not sufficient to pursue downstream 
investigations of estrogen-dependent activities. To overcome this deficit, a rat raphe 
nuclei-derived in vitro model that overexpresses a functional estrogen receptor β was 
initially established (herein termed RNDA cells) by stably transducing its parent cell line, 
RN46A-B14 cells, with a suitable lentiviral expression vector encoding a human estrogen 
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receptor β gene. The stable expression and the functional characterization of the 
transgenic receptor was confirmed by Western blot analysis and luciferase reporter gene 
assays, respectively. The same reporter gene assay was used to scrutinize the 
transactivational activity of the flavonoids in RNDA cells. Key results revealed that 
Genistein, Daidzein, Equol, Naringenin and 8-Prenylnaringenin demonstrated high 
transactivational activity in a concentration-dependent manner by stimulating luciferase 
expression from an estrogen responsive element-regulated reporter gene construct 
transiently transfected in RNDA cells. Low transactivational activity was observed in RNDA 
cells in response to increasing concentrations of 7-(O-prenyl)naringenin-4'-acetate. 
However, no transactivational activity was noticed in response to 
6-(1,1-Dimethylallyl)naringenin in the studied cell model. All effects elicited by the 
flavonoids were antagonized by the pure estrogen receptor antagonist, Fulvestrant, 
indicating that all substances act by binding to and activating the transgenic ERβ. 
Additional effects were observed in RNDA cells in response to a co-treatment of 1 µM of 
either Genistein or Daidzein, but not Equol, with 10 nM 17β-Estradiol. Slight antagonistic 
effects were observed in the same studied cell line when either 8-Prenylnaringenin or 
7-(O-prenyl)naringenin-4'-acetate, but not Naringenin or 6-(1,1-Dimethylallyl)naringenin, 
were co-added with 17β-Estradiol. 
 
Results from the reporter gene assays were validated on the basis of regulation of mRNA 
expression of estrogen responsive genes following the global assessment of 
17β-Estradiol-induced gene expression in this cell line using a DNA microarray technique. 
Out of 212 estrogen-regulated genes with at least two-fold change of expression, six were 
selected according to specific features of estrogenic regulation of expression. The 
expression of the six selected 17β-Estradiol-regulated genes was validated using 
quantitative real-time PCR analysis. The regulation of mRNA expression of the selected 
genes in response to the tested flavonoids was then investigated in RNDA cells. 
Additionally, because RNDA cells encode a temperature-sensitive mutant of the Simian 
Virus 40 large T-antigen, their neuronal differentiation is constitutive upon shifting them 
from conditions promoting proliferation (permissive temperature) to differentiation 
(non-permissive temperature). Hence, the regulation of mRNA expression of the selected 
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genes in response to the tested flavonoids was additionally investigated as RNDA cells 
differentiate. 
 
In RNDA cells grown under proliferative conditions, 17β-Estradiol up-regulated mRNA 
expression of camello-like 5, sex determining region Y-box 18 and keratin type I 
cytoskeletal 19. Similar effects were observed in response to 8-Prenylnaringenin, 
Genistein, Daidzein and Equol. In addition, 17β-Estradiol down-regulated mRNA 
expression of neurofilament medium polypeptide and zinc finger DHHC-type containing 2. 
Similar effects were observed in response to 8-Prenylnaringenin, Naringenin, Genistein, 
Daidzein and Equol. Yet, no effect was observed on the regulation of mRNA expression of 
solute carrier family 6 member 4 in response to 17β-Estradiol or the flavonoids in RNDA 
cells grown under proliferative conditions. When RNDA cells were shifted to conditions 
promoting differentiation, changes in cell morphology, in mRNA expression levels and in 
responsiveness towards 17β-Estradiol or the flavonoids were observed. These expression 
studies additionally highlighted some of the genes as indicator genes for RNDA cellular 
differentiation. 
 
The newly established RNDA cell line should prove useful to elucidate basic physiological 
properties of estrogen receptor β in the raphe nuclei. The present study should serve as 
the basis to help shed light on molecular and cellular mechanisms following the action of 
phytoestrogens, endocrine disruptors or other exogenous estrogen receptor ligands in 
neural cell populations, particularly the raphe nuclei, for further applications within the 
brain.
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1. INTRODUCTION 
 
The transition to menopause is a complex physiological process, often accompanied by 
the additional effects of social adjustment and ageing. Menopause is defined as the 
permanent termination of menstruation due to cessation of ovarian function (i.e. reduced 
secretion of ovarian hormones). Clinically speaking, natural menopause (not associated 
with a pathological cause) is diagnosed after 12 months of amenorrhea. Usually, women 
in their mid to late 40s begin their menopausal transition and this can last for 4 - 5 years. 
The final menstrual period generally happens when women are between 40 and 58 years 
old (Nelson, 2008). It has been estimated in the year 2010 that approximately 171 million 
women from the Western world were living their menopausal transition (Rampp et al., 
2008). 
 
Obvious vasomotor symptoms have been associated with fluctuating hormone levels, 
including hot flushes as well as changes in neuropsychological functioning. Mood 
disorders, including depression, are some of the neuropsychological changes occurring 
during menopause, which are highly prevalent in the general population. They are 
associated with significant morbidity and functional impairment (Wells et al., 1989; 
Wittchen and Hoyer, 2001). Epidemiological studies have consistently demonstrated 
higher rates of depressive illness in women than in men. In fact, rates of depression in 
women are approximately 21.3 % as opposed to 12.7 % for men (Kessler et al., 1994). The 
gender difference in depression is not noticeable until puberty (Angold et al., 1999), 
suggesting that ovarian hormones may contribute to depression. 
 
Given the higher prevalence of depression in women, interest in studying and treating 
mood disorders across the women’s reproductive life cycle, particularly during the 
menopausal transition, is on the rise (Douma et al., 2005; Meltzer-Brody, 2010). It has 
been pointed out that estrogens have favorable effects on mood and cognition, mediated 
through serotonergic neural cell populations that extend from clusters of nuclei in the 
brainstem known as raphe nuclei, where estrogen receptor β is the most abundantly 
expressed estrogen receptor subtype (McEwen and Alves, 1999). Accordingly, 
menopausal women have been treated with hormone replacement therapy (HRT) for 
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more than 60 years, which was shown to alleviate depression and anxiety behavior 
(Klaiber et al., 1979; Schmidt et al., 2000; Rasgon et al., 2002). In addition, HRT has been 
shown to reduce incidence of colon cancer (Chen, 2009) and promote increased bone 
mineral density in osteoporotic postmenopausal women (Tuppurainen et al., 2010); 
resulting in a significant improvement in women’s quality of life.  
 
Despite the benefits of HRT, an increased incidence of breast and endometrial cancer was 
found to be highly associated with long-term use of HRT, where the cancers seem to be 
larger and more advanced amongst hormone-therapy users (Dupont and Page, 1991; 
Steinberg et al., 1991; Beral et al., 1999; Chlebowski et al., 2003; Chlebowski et al., 2009). 
Grodstein et al. (1997) reported lower rates of mortality amongst HRT users as compared 
to women who had never taken hormones. Nevertheless, the overall benefit of long-term 
use of HRT had to be questioned because of increased risk of mortality from development 
of breast cancer (Grodstein et al., 1997). 
 
As a result, a recurrence of consumer interest in phytoestrogens, i.e. plant-derived 
secondary metabolites possessing estrogen-like bioactivity, has been noticed due to their 
occurrence in medicinal plant extracts and a wide variety of food items including dietary 
supplements with respective health claims (Henderson et al., 1994; Sullivan et al., 1997; 
Torgerson and Bell-Syer, 2001). Flavonoids are considered one of the major classes of 
such plant-derived secondary metabolites with low toxicity and weak cytostatic 
properties. Hence, they are classified as suitable candidates for in vitro and in vivo studies 
(Gester et al., 2001; Tokalov et al., 2004) to help identify new alternative therapeutic 
options to possibly alleviate menopause-related mood disorders, without leading to 
additional health risks. Even though these substances are sold as medicinal plant 
remedies or as dietary supplements and have reached quite remarkable market shares, 
conclusive data on their effects in the raphe nuclei remain to be elusive due to the lack of 
suitable raphe nuclei-derived cellular models expressing sufficient amounts of functional 
estrogen receptor β. As a result, it is crucial to create and establish such raphe 
nuclei-derived cellular models to shed light on the estrogenic potencies as well as the 
molecular and cellular events in response to flavonoids and other phytoestrogens for 
further applications within the brain, particularly in the raphe nuclei. 
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2. THEORETICAL BACKGROUND 
 
2.1. The Endocrine System 
The endocrine system is a complex body signaling system consisting of ductless glands 
that produce and secrete chemical messengers called hormones. The term “endocrine” 
refers to the direct secretion of such hormones into the bloodstream in response to 
specific stimuli (Hiller-Sturmhofel and Bartke, 1998). Once in the blood, hormones are 
transported towards specific target cell(s) and ultimately trigger a cascade of biochemical 
reactions via their interaction with associated target cell membrane or intracellular 
receptor proteins. As a result, the development and the regulation of many body 
functions are homeostatically maintained (Kalra and Kalra, 2010). The regulation and the 
process of hormone release mainly relies on constant feedback mechanisms maintained 
via the hypothalamus-pituitary-gonadal axis (Vadakkadath Meethal and Atwood, 2005; 
Meethal et al., 2009). 
 
There exist three main chemical classes of hormones. The first class of hormones are the 
ones consisting of short polypeptide sequences and are primarily secreted from either the 
hypothalamus, pituitary gland or the pancreas (Hiller-Sturmhofel and Bartke, 1998). 
Those include oxytocin (Lee et al., 2009) and insulin (Permutt et al., 1981). More complex 
protein hormones possess oligosaccharide side-chains covalently attached to them. Those 
are often referred to as glycoprotein hormones, which include follicle-stimulating 
hormone and luteinizing hormone (Pierce and Parsons, 1981). The second class of 
hormones are the monoamine hormones which are derivatives of aromatic amino acids: 
phenylalanine, tryptophan or tyrosine; of which serotonin, epinephrine (adrenaline), 
norepinephrine and dopamine are characterized (Bortolato et al., 2008; Enna, 2010). 
 
The third class of hormones are steroid hormones, a group of chemical messengers 
derived from cholesterol (Lucki and Sewer, 2010). These hormones are either produced 
from the adrenal cortex such as glucocorticoids and mineralocorticoids, or the gonads 
such as androgens, progestogens and endogenous estrogens (Simons, 2008). Steroid 
hormones share a common structural arrangement. The steroid core is composed of 17 
carbon atoms bonded together to take the form of four fused rings: three cyclohexane 
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rings (designated as rings A, B, and C) and one cyclopentane ring (designated as ring D) 
(Figure  2-1). They differ by the functional groups attached to these four rings as well as 
the oxidation state of the rings (Moss, 1989). From all five aforementioned steroid 
hormones, endogenous estrogens will be the main focus of the present study. 
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Figure  2-1: The basic skeleton of all steroids including steroid hormones. Carbon atom numbering is 
denoted in red and the IUPAC lettering of the rings is denoted in blue. 
 
2.2. Biosynthesis of Endogenous Estrogens 
Estrogen hormones were first discovered in the 1920s (George and Wilson, 1988). They 
are primarily responsible for the emergence of female secondary sex characteristics, such 
as breast development, typical body proportions, estrogen-dependent changes of the 
female genital tract as well as the distribution of subcutaneous adipose tissue. Typical 
target organs for the estrogens include the external genitalia, vagina, uterus, fallopian 
tubes and the ovaries. However, they could also act on non-reproductive target tissues, 
such as bones, the cardiovascular system, the liver and the central nervous system 
(Dötsch et al., 2001). 
 
The de novo synthesis of endogenous estrogens predominantly takes place in the ovaries, 
one of the main endocrine organs involved in the de novo production of steroid 
hormones. Synthesis takes place by the help of steroidogenic enzymes, such as several 
specific cytochrome P450 enzymes (CYPs) and hydroxysteroid dehydrogenases (HSDs) 
(Miller, 1988). The multienzyme process is stimulated when luteinizing hormone, 
produced from the anterior portion of the pituitary gland, binds to its cognate receptors 
expressed in the highly vascularized theca cells of the ovaries.  
 
The precursor of steroid hormones is cholesterol (a 27 carbon molecule), which is 
transported into the mitochondria of theca cells, where steroidogenesis starts by 
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conversion of cholesterol to pregnenolone (a 21 carbon molecule) by means of the 
CYP11A (a cholesterol side-chain cleaving enzyme bound to the inner membrane of the 
mitochondrion) (Parker and Schimmer, 1995). This transfer of cholesterol across the 
mitochondrial membranes is considered the rate-limiting step of steroidogenesis and is 
mediated by the steroidogenic acute regulatory protein (StAR) (Sugawara et al., 1996). 
The conversion of cholesterol to pregnenolone involves hydroxylation at the side-chain of 
cholesterol at carbon-20 and carbon-22 and ultimately cleavage of the side-chain takes 
place. Pregnenolone then gets converted to progesterone in two steps. The first step 
involves oxidation of the 3-hydroxyl group to a keto group. The second step involves the 
transfer of the double bond from carbon-5 to carbon-4. Both reactions are catalyzed by 
3β-hydroxysteroid dehydrogenase (3β-HSD) and delta 4, 5-isomerase, respectively 
(Sanderson, 2006) (Figure  2-2). Progesterone is further converted to 
17-hydroxyprogesterone by 17α-hydroxylase, where a hydroxyl group is added to 
carbon-17. The 17, 20 lyase enzyme then removes the side-chain from the steroid nucleus 
to form the weak androgen, namely androstenedione. Catalyzed by 17β-hydroxysteroid 
dehydrogenase (17β-HSD), testosterone (a 19 carbon molecule) is formed and both 
androgen molecules diffuse to the neighboring poorly vascularized granulosa cells where 
aromatization takes place (Chung et al., 1987; Sanderson, 2006) (Figure  2-2). 
 
Aromatization is the last step in the formation of endogenous estrogen (i.e. formation of 
the 18 carbon molecules) (Figure  2-3). This reaction is catalyzed by the P450 aromatase 
monooxygenase enzyme complex, which functions as a demethylase, hence removing the 
methyl group from carbon-10. In addition, the keto group on carbon-3 gets converted to 
a hydroxyl group (Ryan, 1982). The first and least abundant endogenous estrogen, 
Estrone (E1), is generally produced in ovaries as well as adipocytes from its androgen 
precursor androstenedione. The second and main physiological endogenous estrogen, 
17β-Estradiol (E2), is produced in the ovaries from testosterone. E2 and E1 usually exist in 
metabolic equilibrium due to the action of 17β-HSD. Almost 98 % of circulating E2 is 
either bound to albumin or to sex hormone binding globulin (SHBG), a specific carrier 
protein that binds estrogens with high affinity. The third endogenous estrogen, Estriol 
(E3), is primarily produced during pregnancy from E1 and E2 (Dötsch et al., 2001; Gruber 
et al., 2002) (Figure  2-3). 
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Figure  2-2: Biosynthesis of endogenous estrogens. Progesterone and the androgen molecules are primarily 
produced in theca cells (unshaded area) from the starting molecule cholesterol. The androgens then diffuse 
to granulosa cells (shaded area), where aromatization results in the synthesis of the three endogenous 
estrogens. Carbon atom numbering is shown in red, enzymes are shown in green and any change in 
biochemical structure is highlighted in light blue. Abbreviations: CYP11A, cytochrome P450 11A; 3β- and 
17β-HSD, 3β- and 17β-hydroxysteroid dehydrogenase; Δ 4, 5 isomerase, delta-4, 5 isomerase.   
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Figure  2-3: Aromatization of androgens in the granulosa cells of the ovaries. Out of all three endogenous 
estrogens, the main physiological estrogen is E2 (the zoomed-in molecule). Carbon atom numbering is 
denoted in red, enzymes are denoted in green, the IUPAC ring lettering is denoted in dark blue and any 
change in biochemical structure is highlighted in light blue. Abbreviations: 17β-HSD, 17β-hydroxysteroid 
dehydrogenase. 
 
Besides the ovaries, Wehrenberg and colleagues (2001) revealed the existence of StAR 
mRNA and protein in rat and marmoset hippocampi using in situ hybridization and 
immunohistochemistry techniques (Wehrenberg et al., 2001). The same group also 
indicated the co-expression of StAR and the aromatase enzyme in their studied 
hippocampi (Wehrenberg et al., 2001). Although it was already known that hippocampal 
neurons express aromatase [Reviewed in (Beyer, 1999)], Wehrenberg and colleagues 
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(2001) strongly proposed, based on their results, that de novo synthesis of E2 may 
certainly occur in hippocampal neurons (Wehrenberg et al., 2001), given that 
StAR-positive cells always contain side-chain cleavage enzyme as well as 3β-HSD 
(Furukawa et al., 1998). 
 
2.3. Estrogen Receptors: The Alpha and Beta 
Endogenous estrogens are retained in target cells by an intranuclear binding protein, 
termed the estrogen receptor (ER). ERs are a subfamily of the nuclear receptor 
superfamily of ligand-activated transcription factors that are highly conserved 
evolutionary from invertebrates to higher organisms. Nuclear receptors also include 
thyroid receptor, progesterone receptor, Vitamin D receptor, mineralocorticoid receptors 
and several “orphan” receptors; whose ligands are not yet identified (Robinson-Rechavi et 
al., 2003; Margolis and Christakos, 2010). 
 
2.3.1. Research History of Estrogen Receptors 
Based on the specific binding of tritium-labelled 17β-Estradiol in the uterus and vagina, 
Jensen and Jacobson (1962) came to the conclusion more than 40 years ago that the 
biological effects of estrogens had to be mediated by a specific receptor (Jensen and 
Jacobson, 1962). These studies were further extended by Noteboom and Gorski (1965), 
who reported that the receptor is stereo-specific and could be classified as a protein 
(Noteboom and Gorski, 1965). Following extensive studies on this protein, Green and 
co-workers (1986) published their landmark paper in 1986 regarding the cloned and 
sequenced complete complementary DNA (cDNA) of the ER from human breast cancer 
cell line MCF-7. The gene is  encoded by 8 exons corresponding to a 595 amino acid 
residue polypeptide with a molecular weight of approximately 66 kilodaltons (kDa) that 
binds E2 with high affinity [dissociation constant (Kd) = 0.4 nM] (Green et al., 1986; Kuiper 
et al., 1998). Following this discovery, homologous receptors, showing significant 
sequence homology, were rapidly isolated from the rat (Koike et al., 1987), mouse (White 
et al., 1987) and chicken (Maxwell et al., 1987).  
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Up until 1995, it was assumed that there was only one ER responsible for mediating the 
physiological and pharmacological effects of estrogens. However, the proposed existence 
of only a single ER gene failed to explain the complicated tissue selectivity of estrogens 
and antiestrogens in vivo as well as the differential effect of these substances in various 
cell lines (Katzenellenbogen et al., 1996). This led to the cloning and identification of a 
second novel ER, named ER-beta (ERβ), at the end of 1995. This ERβ was cloned from a 
rat prostate cDNA library corresponding to a 485 amino acid residue polypeptide with a 
molecular weight of approximately 54 kDa which also binds E2 with high affinity 
(Kd = 0.6 nM) (Kuiper et al., 1996; Kuiper et al., 1998). The former cloned ER was then 
renamed ER-alpha (ERα) to distinguish it from the newly discovered estrogen receptor. 
 
Following this breakthrough, the cDNAs encoding ERβ in humans (Mosselman et al., 1996; 
Enmark et al., 1997) and mice (Tremblay et al., 1997) were all cloned and showed 
significant sequence homology with their respective ERα. Furthermore, human ERβ shows 
the most sequence identity in its translated region, approximately 89%, to the rat ERβ as 
compared to any other mammalian ERβ (Enmark and Gustafsson, 1999). 
 
Both ERs are encoded by two independent genes. In humans, for example, ERα and ERβ 
are encoded by ESR1 and ESR2, respectively. The human ERα and ERβ genes have been 
mapped to band q25.1 of chromosome 6 and q23.2 of chromosome 14, respectively 
(Enmark et al., 1997) . 
 
2.3.2. Structural and Functional Domains of Estrogen Receptors 
ERs, like all other members of the nuclear receptor family, are composed of six 
independent yet interacting structural and functional domains denoted A to F, as shown 
in Figure  2-4 (Beato, 1989; Mangelsdorf et al., 1995). Biochemical and mutational 
analyses of the receptors have revealed two main domains (C and E) that are highly 
conserved between different species (Green and Chambon, 1986). Those two domains 
are mainly essential for the receptor to efficiently activate the transcription of target 
genes (Kumar et al., 1987).  
 
The central cysteine-rich C domain is a highly conserved domain of the ER alpha and beta 
subtypes and is responsible for their DNA-binding activity. It contains two type II zinc 
THEORETICAL BACKGROUND 
_____________________________________________________________________ 
10 
finger clusters, which play an important role in receptor dimerization and in binding to 
specific DNA sequences termed estrogen responsive elements (ERE), located in the 
promoter and/or enhancer regions of target genes (Klinge, 2001).  
 
EREs consist of short palindromic sequences that comprise inverted repeats of 
5’-GGTCA-3’ separated by three variable nucleotides, resulting in 5’-GGTCAnnnTGACC-3’ 
(Walker et al., 1984). The DNA binding domains of ERα and ERβ are highly homologous in 
their amino acid sequence (Figure  2-4) (Kumar et al., 1987; Forman and Samuels, 1990). 
Particularly, there exists a sequence, the P-box, which is identical in the two receptors 
and critical for target-DNA recognition and specificity (Vanacker et al., 1999). As a result, 
ERα and ERβ are expected to bind to a variety of EREs with similar affinity and specificity.  
 
The second moderately conserved domain of the ER alpha and beta subtypes is the E 
domain and corresponds to the ligand-binding domain. This domain mediates ligand 
binding in addition to receptor dimerization, nuclear translocation and efficient 
transactivation of target gene expression (Evans, 1988; Giguere et al., 1988). 
Crystallographic studies have established that the structure of E domain displays an 
α-helical sandwich topology typical for all nuclear receptor ligand-binding domains. It is 
composed of 12 helices (H1 - H12) arranged in three anti-parallel layers separated by 
β-sheets (Moras and Gronemeyer, 1998). As shown in Figure  2-4, the domain harbors a 
complex region, namely ligand-dependent activation function 2 (AF-2), whose structure 
and function are regulated by the binding of ligands (Danielian et al., 1992; Darimont et 
al., 1998). Even though the overall conformation of the ER ligand-binding domain is quite 
similar in the presence of different ligands, the carboxyl-terminal transactivation function 
(AF-2, H12) is highly sensitive to the nature of the bound compound. For example, when 
an agonist, such as 17β-Estradiol, is bound to the ligand-binding domain, H12 is moved 
over the ligand-binding pocket presenting a binding surface for recruitment of 
co-activators (Brzozowski et al., 1997). In contrast, when an antagonist is bound, H12 is 
positioned away from the ligand-binding cavity and instead occupies the hydrophobic 
groove formed by H3, H4 and H5. In such a position, H12 sterically inhibits the 
co-activator interaction surfaces (Shiau et al., 1998). 
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The remaining domains include the N-terminal A/B domain, which encodes a 
ligand-independent activation function 1 (AF-1) (Figure  2-4) (Berry et al., 1990), a region 
regulated by growth factors acting through the mitogen-activated protein kinase 
pathway, where phosphorylation of the serine residue at position 118 is required for its 
full activity (Kato et al., 1995). In addition, the AF-1 region is involved in the activation of 
target gene expression in a promoter- and cell- specific manner (Kobayashi et al., 2000). 
As for the flexible hinge D domain, which joins the DNA- and ligand- binding domains, its 
function is incompletely understood, even though it has been suggested that it is 
probably required in maintaining the integrity of the functional structure of the nuclear 
receptors (Miyamoto et al., 2001). Finally, the F domain is of uncertain function; 
nonetheless this region may affect ER dimerization (Yang et al., 2008). 
 
It is important to note that the greatest sequence diversity between ERα and ERβ is 
present in the A/B domain at the N-terminus (18 %), the hinge D domain (30 %) and in the 
F domain at the C-terminus (18 %) (Figure  2-4). As a result, preparations of specific ERβ 
cDNA probes, primers and antibodies are mostly targeted to those regions 
(Brandenberger et al., 1997; Saunders et al., 1997). 
 
ERα:
ERβ:
H2N- -COOH
H2N- -COOH
A/B
A/B C
C
D
D
E
E F
F
Homology:
(amino acid identity)
AF-1 AF-2
AF-1 AF-2
59 %97 % 18 %18 % 30 %
5301
1 595
148 214 304 500
185 251 355 549
 
Figure  2-4: Schematic diagram representing the domain structure of the estrogen receptors.  The different 
domains are denoted from A to F. Domain C (DNA-binding domain) is the highly conserved domain between 
ERα and ERβ, followed by domain E (Ligand-binding domain). Amino acid sequence numbers are shown in 
red and denote human ERs (Enmark and Gustafsson, 1999). Percentage of amino acid identities in all 
domains are based on (Shao and Brown, 2004). Abbreviations: ERα and ERβ, Estrogen Receptor alpha and 
beta; AF-1, Activation Function-1; AF-2, Activation Function-2.  
 
2.3.3. Anatomical Distribution of Estrogen Receptors 
From rat tissue extracts, messenger RNA (mRNA) encoding ERβ is highly expressed in the 
prostate and ovary (particularly in granulosa cells) (Byers et al., 1997; Kuiper et al., 1997). 
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Moderate ERβ expression was detected in testis, uterus, mammary gland, bladder and 
lung, whereas pituitary, epididymis, thymus and various regions of the central nervous 
system including the hypothalamus, cerebellum, substantia nigra, olfactory lobe as well as 
the spinal cord revealed low expression of ERβ mRNA. However, no mRNA encoding ERβ 
was detected in the spleen, heart, liver, stomach or kidney (Kuiper et al., 1997). The ERα 
mRNA was highly expressed in the pituitary, testis, epididymis, kidney, liver, mammary 
gland, uterus and adrenal, which all showed moderate or no expression of ERβ mRNA. 
Besides the weak expression in hypothalamus, the olfactory lobe, substantia nigra, 
cerebellum and spinal cord were all negative for ERα (Kuiper et al., 1997). It has also been 
shown that ERα mRNA is the dominant expressed ER in adipose tissue (Lundholm et al., 
2004) and pancreatic islets (Geisler et al., 2002). 
 
Additionally, very low expression of ERα has been detected in normal and cancerous 
colons (Waliszewski et al., 1997; Campbell-Thompson et al., 2001). Nevertheless, Foley 
and colleagues (2000) reported the expression of ERβ in normal colon tissues, but not in 
colon adenocarcinoma, using Western blotting (Foley et al., 2000). In contrast to work 
reported by Foley and colleagues (2000), Witte and colleagues (2001) has demonstrated 
ERβ expression in human colorectal cancer tissues (Witte et al., 2001). 
 
Consistent with the documented effects of estrogens on bone physiology, mRNA 
encoding ERα and ERβ has been detected in rat osteoblasts (Oreffo et al., 1999; Windahl 
et al., 2000). In addition, other studies have reported the expression of both ERα and ERβ 
in muscle tissues (Petersen et al., 1998; Kalbe et al., 2007). 
 
The use of ERα and ERβ knockout mice have been employed to investigate the respective 
roles of both estrogen receptor subtypes, where the deletion of one of the ERs can be 
associated with changes in the effects of 17β-Estradiol in various tissues and on different 
responses (Couse et al., 1995; Couse and Korach, 1999). For instance, ERα knockout 
female mice experience cystic hemorrhagic follicles leading to infertility (Lubahn et al., 
1993; Dupont et al., 2000), abnormalities in reproductive behavior (Ogawa et al., 1996) 
and abnormalities in breast development (Bocchinfuso and Korach, 1997). The ERα 
knockout male mice experience testicular atrophy, decreased spermatogenesis and 
inactive sperms leading to infertility irrespective of their motivation to mount female 
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mice (Lubahn et al., 1993; Ogawa et al., 1997). In addition, aggressive behaviors were 
considerably reduced and typical male offensive attacks were hardly displayed by ERα 
knockout male mice (Ogawa et al., 1997). 
 
Conversely, the ERβ knockout male mice have loss of abdominal fat yet are fully fertile. 
However, the ERβ knockout female mice show reduced fertility due to an obstruction in 
the follicle development before ovulation (Krege et al., 1998). It has also been shown that 
ERβ knockout mice show several morphological abnormalities in the brain, such as 
neuronal hypocellularity (Wang et al., 2001). Additionally, ERβ knockout mice seem to 
reveal smaller brains with fewer neurons than those of the wild-type littermates. They 
also encounter more apoptotic cells as well as fragmented processes of glial cells in the 
brain (Wang et al., 2003). Both ERβ knockout male and female mice show profound 
memory and learning impairment (Day et al., 2005). 
 
2.4. Molecular Mechanisms of Estrogen Action 
Nuclear actions of estrogens are usually determined by: (1) the structure of the ligands 
which may include endogenous estrogens or exogenous and synthetic estrogens, (2) the 
ER subtype involved, (3) the characteristics of the promoter and/or enhancer regions of 
target genes and finally (4) the balance of co-regulatory proteins (i.e. co-activators or 
co-repressors) that modulate the final transcriptional response following the ligand/ER 
complexes. 
 
2.4.1. Classical Pathway via Estrogen Responsive Elements 
17β-Estradiol exerts its effects mainly via a classical genomic mechanism of action 
involving the interaction of estrogen to ERs and subsequent regulation of gene 
transcription. Typically, the classical genomic pathway takes several hours for the effect 
to be manifested because of the time required for transcription and translation of 
estrogen-regulated genes (O'Lone et al., 2004). In principle, ERs mainly exist in the 
cytoplasm in their unbound apoprotein state. The unbound cytoplasmic ER monomers are 
usually coupled with receptor-associated proteins that are largely located in the 
cytoplasm, such as heat shock proteins (hsp90 or hsp70) or immunophilins (Figure  2-5) 
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(Smith and Toft, 1993; Pratt and Toft, 1997). It has been proposed that heat shock 
proteins or other molecular chaperones play a structural role in: (1) stabilizing the ERs in 
their inactivated unbound state, (2) masking their hydrophobic ligand-binding domain to 
avoid inappropriate interactions and (3) allowing for high affinity-ligand binding 
conformation (Ellis et al., 1989). 
 
As illustrated in Figure  2-5, free 17β-Estradiol enters the cell by simple or facilitated 
diffusion; resulting in the dissociation of the cytoplasmic molecular chaperone as well as 
inducing a conformational change in the receptor. This change allows the receptor 
ligand-binding domain to be exposed for 17β-Estradiol interaction. The E2-ER complex 
then shuttles into the cell nucleus and binds simple sequences of EREs as either 
homodimers (either ERα-ERα or ERβ-ERβ) or heterodimers (ERα-ERβ) (Pettersson et al., 
1997; Gruber et al., 2002). The exact mechanism of the nuclear translocation of E2-ER 
complex remains elusive. However, it is well-known that the cytosolic protein caveolin-1 
stimulates the nuclear shuttling process through direct interaction with the receptor 
molecule (Schlegel et al., 1999). 
 
Translation
Transcription
mRNA
Nucleus
Plasma Membrane
E2
ER
ER
Cytoplasm
Target Gene
ER ER
ER ER
hsp90
hsp90
ERE
PROTEIN !
PROTEIN !
TATA
hsp90
hsp90
 
 
Figure  2-5: A simple schematic illustration representing the classical pathway of estrogen signaling via 
estrogen responsive elements. Abbreviations: E2, 17β-Estradiol; ER, Estrogen Receptor; hsp90, heat shock 
protein 90; ERE, Estrogen Responsive Element; mRNA, messenger RNA. 
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Only a small number of the most estrogen-inducible genes contain the common 
consensus of EREs (i.e. 5’-GGTCAnnnTGACC-3’). In some cases, alternative EREs have been 
described. For example, 5’-GGTCAnnnTGGCC-3’ is a variant sequence differing from the 
consensus sequence by 1 bp. These variant sequences have been shown to bind ERs with 
less affinity, depending on the flanking bases (Driscoll et al., 1998). Finally, the E2-ER 
complex binds to nuclear receptor co-activators or co-repressors (Section  2.4.2) to form a 
transcription-initiation complex, which includes the assembly of various factors; such as 
the TATA-box-binding protein and other associated factors that subsequently regulate the 
transcription and translation of target genes. 
 
In humans, most of the genes regulated by ERs lack ERE-like sequences (O'Lone et al., 
2004). As a result, it has been extensively discussed whether estrogens can regulate the 
transcription of target genes that lack functional EREs by modulating the activity of other 
transcription factors. This action is often referred to as the alternative genomic pathways. 
These include regulation of target genes by ERs without directly binding to DNA, but 
rather via the formation of the pre-initiation complex through protein-protein 
interactions with transcription factors, such as the Activator Protein-1, Specificity 
Protein-1 and the Nuclear Factor-kappa B (Nilsson et al., 2001; Bjornstrom and Sjoberg, 
2005; Cheskis et al., 2007). 
 
Accumulating evidence suggests that E2 also exert non-genomic actions, i.e. actions that 
are very rapid and occur within minutes, hence cannot be attributed to a genomic 
mechanism of action. Non-genomic actions are a common property of all steroid 
hormones and are frequently associated with the activation of various protein-kinase 
cascades (Losel and Wehling, 2003). When ERs are targeted to the plasma membrane, it 
appears that functional domains, besides the ligand-binding domain, contribute to the 
level of non-genomic actions through protein-protein interactions (Kousteni et al., 2001). 
It is more likely that the interaction of ERs with signaling molecules facilitates their 
activity. For example, it has been shown that ERs at the plasma membrane may associate 
with the scaffold protein caveolin-1 (Razandi et al., 2002) in addition to a variety of 
proximal signaling molecules such as the G proteins (Wyckoff et al., 2001). Non-genomic 
effects of E2 in neurons, for instance, leads to either changes in Ca+2 currents (Kurata et 
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al., 2001), changes in the cyclic AMP pathway (Gu and Moss, 1996), activation of 
mitogen-activated protein kinase pathway (Bulayeva et al., 2004) or activation of protein 
kinase C pathway (Kelly et al., 1999), which in turn greatly affects neuronal survival and 
transmission. 
 
Even though evidence suggests that the classical ERs are capable of mediating many of 
the abovementioned events, more recent discoveries reveal the potential existence of a 
plasma membrane-associated receptor capable of responding to estrogens (Hasbi et al., 
2005). The proposed receptor is GPR30, a member of the G protein-coupled receptor 
superfamily that supposedly mediates the activation of estrogen-dependent kinase 
cascades in addition to gene transcriptional responses (Kelly et al., 1999; Prossnitz et al., 
2008). Nevertheless, given the amount of perplexed data reported on the role of GPR30 
as a membrane estrogen receptor from studies utilizing GPR30 knockout mice, further 
investigations shall be required to unravel such controversies [Reviewed in (Langer et al., 
2010; Maggiolini and Picard, 2010)]. 
 
2.4.2. Co-regulatory Proteins 
The past decades have provided significant clarification of a large number of 
co-regulatory proteins associated with ERs and have been biochemically and functionally 
characterized as either co-activators or co-repressors of specific transcriptional 
machineries according to their mode of action (Malik and Roeder, 2005; Margueron et al., 
2005; Perissi and Rosenfeld, 2005).  
 
The first are co-activator complexes that regulate promoter accessibility to various 
transcription factors and to basal transcriptional machinery to activate and initiate target 
gene expression (Dilworth and Chambon, 2001; Jenuwein and Allis, 2001). Most of them 
are characterized by the helical LXXLL motifs, known as nuclear receptor boxes. Those 
include the ATP-dependent chromatin remodeling factors, such as the SWI/SNF complex 
(Dilworth et al., 2000); histone arginine methyltransferases, such as the p160/SRC 1-3 
family (Steroid Receptor Co-activator family) that interacts with the AF-2 domain (Koh et 
al., 2001); histone acetyltransferases, such as the CBP (CREB Binding Protein)/p300 
proteins (Chan and La Thangue, 2001) in addition to factors of the so-called mediator 
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complex that mediate the interaction with the RNA polymerase II machinery, such as the 
TRAP/SMCC/DRIP/ARC complex (Rachez et al., 1999).  
 
The second are co-repressor complexes that inhibit gene activation and possibly turn off 
the expression of activated target genes. Those include basal or specific co-repressors. 
Basal co-repressors, such as NCoR (Nuclear Receptor Co-repressor) and SMRT (Silencing 
Mediator of Retinoid and Thyroid Receptors), function as platforms for the recruitment of 
other various subcomplexes that contain histone deacetylase activity (Li et al., 2000). 
Specific co-repressors, such as LCoR (Ligand-dependent Co-repressor) and RIP140 
(Receptor Interacting Protein of 140 kDa), interact with the AF-2 domain and function as a 
molecular scaffold that recruits several proteins that function in transcriptional repression 
in response to ligand induction (White et al., 2004).  
 
One important debate is whether or not ligand-bound ERα and ERβ recruit and contact 
different co-activators and/or co-repressors. Since both receptors show amino acid 
sequence homology in their AF-2 domain, it was expected that both ERs would show 
similar activity in co-activator recruitment, yet some differences have been pointed out. 
For instance, ERα shows higher affinity for SRC-3 than ERβ (Suen et al., 1998). In contrast 
to ERα, ERβ strongly binds to the TRAP/SMCC/DRIP/ARC complex (Nilsson et al., 2001). 
 
The different binding specificities of the nuclear receptor box LXXLL motif could be one 
possible explanation associated with such differences (Darimont et al., 1998; McInerney 
et al., 1998). Additionally, since there are distinct ligand-binding specificities of the two 
ERs, and as ligands can alter receptor conformations, ligand-binding specificity is likely to 
affect co-regulator binding affinities and specificities. Affinity-selection approaches have 
been utilized to study such differences in receptor conformation. These set of 
experiments clearly revealed that different ER conformations are induced by different 
agonists and antagonists, which results in the recruitment of different ER-binding 
co-regulatory proteins (Norris et al., 1999; Paige et al., 1999). 
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2.5. Estrogen Receptor Ligands 
The difference in the anatomical distribution between ERα and ERβ supports the 
possibility of achieving selectivity at the receptor level (Mosselman et al., 1996; Kuiper et 
al., 1997). Even though both ER subtypes are activated by binding 17β-Estradiol (Green et 
al., 1986; Kuiper et al., 1996), their ligand-binding domains share only 59 % of amino acid 
sequence identity (Shao and Brown, 2004). This implies that estrogen receptor ligands, 
besides the endogenous estrogens, will likely exist with different affinities, potencies and 
effects with regards to both ERα and ERβ (Kuiper et al., 1998). 
 
Besides the main endogenously synthesized estrogens, there exist numerous structurally 
diverse compounds that originate from both synthetic as well as natural sources and are 
known to possess estrogenic activity (Figure  2-6). Since these compounds interfere or 
alter functions of the endocrine system, they are often referred to as endocrine 
disrupting compounds or xenoestrogens. On one hand, humans are often exposed 
through the food chain to a selection of synthetic endocrine disrupting compounds, 
including, pesticides such as DDT and methoxychlor, industrial lubricants such as 
polychlorinated biphenyls as well as plasticizers such as phthalates and bisphenol A. 
Moreover, pharmaceutical estrogens such as ethinylestradiol can also be classified as 
synthetic xenoestrogens [Reviewed in (Cos et al., 2003; Patisaul and Jefferson, 2010)]. It 
has been reported that synthetic xenoestrogens are often associated with female 
reproductive disorders and increasing rates of obesity and cancer (Fisher, 2004; Crain et 
al., 2008). 
 
On the other hand, most of the natural xenoestrogens are produced by fungi or plants 
and are therefore classified as mycoestrogens or phytoestrogens, respectively (Figure  2-6) 
(Cos et al., 2003) . The most common mycoestrogen is zearalenone, which was reported 
to reduce the prevalence of breast cancer (Hilakivi-Clarke et al., 1999). Based on the 
chemical structures of phytoestrogens, they are classified into three main groups, namely 
flavonoids, lignans and stillbenes (Figure  2-6) (Cos et al., 2003). Phytoestrogens remain 
widely believed to provide a range of beneficial effects, including therapeutic actions in 
carcinogenesis, osteoporosis and atherosclerosis (Cassidy et al., 2006; Kim, 2008). 
Nonetheless, the potential dangers of consuming high levels of these compounds have 
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raised concerns. As a result, phytoestrogens are currently under numerous investigations 
for their impact on human health (Abe, 1999). From the abovementioned natural 
xenoestrogens, the main focus of the present study will be the phytoestrogens 
particularly the flavonoids, where the isoflavones and the naringenin-type flavanones are 
classified. 
E1
E2
E3
Endogenous
Estrogens
Estrogen Receptor Ligands
Endocrine Disrupting Compounds
(Xenoestrogens)
Natural 
Compounds
Mycoestrogens
Synthetic Compounds
Phytoestrogens
Flavonoids
Lignans
Stillbenes
 
Figure  2-6: The classification of estrogen receptor ligands. Phytoestrogens, particularly the Flavonoids, are 
the main focus of the present study and are highlighted in red. Examples for each group are pointed out in 
the text. 
  
2.5.1. Phytoestrogens: The Flavonoids 
Phytoestrogens are polyphenolic naturally-occurring dietary compounds of plant origin 
that mostly resemble the structure of the mammalian steroidal endogenous estrogens. 
They cannot be classified as nutrients as lack in the diet does not lead to a deficiency 
syndrome; hence they are also known as plant-derived secondary metabolites (Patisaul 
and Jefferson, 2010). The potential use of phytoestrogens as therapeutic agents to 
overcome menopausal symptoms, which often lead to reduced quality of life for many 
women, has been receiving widespread interest due to their occurrence in medicinal 
plant extracts and a wide range of food items including dietary supplements with 
respective health claims (Brown and Setchell, 2001; Singleton and Khan, 2003). 
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The interest in phytoestrogens is mainly due to their estrogen-like bioactivity. They have 
the ability to bind both ERs and transactivate target genes. They also show both 
estrogenic or antiestrogenic properties depending on the circulating levels of endogenous 
estrogens (Cos et al., 2003; Ososki and Kennelly, 2003). Medically, they have been studied 
as chemopreventors against various forms of cancers in addition to ameliorating 
symptoms in menopausal women. Their estrogenic effects vary according to the 
phytoestrogenic substance studied, the species and the experimental system (Davis et al., 
1999). 
 
Numerous in vitro and in vivo mammalian model systems have been designed to 
elucidate gene expression profiles distinctive to substances with estrogenic activity as 
compared to 17β-Estradiol (Moggs et al., 2004; Ise et al., 2005). This indicates that 
estrogen-like substances of different origin may reveal similar molecular effects and 
perhaps share a significant potential for both beneficial and adverse health effects. 
 
2.5.1.1. Isoflavones 
Isoflavones are a group of bi-phenolic organic compounds with roughly 230 individual 
compounds and are most commonly found in legumes. Human exposures to such 
compounds primarily occurs through the consumption of soy-based food and beverage 
products, such as tofu and soy milk (Knight and Eden, 1996). 
 
Genistein (GEN) (Figure  2-7 A) and Daidzein (DAI) (Figure  2-7 B) are the two best 
characterized isoflavones. Following oral uptake, the β-glucosides (i.e. Genistin and 
Daidzin) are broken down in the gut by intestinal glucosidases to their aglycones: 
Genistein and Daidzein, respectively. The aglycones can be either directly absorbed or 
metabolized by resident microflora in the gastrointestinal tract before absorption. 
Genistein is converted to several metabolites, such as dihydrogenistein, while Daidzein is 
converted to its main metabolite Equol (EQ) (Figure  2-7 C) (Axelson et al., 1984; Munro et 
al., 2003). 
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Figure  2-7: Chemical structure of the three isoflavones. Carbon atom numbering is denoted in red. 
 
The chemical structure of isoflavones is similar to the chemical structure of 17β-Estradiol. 
The phenolic A-ring is one key structural feature of most compounds that bind to ERs. 
Another important key structural element that allows for binding to ERs is the distance 
between the hydroxyl groups at carbon-7 and carbon-4’ of the isoflavone molecules, 
which is virtually identical to the 17β-Estradiol molecule (Zand et al., 2000). It has been 
shown, using in vitro assays, that several isoflavones bind both ERα and ERβ, albeit to a 
lower affinity than 17β-Estradiol, thereby inducing or modulating the estrogen-signaling 
pathway, such as regulation of gene transcription and kinase pathways (Kuiper et al., 
1998). In vitro assays have shown that Genistein binds both ERs, with higher relative 
binding affinities for ERβ than for ERα (7.4 % and 0.017 %, respectively, where 
17β-Estradiol has an affinity of 100 %) (Martin et al., 1978; Muthyala et al., 2004). Equol 
also reveals a higher relative binding affinity for ERβ than for ERα (3.2 % and 0.1 %, 
respectively, where 17β-Estradiol has an affinity of 100 %). Interestingly, Equol 
demonstrates an overall higher relative binding affinity values than its parent compound 
Daidzein (0.01 % for ERα and 0.04 % for ERβ, where 17β-Estradiol has an affinity of 100 %) 
(Markiewicz et al., 1993; Muthyala et al., 2004). 
 
Epidemiological observations have indicated that high intake of isoflavones are associated 
with low incidences of breast cancer, cardiovascular diseases and osteoporosis 
(Adlercreutz and Mazur, 1997). However, data on isoflavones and their effects in brain 
cells are variable. On one hand, Zhao and colleagues (2002) reported that Genistein, 
Daidzein and Equol exerted a modest yet significant reduction in lactate dehydrogenase 
release, a marker of plasma membrane damage, in cultured hippocampal neurons. On the 
other hand, the isoflavones did not promote hippocampal neuron process outgrowth as 
opposed to 17β-Estradiol (Zhao et al., 2002). Furthermore, it has recently been reported 
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that high concentrations of Genistein and Daidzein induce neurotoxicity in primary rat 
neuronal cultures (Jin et al., 2007). Judging by these conflicting findings, biological 
properties of isoflavones in different brain cells are of significant interest, especially if it 
has been shown from a recent in vivo study that Genistein, for instance, has the ability to 
cross the blood brain barrier (Friso et al., 2010). 
 
2.5.1.2. Naringenin-type flavanones 
A second recently described class of the flavonoids is the so-called naringenin-type 
flavanones. These are also bi-phenolic organic compounds where a large body of 
literature states their occurrence in various foodstuffs and medicinal plants, including 
Naringenin (NAR) (Figure  2-8 A) which is found in tomatoes (Solanum lycopersicum) and 
grapefruits (Citrus grandis). Additionally, 8-Prenylnaringenin (8-PN) (Figure  2-8 B) is a very 
potent naringenin-type flavanone in female hop cones (Humulus lupulus), a beer flavoring 
agent (Milligan et al., 2000; Zierau et al., 2005). It can be prepared by direct prenylation 
of the naturally occurring Naringenin (Gester et al., 2001). Finally 
6-(1,1-Dimethylallyl)naringenin (6-DMAN) (Figure  2-8 C) is a naringenin-type flavanone 
that has been isolated from the leaves of the African tree Monotes engleri (Seo et al., 
1997). The analysis of naringenin-type flavanones for pharmacological applications has 
recently become more attractive because of the possibility to chemically synthesize 
naringenin derivatives using an efficient europium (III)-catalyzed Claisen rearrangement 
(Gester et al., 2001; Tokalov et al., 2004). This allowed access to larger quantities of the 
substances of interest as well as the development and synthesis of artificial structural 
variations, such as 7-(O-prenyl)naringenin-4'-acetate (7-O-PN) (Figure  2-8 D), which in 
contrast to the abovementioned compounds, has not yet been identified in any plant 
(Kretzschmar et al., 2007). 
 
ER binding studies have demonstrated the interaction of the most studied 
naringenin-type flavanones, Naringenin and 8-Prenylnaringenin, with both ERs. It has 
been shown that Naringenin binds both ERs, with higher relative binding affinity for ERβ 
than ERα (0.11 and 0.01, respectively) (Kuiper et al., 1998). 8-Prenylnaringenin can 
strongly compete with E2 for binding both ERs, although there is no marked difference in 
the binding affinity for the two receptors (Milligan et al., 2002). 8-Prenylnaringenin 
THEORETICAL BACKGROUND 
_____________________________________________________________________ 
23 
reveals a strong ER-binding affinity that is only 0.5 orders of magnitude lower as 
compared to 17β-Estradiol (Effenberger et al., 2005). In the case of 
6-(1,1-Dimethylallyl)naringenin and 7-(O-prenyl)naringenin-4'-acetate, nothing is known 
about their relative binding affinities and receptor selectivity so far, however studies have 
shown that they have the ability to bind both ER subtypes in a cell- and tissue-specific 
manner (Zierau et al., 2002; Zierau et al., 2004; Kretzschmar et al., 2007; Kretzschmar et 
al., 2010). 
 
Since the influence of naringenin-type flavanones on human health and their potential 
risks or benefits of usage are still debatable, they have lately gained considerable 
scientific interest. For instance, the estrogenic potency of Naringenin is highly 
controversial (Ruh et al., 1995; Zand et al., 2000). In addition, the estrogenic potency of 
8-Prenylnaringenin is extensively discussed, yet its benefits and risks are poorly identified 
(Christoffel et al., 2006). Moreover, nothing is known so far about the ability of the 
naringenin-type flavanones to cross the blood brain barrier. As a result, data on the 
biological effects of naringenin-type flavanones are of great interest. 
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Figure  2-8: Chemical structure of the four naringenin-type flavanones. Carbon atom numbering is the 
same as denoted in the isoflavone chemical structures in Figure  2-7. 
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2.5.2. Characterization of Other Selected Substances 
2.5.2.1. Estrogen Receptor Agonists 
A number of subtype-specific ER agonists have been developed as useful tools in 
understanding the differences in structure and biological function of each ER subtype. 
Propyl pyrazole triol (PPT) (Figure  2-9 A) is a synthetic triarylpyrazole that was reported to 
bind ERα with high affinity (approximately 50 % that of 17β-Estradiol) and has a 410-fold 
higher binding affinity preference for ERα than for ERβ. This high ERα binding selectivity is 
mediated through interactions between the pyrazole core with the ligand-binding pocket; 
where ERα has a smaller Leucine 384 residue than the Methionine 384 of ERβ (Stauffer et 
al., 2000). 
Diarylpropionitrile (DPN) (Figure  2-9 B) acts as an agonist for both ER subtypes. However, 
it exhibits a 70-fold relative binding preference and a 170-fold higher relative 
transactivational potency for ERβ than for ERα (Meyers et al., 2001). The ERβ selectivity of 
DPN is mediated by the N-terminal region of the ERβ ligand-binding domain, specifically 
through helix 6. However, amino acid residues in helix 3 are also important in achieving 
ERβ selectivity of DPN. Using molecular modeling, it has been shown that the nitrile group 
is strongly engaged in stabilizing interactions with amino acid residues in the 
ligand-binding pocket of ERβ (Sun et al., 2003). 
Propyl pyrazole triol (PPT)
(A)
Diarylpropionitrile (DPN) 
(B)
HO
CN
OH
HO
N
N
OH
OH
 
Figure  2-9: Chemical structure of the estrogen receptor selective agonists. The pyrazole core in PPT and 
the nitrile group in DPN are marked in blue. 
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2.5.2.2. Estrogen Receptor Antagonist or Antiestrogen  
Antiestrogens are classified as substances that inhibit ER function. Fulvestrant (F) [also 
known as ICI 182,780 (FASLODEX®)] is considered a "pure" antiestrogen and a derivative 
of 17β-Estradiol containing a pentafluoropentylsulfinyl side extension in its 7α position 
(Figure  2-10) with no agonistic activities reported so far (Wakeling et al., 1991). 
 
The relative binding affinity of Fulvestrant is 0.89 as compared to 17β-Estradiol (1.0) 
(Bowler et al., 1989; Wakeling et al., 1991). At the molecular level, Fulvestrant competes 
with 17β-Estradiol for ER binding, inhibits the AF-1 and AF-2 transactivating domains, and 
prevents ER dimerization, thus disrupting its nuclear localization. Another property of 
Fulvestrant is that it down-regulates or reduces the steady-state levels of the ERs by 
increasing their turnover rate (Dauvois et al., 1993; Johnston and Cheung, 2010). 
17β-Estradiol
Fulvestrant
H O
O H
C H 3
H O
O H
C H 3
(C H2)9SO(C H2)3C F2CF3
 
Figure  2-10: Comparison of the structure of Fulvestrant with that of 17β-Estradiol. The similarity of the 
two molecules is shown in planar spatial arrangement. 
 
2.6. The Raphe Nuclei 
The raphe nuclei are clusters of nuclei that are distributed near the midline of the 
brainstem along its rostrocaudal extension. Heterogeneous populations of neurons are 
located in the raphe nuclei, with distinct morphologies, projections and neurochemical 
characteristics. However, the major constituents of the raphe nuclei are cell bodies of 
serotonergic neurons which project to all cerebral regions and produce serotonin; a 
biogenic amine that functions as a neurotransmitter and as a hormone in the mammalian 
central nervous system and its periphery (Parent et al., 1981; Hornung, 2003). 
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Serotonin is biochemically synthesized from the amino acid tryptophan by a short 
metabolic pathway that primarily involves the rate-limiting enzyme tryptophan 
hydroxylase (Walther et al., 2003). It mediates various physiological functions such as 
appetite, thermoregulation, regulation of sleep-wake cycles, sexual behavior and 
memory. It also intervenes psychiatric behaviors including mood swings, depression and 
anxiety as well as panic disorders (Hoyer et al., 2002). The large diversity of serotonin 
receptors is linked to the multiplicity of physiological functions and behaviors that 
serotonin participates in. Using molecular and pharmacological techniques, at least 15 
distinct members of serotonin receptors have been determined. They represent one of 
the most complex families of neurotransmitter receptors that are classified into seven 
families according to their patterns of distribution, coupling mechanisms and 
pharmacological profiles (Julius, 1991). With the exception of the serotonin receptor 
subtype 3, which is a ligand-gated ion channel, all serotonin receptors belong to the 
G-protein coupled receptor superfamily (Kroeze et al., 2002). Another important 
component of the serotonergic system is the serotonin re-uptake transporter; a 
monoamine transporter protein which functions in all serotonergic neurons by means of 
transporting serotonin from synaptic spaces into presynaptic neurons, thus terminating 
serotonin action. Changes in the serotonin re-uptake transporter may alter the expression 
and/or function of most, if not all, serotonin receptors in addition to the synthesis, 
metabolism and clearance of serotonin (Murphy et al., 2008).    
 
Neuroanatomical studies have shown that ERα and ERβ are widely distributed in different 
brain regions. In particular, ERβ immunoreactive cells were abundantly observed 
throughout the raphe nuclei (Shughrue et al., 1996; Shughrue et al., 1997; Perez et al., 
2003; Nomura et al., 2005). Animal studies were also used to co-localize ERs and 
serotonin neurons. For instance, studies in macaques have shown the existence of ERβ 
mRNA as well as its protein in serotonin neurons (Gundlah et al., 2001). Another group of 
researchers have pointed out the expression of ERβ in rat raphe nuclei (Lu et al., 2001). 
Hence, the above observations support the general assumption that ERβ is more likely 
associated with the estrogenic regulation of serotonin neurons in the raphe nuclei than 
ERα. 
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A huge body of data has postulated a significant interaction between estrogens and 
serotonin (McEwen, 2001; Grigoriadis and Kennedy, 2002; Amin et al., 2005). For 
instance, 17β-Estradiol acts through ERβ and increases the expression of tryptophan 
hydroxylase; the rate limiting-enzyme in the synthesis of serotonin (Pecins-Thompson et 
al., 1996). Besides tryptophan hydroxylase, 17β-Estradiol may regulate other components 
of the serotonin system, such as increasing mRNA expression for the progesterone 
receptor (Bethea, 1994), while decreasing mRNA expression of serotonin re-uptake 
transporter (Pecins-Thompson et al., 1998), the serotonin autoreceptor subtype 1 
(Pecins-Thompson and Bethea, 1999) and the monoamine oxidase genes (Gundlah et al., 
2002). As a result, estrogen acts to serve towards serotonin neurotransmission, thereby 
regulating mood swings and depression as well as anxiety behaviors. 
 
2.6.1. The RN46A-B14 Cell Line 
RN46A-B14 is a rat serotonergic cell line and a sub-clone of the parent raphe 
nuclei-derived cell line, RN46A-V1. These have been isolated from a dissociated 
embryonic day 13 rat medullary raphe cells. They have been immortalized with the 
temperature-sensitive mutant of the Simian Virus 40 (SV40) large T-antigen. Based on this 
property, neuronal differentiation of this cell line is initiated in response to shifting cells 
from their proliferative conditions (i.e. permissive temperatures) to differentiation 
conditions (i.e. non-permissive temperatures); in which the cells are no longer under the 
mitotic drive of the temperature-sensitive mutant of the SV40 large T-antigen (White and 
Whittemore, 1992; Whittemore and White, 1993; White et al., 1994). Potential markers 
for cellular differentiation can be represented by neurofilament proteins which are class 
IV intermediate 10 nm filamentous proteins composed of three subunits (low, medium 
and high). The names were designated according to their distinct molecular weights; 
where neurofilament low (NF-L) is 68-70 kDa, neurofilament medium (NF-M) is 145-160 
kDa and finally neurofilament high (NF-H) is 200-220 kDa. Neurofilaments are found in 
neurons of vertebrates and are known to be formed in high concentrations during the 
development of neuronal axons (Cleverley et al., 1998; Lalonde and Strazielle, 2003). 
Neuron specific enolase (NSE), an acid soluble protein of the glycolytic isoenzyme enolase 
that is composed of two gamma subunits, has been also utilized as an additional 
identifying neuronal molecular marker (White et al., 1994). It is exclusively confined to 
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neurons of the central and peripheral nervous systems as well as cells of neuroendocrine 
origin and is thought to serve as a growth factor in neurons (Schmechel et al., 1978; 
Schmechel et al., 1980; Kirino et al., 1983). It has been reported that RN46A-B14 cells 
should express the same complement of the nuclear ERβ as the rat raphe serotonin 
neurons, hence providing a convenient in vitro model that mimics the in vivo situation to 
help study estrogenic action in the raphe nuclei (Bethea et al., 2003). 
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2.7. Aims of the Present Study 
To evaluate the biological effects of the isoflavones and the naringenin-type flavanones 
within the raphe nuclei region of the brain, a region that plays a central role in regulating 
depression, mood swings and anxiety behavior, it is important to initially elucidate their 
transactivational activity on ERβ as well as their potential to regulate endogenous gene 
expression of estrogen responsive genes. To achieve this, RN46A-B14 cells were utilized 
as the main raphe nuclei-derived cellular model in the present study. However, 
preliminary findings have shown that the endogenous expression of ERβ in RN46A-B14 
cells was insufficient for downstream investigations of estrogen-dependent activities 
(Appendix  7-1). As a result, the aims of the present study, as depicted in Figure  2-11, 
were proceeded as follows: 
 
Assess transactivational activity
of Flavonoids using 
luciferase reporter gene assays
Map E2-dependent 
gene regulation using Microarray
Test effects of Flavonoids on regulation of
mRNA expression of selected target genes in: 
(1) RNDA cells
and
(2) D-RNDA cells at day 1 and day 4  following
initiation of differentiation
Generate new cell line
(RNDA cells)
Validate expression of
selected target genes
using quantitative real-time PCR
using Retroviral 
Expression System
Validate expression and 
functional acitivity 
of transgenic ERβ
RN46A-B14 cells
ESR2
 
 
Figure  2-11: Schematic illustration representing the main workflow of the present study 
 
(1) To stably integrate the human ERβ gene (ESR2) in RN46A-B14 cellular genome using a 
suitable Retroviral Expression System. The expression of the transgenic ERβ in the newly 
generated cell line (herein termed RNDA cells) as well as its functional activity shall be 
validated using standard Western blot techniques and firefly luciferase reporter gene 
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assays utilizing a plasmid containing the firefly luciferase reporter gene under the control 
of a double ERE-dependent promoter. 
 
(2) To investigate the transactivational activity of selected flavonoids on the transgenic 
ERβ in RNDA cells using the same abovementioned reporter gene assay. 
 
(3) To map the E2-dependent changes in the expression of the whole rat transcriptome in 
RNDA cells using a DNA microarray technique. 
 
(4) To validate, using quantitative real-time PCR, the mRNA expression of E2-responsive 
genes that are specifically selected from the microarray according to specific features of 
estrogenic regulation of expression. 
 
(5) To evaluate the effects of the flavonoids on the regulation of mRNA expression of the 
selected genes, including serotonin-related genes, using quantitative real-time PCR. Since 
RNDA cells encode a temperature-sensitive mutant of the SV40 large T-antigen, neuronal 
differentiation of these cells is constitutive upon shifting them from proliferative 
conditions (permissive temperature) to differentiation conditions (non-permissive 
temperature). Hence, the regulation of mRNA expression of the selected genes shall be 
investigated in: (a) RNDA cells (proliferating cells) and (b) D-RNDA cells (i.e. RNDA cells 
grown under differentiating conditions) at day 1 and day 4 following initiation of 
differentiation.  
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3. MATERIALS AND METHODS 
 
3.1. Materials 
3.1.1. Cell Lines 
Besides the RN46A-B14 cell line, which was kindly provided by Professor Scott 
Whittemore (Department of Neurological Surgery; University of Miami School of 
Medicine, Miami), the following cell lines were also utilized in the present study: 
 
• RNDA cell line: 
RNDA cells are derivatives of the parent cell line RN46A-B14 cells, yet they are genetically 
modified to stably overexpress transgenic human ERβ using a suitable retroviral 
expression system. Like their parent cell line, the cells encode a temperature-sensitive 
mutant of the SV40 large T-antigen. Based on this property, neuronal differentiation is 
constitutive upon shifting them from proliferative conditions (permissive temperature) to 
differentiation conditions (non-permissive temperature) (White and Whittemore, 1992; 
Whittemore and White, 1993; White et al., 1994). It is important to note that when RNDA 
cells are shifted to conditions promoting differentiation, cells are denoted as D-RNDA 
cells in the present study. 
 
• HEK-293T cell line: 
HEK-293T cells are human embryonic kidney cell line having a eukaryotic expression 
plasmid encoding the temperature-sensitive mutant of the SV40 large T-antigen 
(DuBridge et al., 1987). In this study, they serve as the standard cell line for packaging and 
producing lentiviral particles. The cells were kindly provided by Professor Dirk Lindemann 
(Institute of Virology, Medical Faculty Carl Gustav Carus, TU-Dresden, Germany).  
 
• HT-1080 cell line: 
HT-1080 cells are human fibrosarcoma cell line commonly used as the reference cell line 
to verify efficiency of viral transduction (Rasheed et al., 1974). The cells were also kindly 
provided by Professor Dirk Lindemann (Institute of Virology, Medical Faculty Carl Gustav 
Carus, TU-Dresden, Germany).  
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All outlined cell lines were grown in phenol-red free Dulbecco’s Modified Eagle 
Medium/Nutrient Mixture F12 1:1 (DMEM/F12 1:1) containing L-Glutamine, sodium 
bicarbonate, 15 mM HEPES and high glucose (Biowest, Nuaillé, France). The medium was 
further supplemented with additional additives as shown in Table  3-1. 
 
Table  3-1: Cell lines and their culture conditions 
Cell Line Media Additives / Final Concentration 
(including 1 % Penicillin / Streptomycin)                
Temperature & 
5 % CO2 
RN46A-B14 cells 
 
Hygromycin B (50 mg/ml)                             100 µg/ml 
Geneticin® (G418) (50 mg/ml)                     250 µg/ml 
Fetal Calf Serum (FCS)                                    10 % (v/v) 
33 °C 
(permissive 
temperature) 
RNDA cells 
 
Hygromycin B (50 mg/ml)                             100 µg/ml 
G418 (50 mg/ml)                                            250 µg/ml 
FCS                                                                     10 % (v/v) 
Zeocin™ (100 mg/ml)                                       60 µg/ml 
33 °C 
(permissive 
temperature: 
proliferation 
conditions) 
D-RNDA cells 
(Weigt, 2008) 
Hygromycin B (50 mg/ml)                             100 µg/ml 
G418 (50 mg/ml)                                            250 µg/ml 
B27 Supplement (50x)                                      1 % (v/v) 
BSA Fraction V                                                   1 % (w/v) 
39 °C 
(non-permissive 
temperature: 
differentiation 
conditions) 
HEK-293T cells 
 
FCS                                                                     10 % (v/v) 37 °C 
HT-1080 cells 
 
FCS                                                                     10 % (v/v) 37 °C 
 
3.1.2. Antibodies 
Table  3-2: Primary antibodies used for either Western blot or Immunocytochemistry techniques 
Primary Antibody Catalogue No. Distributor City Country 
Mouse monoclonal anti 
NF-L 
sc-58559 Santa Cruz 
Biotechnology® 
Heidelberg Germany 
Mouse monoclonal anti 
NF-M 
sc-58561 Santa Cruz 
Biotechnology® 
Heidelberg 
 
Germany 
Mouse monoclonal anti 
NF-H 
sc-133165 Santa Cruz 
Biotechnology® 
Heidelberg Germany 
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Primary Antibody 
(continued) 
Catalogue No. Distributor City Country 
Mouse monoclonal anti 
NSE γγ 
MAB314 Millipore GmbH Schwalbach/
Ts. 
Germany 
 
Rabbit polyclonal anti 
ERβ 
PA1-311 Thermo Fisher 
Scientific 
Bonn Germany 
Rabbit polyclonal anti 
β-Actin 
A5060 Sigma-Aldrich  Hamburg Germany 
 
Table  3-3: Secondary antibodies used for either Western blot or Immunocytochemistry techniques  
Secondary Antibody Catalogue No. Distributor City Country 
Alexa Flour 488 goat 
anti-mouse IgG (H + L) 
A-11001 Molecular Probes Darmstadt Germany 
HRPO-conjugated goat 
anti-rabbit IgG 
303-035-003 Dianova Hamburg Germany 
 
 
3.1.3. Enzymes 
Table  3-4: Enzymes used for gene cloning techniques 
Enzyme Distributor City Country 
Age1restriction enzyme Fermentas St. Leon-Rot Germany 
Calf Intestinal Alkaline Phosphatase 
(CIAP) Enzyme 
Promega GmbH Mannheim Germany 
EcoR1 restriction enzyme Fermentas St. Leon-Rot Germany 
T4-DNA-Ligase enzyme Promega GmbH Mannheim Germany 
Xba1 restriction enzyme Fermentas St. Leon-Rot Germany 
 
Table  3-5: Enzymes used for PCR and quantitative real-time PCR 
 Enzyme Distributor City Country 
10x Platinum® Pfx DNA Polymerase 
(2.5 U/µl) 
Invitrogen Karlsruhe Germany 
Moloney Murine Leukemia Virus 
Reverse Transcriptase (MMLV-RT) 
(200 U/µl) 
Promega GmbH Mannheim Germany 
Platinum® Taq DNA Polymerase 
(5 U / µl) 
Invitrogen Karlsruhe Germany 
RNaseOUT™ Recombinant 
Ribonuclease Inhibitor (40 U / µl) 
Invitrogen Karlsruhe Germany 
RQ1 RNase-Free DNase (1 U / µl) Promega GmbH Mannheim Germany 
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 Enzyme (continued) Distributor City Country 
Taq DNA Polymerase (Recombinant) 
(5 U / µl) 
Invitrogen Karlsruhe Germany 
 
 
3.1.4. Miscellaneous 
Table  3-6: Lab Machines and Cell cultureware utilized throughout the study 
Equipment Distributor City Country 
Agilent 2100 bioanalyzer Agilent Technologies Waldbronn Germany 
Agilent DNA Microarray Scanner 
employing SureScan High Resolution 
Technology 
Agilent Technologies Waldbronn Germany 
All cell cultureware  Techno Plastic 
Products (TPP®) 
Trasadingen Switzerland 
Avanti® Centrifuge J-26 XP BECKMAN COULTER™ 
GmbH 
Krefeld Germany 
Biofuge fresco Heraeus Instruments Leipzig Germany 
Canon Power Shot G9 Digital Camera Canon Krefeld Germany 
Carl Zeiss Apotome camera Carl Zeiss  Jena Germany 
Carl Zeiss Axiovert 200 Imaging 
Microscopy 
Carl Zeiss  Jena Germany 
CFX96™ Real-Time System BIO-RAD GmbH Munich Germany 
EpiChemi3 Benchtop Darkroom UVP Ltd. Cambridge UK 
FACSCalibur™  Flow Cytometer BD Biosciences Heidelberg Germany 
Gene Pulser II BIO-RAD GmbH Munich Germany 
HB-1000 Hybridizer UVP Ltd. Cambridge UK 
Infinite F200 spectrophotometer 
machine 
TECAN Männedorf  Switzerland 
Megafuge 2.0R Heraeus Instruments Leipzig Germany 
Multifuge 3 S-R  Heraeus Instruments Leipzig Germany 
NanoDrop® ND-1000 UV-Vis 
Spectrophotometer 
NanoDrop® 
Technologies 
Hilden Germany 
OLYMPUS® Culture Microscope 
Model CK40 
OLYMPUS® Hamburg Germany 
Primus 96 plus bench cycler MWG-BIOTECH Ebersberg Germany 
Trans-Blot® SD Semi-Dry Transfer Cell BIO-RAD GmbH Munich Germany 
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Table  3-7: Software products utilized throughout the study 
 
Table  3-8: Commercial kits utilized throughout the study 
Software Product Distributor City Country 
Agilent Feature Extraction Software 
Version 9.5 
 
Agilent Technologies Waldbronn Germany 
Agilent Technologies GeneSpring GX 9 
Software 
 
Agilent Technologies Waldbronn Germany 
AxioVert Software Release 4.8.1 Carl Zeiss  Jena Germany 
Becton Dickinson CellQuest™ Software BD Biosciences Heidelberg Germany 
Bio-Rad CFX Manager Version 1.6 BIO-RAD GmbH Munich Germany 
Labworks™ Image Acquisition and 
Analysis Software Version 4.6. 
UVP Ltd Cambridge UK 
Magellan Software TECAN Männedorf Switzerland 
Microsoft Office Excel 2003 Microsoft Deutschland  Munich Germany 
Sigma Plot® Version 9.0 Systat Software  Erkrath Germany 
Kit Distributor City Country 
Agilent’s Quick Amp Labelling Kit Agilent Technologies Waldbronn Germany 
Bicinchoninic Acid Protein Assay Kit VWR Darmstadt Germany 
Luciferase Assay System Kit Promega Mannheim Germany 
NucleoSpin® RNA/Protein Isolation Kit MACHEREY-NAGEL Düren Germany 
peqGOLD Gel Extraction Kit PEQLAB 
Biotechnologie GmbH 
Erlangen Germany 
QIAGEN® Plasmid Midi Kit (100) QIAGEN GmbH Hilden Germany 
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Table  3-9: Reagents, solutions and supplies utilized throughout the study 
Item Distributor City Country 
10,000 U/ml Penicillin and 
10,000 µg/ml Streptomycin 
Gibco-BRL Eggenstein Germany 
17β-Estradiol crystalline 
 
Sigma-Aldrich  Hamburg Germany 
 
50 bp DNA Ladder (1000 µg/ml) 
 
 
NEW ENGLAND 
BioLabs GmbH 
Frankfurt 
am Main 
Germany 
6-(1,1-Dimethylallyl)naringenin Synthesized from Naringenin by a europium 
(III)-catalyzed Claisen rearrangement 
(Gester et al., 2001) 
7-(O-prenyl)naringenin-4'-acetate 
 
Byproduct of a Mitsunobu reaction used for the 
synthesis of 8-PN and 6-DMAN 
(Gester et al., 2001; Tokalov et al., 2004) 
8-Prenylnaringenin Synthesized from Naringenin by a europium 
(III)-catalyzed Claisen rearrangement 
(Gester et al., 2001) 
Amersham™ ECL Hyperfilm GE Healthcare Munich Germany 
Amersham™ ECL Plus Western 
Blotting Detection System 
GE Healthcare Munich Germany 
B27 Supplement (50x) Gibco-BRL Eggenstein Germany 
BSA Fraction V SERVA Electrophoresis Heidelberg Germany 
Collagen Type I from calf skin Sigma-Aldrich  Hamburg Germany 
Daidzein Sigma-Aldrich  Hamburg Germany 
DAPI Santa Cruz 
Biotechnology® 
Heidelberg Germany 
DEPC Solution AppliChem GmbH Darmstadt Germany 
Developing and Fixing Solution Kodak La Hulpe Belgium 
Diarylproprionitril Tocris Biosciences Bristol UK 
dibutyryl cyclic AMP Sigma-Aldrich  Hamburg Germany 
dNTPs (100 mM each) Invitrogen Karlsruhe Germany 
DOTAP Liposomal Transfection 
Reagent 
Roth Karlsruhe Germany 
Equol Sigma-Aldrich  Hamburg Germany 
Fulvestrant (ICI 182,780) Tocris Biosciences Bristol UK 
Geneticin® (G418) (50 mg/ml)  CALBIOCHEM® Darmstadt Germany 
Genistein  Sigma-Aldrich  Hamburg Germany 
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Item (continued) Distributor City Country 
HPLC water AppliChem GmbH Darmstadt Germany 
Hygromycin B (50 mg/ml)  Invitrogen Karlsruhe Germany 
Mowiol 4-88 granules Carl Roth GmbH Karlsruhe Germany 
Naringenin Sigma-Aldrich  Hamburg Germany 
n-Butyric Acid, Sodium Salt  Sigma-Aldrich  Hamburg Germany 
Non-fat dried milk powder Merck KGaA,  Darmstadt Germany 
Oligo (dT)18-primers (100 µM) Eurogentec Germany 
GmbH 
Cologne Germany 
PageRuler™ Prestained Protein Ladder Fermentas St. Leon-Rot Germany 
peqGOLD TriFast™ Reagent PEQLAB Biotechnologie 
GmbH 
Erlangen Germany 
Phenol-red free DMEM/F12 1:1 
Medium 
Biowest Nuaillé France 
Polyethylenimine (PEI) Transfection 
Reagent 
Sigma-Aldrich  Hamburg Germany 
Propyl pyrazole triol  Tocris Biosciences Bristol UK 
PVDF Membrane (pore size: 0.45 µm) Millipore GmbH Schwalbach
/Ts. 
Germany 
 
Quick Load 1 kb DNA Ladder 
(50 µg/ml) 
NEW ENGLAND 
BioLabs GmbH 
Frankfurt 
am Main 
Germany 
Rotiphorese® Gel 30 Carl Roth GmbH Karlsruhe Germany 
SYBR® Green I Sigma-Aldrich  Hamburg Germany 
TEMED Carl Roth GmbH Karlsruhe Germany 
Trypsin / EDTA (10x) Biowest Nuaillé France 
VS Membrane (pore size: 0.025 µm) Millipore GmbH Schwalbach
/Ts. 
Germany 
 
Zeocin™ (100 mg/ml) Invitrogen Karlsruhe Germany 
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3.2. Methods  
3.2.1. Cell Culture 
3.2.1.1. Trypsin Digestion, Counting and Preserving Cells 
Adherent cells were washed twice with Phosphate Buffered Saline (PBS) (Table  3-10) and 
detached with 1x Trypsin / EDTA solution (Biowest, Nuaillé, France) for 5 minutes at 
either 33 °C, 37 °C or 39 °C and 5 % CO2. Once detached, Trypsin was inactivated by 
adding a few milliliters of medium to cells. The cell suspension was then harvested using 
the Multifuge 3 S-R (Heraeus Instruments, Leipzig, Germany) at 900 rpm for 5 minutes. 
The cell pellet was subsequently re-suspended in 5 to 10 ml of medium. After 
re-suspension, cell count was determined using a Neubauer cell counting chamber and 
the exclusion dye Trypan blue (0.2 % w/v Trypan blue in 85 % w/v PBS). Cells were then 
plated at the desired density according to specified experimental design. The remaining 
cell suspension was centrifuged and the pellet was re-suspended in freezing medium 
(90 % FCS and 10 % DMSO) and placed in liquid nitrogen for long-term storage. 
 
Table  3-10: PBS composition per 1 Liter (Sambrook et al., 1989) 
Component Required Amount 
Sodium Chloride  8.00 g 
Disodium hydrogen phosphate dihydrated 1.44 g 
Potassium Chloride 0.20 g 
Potassium dihydrogen phosphate 0.24 g 
Deionized distilled water added up to 1 Liter 
Autoclaved and stored at room temperature until use 
 
3.2.1.2. Phase Contrast Microscopy 
Throughout this study, cells were visualized on an OLYMPUS® Culture Microscope Model 
CK40 (OLYMPUS®, Hamburg, Germany) to verify cell appearance before proceeding to the 
next steps. In particular, RNDA and D-RNDA cells were visualized and photographed via 
the Canon Power Shot G9 Digital Camera (Krefeld, Germany). 
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3.2.2. Genetic Engineering 
Genetic engineering technologies using retroviral-based vectors have emerged in 
biomedical areas and basic research as an invaluable tool to manipulate target cellular 
genome. However, most of these retroviral vectors, such as oncoretroviral-based vectors, 
possess certain gene delivery limitations, including: (1) instability of the viral vector in the 
target cellular genome (Andreadis et al., 1997), (2) production of low viral titers (Le Doux 
et al., 1999) and (3) inability to transduce non-proliferating and possibly differentiating 
cells (Lewis and Emerman, 1994; Ryser et al., 2007). To overcome these shortcomings, 
basic and applied research has focused their interest on utilizing lentiviral-based vectors 
to stably integrate transgenic DNA into any cellular target and eventually manipulate its 
original function according to the researcher’s needs (Bukrinsky et al., 1993). 
Lentiviral-based vectors have superior transduction efficiencies in modifying cells in vitro 
and in vivo, leading to the most desirable feature that is long-term gene expression (Park, 
2007). DNA insertional mutagenesis is also induced at lower frequencies as opposed to 
other retroviral-based systems. Finally, lentiviral-based vectors are capable of stably 
transducing quiescent non-dividing cells (Naldini et al., 1996; Breckpot et al., 2004). 
 
In this study, the lentiviral expression vector, p6NST50 (Figure  3-1), was the method of 
choice to insert and stably integrate the human ERβ gene (ESR2) into the RN46A-B14 
cellular genome. This vector was kindly provided by Professor Dirk Lindemann (Institute 
of Virology, Medical Faculty Carl Gustav Carus, TU-Dresden, Germany). Cloning of human 
ESR2 fragment into p6NST50 was initially conducted prior to viral transduction / infection. 
 
p6NST50:
MCS
CMV SFFV U3 ∆U3 R U5R U5 IRESRRE cPPT WPRE
Ψ
EGFP-Zeo
 
Figure  3-1: Schematic linear illustration of the lentiviral transfer vector construct employed in the present 
study. Self-inactivating HIV-1 based retroviral transfer vector p6NST50 contains an internal spleen focus 
forming virus (SFFV) U3 promoter with downstream multiple cloning site (MCS) and an internal ribosomal 
entry site (IRES) driven enhanced green fluorescent protein-Zeocin marker gene cassette (EGFP-Zeo). 
Abbreviations: Ψ: packaging sequence; RRE: rev-responsive-element; cPPT: central poly purine tract; WPRE: 
Woodchuck hepatitis virus posttranscriptional regulatory element; CMV: cytomegalo virus immediate early 
enhancer-promoter; R: long terminal repeat (LTR) region; U5: LTR unique 5’ region; ∆U3: 
enhancer-promoter deleted LTR unique 3’ region. 
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3.2.2.1. Dialysis of p6NST50 and Transformation of Escherichia coli with p6NST50 by 
Electroporation 
Initially, the provided p6NST50 was dialysed to eliminate any inhibitory substances, such 
as salts, that could obstruct the process of transformation of Escherichia coli (E. coli) using 
electroporation. Deionized distilled water was poured into a Petri dish and a 25 mm 
diameter VS Membrane (pore size = 0.025 µm) (Millipore GmbH, Schwalbach/Ts., 
Germany) was allowed to float with shiny side facing upwards while avoiding any bubbles. 
The floating membrane was kept on water for 5 minutes. 10 µl of the provided p6NST50 
was carefully pipetted onto the centre of the filter and allowed to incubate for 15 
minutes.  Carefully, the vector droplet was retrieved for subsequent steps.  
 
Bacterial stocks of p6NST50 were prepared by adding 1 µl of the dialysed p6NST50 to 
40 µl electrocompetent DH10B E. coli cell suspension and allowed to stand on ice for 
1 minute. The mixture was then transferred to a 0.2 cm gap sterile electroporation 
cuvette and electroporated with Gene Pulser II (BIO-RAD, Munich, Germany) using a 
single impulse at 2.5 volts, 25 µF, 200 Ω for 4.5 – 5.0 ms. 1 ml of Super Optimal Broth 
medium (Table  3-11) was immediately added to the cuvette and the content was 
transferred to a new Eppendorf tube and incubated at 37 °C for 1 hour. Finally, 100 µl of 
the transformed E. coli was plated on Lysogeny Broth (LB)-Agar-containing ampicillin 
(Table  3-12) and incubated overnight at 37 °C. 
 
Table  3-11: Super Optimal Broth medium per 100 ml (Sambrook et al., 1989) 
Component Final Concentration 
Bacto-Tryptone 2 % (w/v) 
Bacto-Yeast Extract 0.5 % (w/v) 
Sodium Chloride  10 mM 
Potassium Chloride  2.5 mM 
Magnesium Chloride 10 mM 
Glucose 20 mM 
Deionized distilled water added up to 100 ml 
Aliquots were autoclaved and stored at -20 °C until use 
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Table  3-12: LB-Agar-containing ampicillin (Sambrook et al., 1989) 
Component Required Amount 
Sodium Chloride 1 % (w/v) 
Peptone 1 % (w/v) 
Bacto-Yeast Extract 0.5 % (w/v) 
Agar 1.5 % (w/v) 
Autoclaved and left to cool down. Later, ampicillin was added at a dilution of 1:1000 
Aseptically poured in 10-cm Petri dishes and left to solidify. Finally, stored at 4 °C until use 
 
Following overnight incubation, glycerol stocks of DH10B E. coli cells carrying the p6NST50 
lentiviral vector were prepared. A single bacterial colony was picked from the plate into 
6 ml LB medium-containing ampicillin (Table  3-13) and allowed to grow overnight at 37 °C 
with constant shaking (approximately 200 rpm). The bacterial suspension was 
subsequently centrifuged at 11,000 x g for 1 minute and bacterial pellet was 
re-suspended in bacterial freezing medium (Table  3-14). The mixture was transferred to 
cryovials and stored at -80 °C until further use. 
 
Table  3-13: LB medium-containing ampicillin (Sambrook et al., 1989) 
Component Required Amount 
Sodium Chloride 1 % (w/v) 
Peptone 1 % (w/v) 
Yeast Extract  0.5 % (w/v) 
Autoclaved and left to cool down. Later, ampicillin was added at a dilution of 1:1000   
Stored at 4 °C until use 
 
Table  3-14: Bacterial freezing medium 
Component Required Amount 
Glycerol 40 % (v/v) 
LB medium-containing ampicillin 60 % (v/v) 
Stored at 4 °C until use 
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3.2.2.2. Cloning of Human ESR2 into p6NST50 
 
• 1st step: Amplification of human ESR2 
A 1.5-kb DNA fragment encoding human ERβ (ESR2) (Appendix  7-2), kindly provided by 
Dr. Luisella Toschi (Schering AG, Berlin), was amplified using standard polymerase chain 
reaction (PCR). The reason for amplifying and subsequently cloning human ESR2 instead 
of a rat Esr2 in the studied rat cell line was due to two reasons: (1) availability of human 
ESR2 DNA fragment in the lab and (2) human ERβ shows approximately 89% identity in its 
translated region to the rat ERβ as compared to any other mammalian ERβ (Enmark and 
Gustafsson, 1999). Specific primer sequences used during amplification were designed to 
include ESR2 fragment flanked by Age1 – Xba1 restriction sites of the 9-kb p6NST50 
(Appendix  7-3). Primer pairs (Forward (Fwd) and Reverse (Rev)) were commercially 
synthesized by Biomers.net GmbH (Ulm, Germany) and the delivered lyophilized primers 
were re-suspended in High Performance Liquid Chromatography (HPLC) water 
(Applichem, Darmstadt, Germany) such that stock concentrations were adjusted to 
100 pmol/µl (100 µM) each. A primer mix was further prepared in which the final 
concentration of the forward and reverse primers was 10 pmol/µl (10 µM) each. The 
reaction mixture was set as shown in Table  3-15. The reaction took place in the Primus 
96 plus bench cycler (MWG-BIOTECH, Ebersberg, Germany) under cycling conditions 
recommended for Platinum® Pfx DNA Polymerase (Invitrogen, Karlsruhe, Germany) as 
shown in Table  3-16. 
 
Table  3-15: PCR amplification of ESR2 fragment (100 µl total volume per reaction) 
Component Required  
Volume 
10x Pfx Amplification Buffer (supplied with the Platinum® Pfx enzyme) 10 µl 
Deoxyribonucleotide triphosphate (dNTP) mixture  
(Final Concentration: 10 mM each) 
3 µl 
50 mM Magnesium Sulphate 2 µl 
Human ESR2 Primer Mix (Final Concentration: 10 µM each) 
Fwd: TAT ATA ACC GGT CCA TGG ATA TAA AAA ACT CAC CAT CTA G 
Rev: TAT ATA TCT AGA TCA CTG AGA CTG TGG GTT CT 
3 µl 
Human ESR2 DNA template 2 µl 
10x Platinum® Pfx DNA Polymerase (2.5 U/µl)  1 µl 
HPLC water added up to 100 µl 
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Table  3-16: Cycling conditions for Platinum® Pfx DNA Polymerase 
Step Temperature [°C] Required Time Number  
of Cycles 
1. Initial Denaturation 94.0 2 minutes 1x 
2. Denaturation of dsDNA 94.0 15 seconds 
3. Annealing 51.0 30 seconds 
4. Extension 68.0 1 minute and 40 seconds 
 
35x 
5. Further Extension 68.0 10 minutes 1x 
 
Subsequently, successful PCR verification was confirmed by agarose gel electrophoresis. 
0.2 volumes of 6x loading buffer (Table  3-17) was added to 5 µl of the resultant PCR 
reaction and the mixture was loaded on a 1 % agarose gel (+ 0.004 % ethidium bromide) 
against a Quick Load 1 kb DNA Ladder (50 µg/ml) (NEW ENGLAND BioLabs GmbH, 
Frankfurt am Main, Germany). The gel was left to run at 100 volts for 30 minutes in 
1x Tris-Acetate-EDTA Buffer (TAE buffer) (Table  3-18). Gel visualization took place under 
the UV-light (EpiChemi3 Benchtop Darkroom, UVP Ltd, Cambridge, UK) and gel image was 
captured using Labworks™ Image Acquisition and Analysis Software Version 4.6. 
 
Table  3-17: 6x loading stock buffer per 10 ml (Sambrook et al., 1989) 
 
Table  3-18: 50x TAE stock buffer per 1 Liter (Sambrook et al., 1989) 
Component Required Amount 
Sucrose 4 g 
Bromophenol Blue 25 mg 
Xylene Cyanol 25 mg 
Deionized distilled water added up to 10 ml 
Aliquots were stored at 4 °C 
Component Required Amount / Volume 
Tris 242 g 
Glacial acetic acid 57.1 ml 
0.5 M EDTA 100 ml 
Deionized distilled water added up to 1 Liter 
pH adjusted to 8.0 and stored at 4 °C 
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• 2nd step: Digestion of p6NST50 and ESR2 fragment using restriction enzymes 
After verifying the correct size of the ESR2 fragment, the remaining PCR product was 
purified using the peqGOLD Gel Extraction Kit (PEQLAB Biotechnologie GmbH, Erlangen, 
Germany) as per manufacturer’s protocol. The kit was used to purify the amplified ESR2 
fragment for further cloning steps. Concentration of the purified ESR2 fragment was then 
measured using the NanoDrop® ND-1000 UV-Vis Spectrophotometer (Tab: Nucleic Acid; 
Sample type: DNA-50). Finally, p6NST50 and the purified ESR2 fragment were digested by 
Age1 and Xba1 restriction enzymes (Fermentas, St. Leon-Rot, Germany) according to the 
reaction parameters shown below in Table  3-19. 
 
Table  3-19: Restriction enzyme digestion (100 µl total volume per reaction) 
Component Required Amount / Volume 
Purified ESR2 fragment / p6NST50 vector up to 6 µg each 
10x Restriction Buffer (supplied with restriction enzyme) 10 µl 
Restriction Enzyme 1 – 2 µl 
Deionized distilled water added up to 100 µl 
Incubated overnight at 37 °C  
 
Successful digestion was further verified by running the samples on a 1 % agarose gel, as 
previously described. Once again, the remaining products of the restriction enzyme 
digestion were purified using the peqGOLD Gel Extraction Kit (PEQLAB Biotechnologie 
GmbH, Erlangen, Germany). 
 
• 3rd step: Dephosphorylation of p6NST50 and ligation of ESR2 into p6NST50 
The purified linearized vector was dephosphorylated (i.e. removing phosphate group from 
the vector’s sticky ends to ensure proper ligation of the ESR2 fragment) using the Calf 
Intestinal Alkaline Phosphatase (CIAP) Enzyme (Promega GmbH, Mannheim, Germany). 
The dephosphorylation reaction was set up as shown in Table  3-20. 
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Table  3-20: Vector dephosphorylation (100 µl total volume per reaction) 
Component Required Volume 
Linearized p6NST50 The whole purified sample volume 
10x Phosphatase Buffer (supplied with enzyme) 10 µl 
CIAP Enzyme 2 µl 
Deionized distilled water added up to 100 µl 
Incubated at 37 °C for 30 minutes. Later, reaction was inactivated at 85 °C for 15 minutes   
 
Following vector dephosphorylation, DNA ligation was set up such that the vector to 
fragment molar ratio is 1:3. The reaction was prepared as shown in Table  3-21 using the 
T4-DNA-Ligase enzyme (Promega GmbH, Mannheim, Germany). For a negative control 
setup, an identical reaction mixture was arranged but devoid of any DNA fragment.  
 
Table  3-21: DNA fragment ligation into vector (10 µl total volume per reaction) 
Component Required Volume / Amount 
p6NST50 to ESR2 molar ratio 1 : 3 
10x T4-DNA-Ligase Buffer (supplied with enzyme) 1 µl 
T4-DNA-Ligase Enzyme (3U/µl) 0.3 µl 
Deionized distilled water added up to 10 µl 
Incubated overnight at 4 °C 
 
The resulting ligation product was then dialysed and transformed into DH10B E. coli cells 
(Section  3.2.2.1) and later plated on an LB-Agar-containing ampicillin. To verify successful 
ligation, ten bacterial colonies were randomly chosen for another restriction enzyme 
digestion (Table  3-19) using a different restriction enzyme, such as EcoR1 (Fermentas, St. 
Leon-Rot, Germany). The digestion product was visualized on a 1 % agarose gel, as 
previously described. From at least two positive clones, the new p6NST50 encoding ESR2 
(herein termed p6NST50 + ERβ) (Figure  3-2) was sequenced at MWG-BIOTECH 
(Ebersberg, Germany) to confirm sequence identity. 
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p6NST50:
MCS
CMV SFFV U3 ∆U3 R U5R U5 IRESRRE cPPT WPRE
Ψ
EGFP-Zeo
ESR2p6NST50 + ERβ:
 
Figure  3-2: Schematic linear illustration of p6NST50 encoding human ERβ transgene (ESR2). The transgenic 
human ERβ was cloned into Age1 - Xba1 restriction site of the parent lentiviral vector (p6NST50). The new 
vector is named p6NST50 + ERβ. Abbreviations: refer to Figure  3-1. 
 
3.2.2.3.  Plasmid Midi-Preparation 
Plasmid stocks were prepared according to QIAGEN® Plasmid Midi Kit (100) standard 
protocol (QIAGEN GmbH, Hilden, Germany). A transformed E. coli glycerol streak or a 
single bacterial colony from a streaked LB-Agar-containing ampicillin was inoculated into 
100 ml LB medium-containing ampicillin (Table  3-13) and grown at 37 °C for 16 hours with 
constant shaking (approximately 200 rpm). Bacterial cells were harvested using the 
Avanti® Centrifuge J-26 XP (BECKMAN COULTER™ GmbH, Krefeld, Germany) at 6000 x g 
for 15 minutes at 4 °C. Next, the bacterial pellet was re-suspended in 4 ml of the supplied 
Re-suspension Buffer. 4 ml of the supplied Lysis Buffer was then added with vigorous 
mixing (without vortexing). The mixture was incubated at room temperature for 5 
minutes. Then, 4 ml of chilled supplied Neutralization Buffer was added and the mixture 
was vigorously shaken and kept on ice for further 15 minutes. Subsequently, the mixture 
was centrifuged at 20,000 x g for 1 hour at 4 °C. Supernatant-containing plasmid DNA was 
promptly removed and centrifuged again at 20,000 x g for 15 minutes at 4 °C. The 
supernatant was then applied to the pre-equilibrated supplied QIAGEN-tip100 and bound 
to the resin by gravity flow. The QIAGEN-tip was washed twice with 10 ml of the supplied 
Wash Buffer and the plasmid DNA was eluted with 5 ml of the supplied Elution Buffer. To 
precipitate the eluted plasmid DNA, 3.5 ml 100 % isopropanol was added at room 
temperature and mixed well prior to centrifugation at 15,000 x g for 30 minutes at 4 °C. 
The supernatant was then discarded and the pellet-containing plasmid DNA was washed 
with 2 ml of 70 % ethanol and centrifuged at 15,000 x g for 10 minutes at 4 °C. Finally, 
plasmid DNA was air-dried and re-dissolved in 300 µl of Tris-EDTA (TE) Buffer, pH 8.0 
(Table  3-22) and stored at -20 °C until further use. 
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Table  3-22: TE Buffer per 1 Liter (Sambrook et al., 1989) 
Component Required Amount 
1 M Tris pH 8.0 10 ml 
0.5 M EDTA pH 8.0 2 ml 
Deionized distilled water added up to 1 Liter 
pH adjusted to 8.0 and stored at room temperature 
 
3.2.3. Production of Viral Particles and Transduction of Target Cells  
All viral-related experiments were conducted according to Level 2 Biosafety requirements 
and in collaboration with Professor Dirk Lindemann’s laboratory (Institute of Virology, 
Medical Faculty Carl Gustav Carus, TU-Dresden, Germany). 
 
3.2.3.1.  Determination of Zeocin™ Sensitivity 
Since the employed lentiviral-based plasmids encode a Zeocin marker gene cassette 
(Figure  3-1 and Figure  3-2), minimal Zeocin™ concentration (Invitrogen, Karlsruhe, 
Germany) required to kill almost 100 % of RN46A-B14 cells had to be initially established. 
RN46A-B14 cells were grown in two 6-well cell culture plates for 24 hours. The medium 
was then replaced with fresh medium-containing Zeocin™ in a concentration gradient 
(500, 250, 125, 60, 30, 15, 8, 4, 2, 1, 0.5 and 0 µg/ml). Medium-containing Zeocin™ was 
replenished every 3 - 4 days and the percentage of surviving cells was roughly determined 
under the microscope. Finally, the Zeocin™ concentration that killed almost 100 % of cells 
within 2 weeks was defined and subsequently used to culture raphe nuclei-derived cells 
bearing p6NST50 or p6NST50 + ERβ. 
 
3.2.3.2. Production of Viral Particles 
Infectious lentiviral particles are generally produced via three main lentiviral genes that 
are encoded in the retroviral genome. Those include: (1) Gag: encodes a polyprotein 
required for viral capsid assembly, (2) Pol: encodes four main enzymes, such as protease, 
integrase, reverse transcriptase and RNase H required for reverse transcription of the 
RNA genome and finally (3) Env: encodes the necessary viral glycoproteins required for 
budding at cellular membranes (Richter et al., 2009). Since p6NST50 and p6NST50 + ERβ 
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lack all of the aforementioned viral structural genes, two additional plasmids encoding 
the lentiviral structural genes were employed, as illustrated in Figure  3-3. 
 
 
CMVEnv (pcoPE1):
Env
bGH pA
CMVGag / Pol (pCD/NL-BH):
Gag
Pol
bGH pA
 
Figure  3-3: Schematic linear illustration of the lentiviral packaging constructs employed in the present 
study. Both Gag and Pol are represented in one construct, namely pCD/NL-BH. The Env is represented in a 
different construct, namely pcoPE1. Both constructs were kindly provided by Professor Dirk Lindemann. 
Abbreviations: CMV: cytomegalo virus immediate early enhancer-promoter; bGH pA: Bovine Growth 
Hormone and Polyadenylation element serving as a sequence for termination of transcription.  
 
Stocks of all viral plasmids were prepared using QIAGEN® Plasmid Midi-Preparation Kit 
(Section  3.2.2.3) and stock concentrations were adjusted to 1 µg/µl. Production of viral 
particles was conducted over a period of four days as follows: 
 
• Day 1: Plating the viral packaging cell line 
The HEK-293T cells were used as the standard cell line for packaging and producing 
infectious viral particles. HEK-293T cells were plated at a density of 6 x 106 cells in a 10-cm 
cell culture dish in 8 ml aliquots of medium and were left to grow overnight at 37 °C and 
5 % CO2. 
 
• Day 2: Transfection of HEK-293T cells with all viral plasmids 
HEK-293T cells were transfected with all employed viral plasmids using the standard 
polyethylenimine (PEI) transfection reagent (Sigma-Aldrich, Hambrug, Germany). PEI is an 
organic polymer with a high cationic-charge potential. PEI binds to nucleic acids and 
ionically condenses them to aid binding to anionic surface receptors; hence promoting 
the process of endocytosis (Boussif et al., 1995). At first, basal phenol red-free 
DMEM / F12 medium (i.e. medium with no FCS and other additives) was used to prepare 
the transfection solution. Stock and working PEI solutions were prepared as shown in 
Table  3-23 and Table  3-24, respectively. Subsequently, the transfection solution for each 
10-cm cell culture dish was set up as shown in Table  3-25. 
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Table  3-23: PEI stock solution (100 mg/ml) per 10 ml 
Component Required Amount / Volume 
PEI 1 g 
Deionized distilled water added up to 10 ml 
Filter sterilized and stored at 4 °C 
 
Table  3-24: PEI working solution (1 mg/ml) per 10 ml 
Component Required Volume 
PEI stock solution (100 mg/ml) 100 µl  
Deionized distilled water added up to 10 ml 
Aliquots were stored at 4 °C 
 
Table  3-25: Transfection solution per 10-cm cell culture dish 
Component Required Volume 
PEI working solution (1 mg/ml) 45 µl 
Basal phenol red-free DMEM / F12 medium 955 µl 
Total Volume 1000 µl 
 
Meanwhile, all viral plasmids (i.e. p6NST50 or p6NST50 + ERβ together with the 
Gag/Pol/Env plasmids) were also prepared in basal phenol red-free DMEM / F12 medium 
such that the total plasmid concentration per 10-cm cell culture dish was 15 µg. The 
required co-transfection mixture was prepared as shown in Table  3-26. 
 
Table  3-26: Co-transfection mixture per 10-cm cell culture dish 
Viral plasmid 
(Stock Concentration: 1 µg/µl)  
Required Amount / Volume 
p6NST50 / p6NST50 + ERβ 7 µg each 
pcoPE1 encoding the Env gene 1 µg 
pCD/NL-BH encoding the Gag and Pol genes 7 µg 
Basal phenol red-free DMEM / F12 medium 985 µl  
Total Volume 1000 µl 
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Rapidly, the prepared PEI solution was added to the viral plasmid mixture at a ratio of 1:1 
and vortexed. The mixture was incubated at room temperature for 20 minutes. 
Meanwhile, culture medium was aspirated from the HEK-293T cells and replaced with 
4 ml of phenol red-free DMEM / F12 medium containing 15 % FCS only and no further 
supplements. After 20 minutes, the 2 ml transfection mixture was added to the dish in a 
drop-wise fashion and cells were finally incubated overnight at 37 °C and 5 % CO2. 
 
• Day 3: Induction of HEK-293T cells 
Since every third atom of PEI is a protonable amino nitrogen, amine protonation results in 
counter-ion influx followed by lowering of the cell’s osmotic potential once the cationic 
complex (i.e. PEI + plasmids) has been endocytosed by the cell. Osmotic swelling bursts 
the vesicle releasing the polymer-plasmid complex into the cytoplasm (Akinc et al., 2005). 
Based on the publication of Olsen and Sechelski (1995), an adapted step was included to 
increase retroviral production prior to harvesting of viral particles (Olsen and Sechelski, 
1995). 120 µl of 500 mM sodium butyrate (Table  3-27) was added to each 10-cm cell 
culture dish to obtain a final working concentration of 10 mM sodium butyrate per dish. 
Cells were further incubated for 6 - 8 hours at 37 °C and 5 % CO2. Induction was then 
stopped by aspirating out medium and adding, in a drop-wise fashion, new phenol 
red-free DMEM / F12 medium containing 10 % FCS only and no further supplements. Cells 
were finally incubated overnight before harvesting supernatant-containing viral particles. 
 
Table  3-27: 500 mM stock solution of sodium butyrate in 50 ml PBS 
Component Required Amount / Volume 
n-Butyric Acid, Sodium Salt 2.75 g 
PBS added up to 50 ml 
Filter sterilized and aliquots were stored at 4 °C 
 
• Day 4: Harvesting of viral particles and storage 
HEK-293T supernatants-containing infectious viral particles were filter-sterilized using a 
0.45 µm nitrocellulose filter and aliquots of the sterilized cell-free supernatants were 
stored at -80 °C until further use. 
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3.2.3.3. Transduction (Infection) of Target Cells 
In virology, transduction or infection means the incubation of target cells with the 
produced infectious viral particles resulting in the entry of the virus into the host cell and 
eventually integrating in its cellular genome. This process proceeded as follows: 
 
• Day 1: Plating target cells 
RN46A-B14 cells and HT-1080 cells (the reference cell line) were plated in 12-well cell 
culture plates at a density of 1 x 105 and 2 x 104 cells per well, respectively, in 1 ml 
aliquots of medium and allowed to grow overnight. 
 
• Day 2: Transduction of target cells 
For transduction of target cells, all viral stock dilutions were prepared in phenol red-free 
DMEM / F12 medium containing 10 % FCS only and no further supplements. Medium was 
aspirated and replaced with either 2 ml of undiluted (UD) viral stocks or 1:10 dilution of 
viral stocks. For the negative controls (i.e. untransduced cells), viral particles were 
omitted. Cells were incubated for 6 - 8 hours. Transduction was ultimately stopped by 
incubating cells in their own medium (Table  3-1) for 72 hours prior to cell harvesting and 
flow cytometry analysis. 
 
To downgrade transduced cells from Biosafety Level 2 to Biosafety Level 1, supernatants 
of cultured transduced cells were harvested after 72 hours of transduction and 
filter-sterilized using 0.45 µm nitrocellulose filters. The cell-free filtrate was later 
subjected to flow cytometry analysis. 
 
3.2.3.4. Fluorescence-Activated Cell Sorting Analysis 
Fluorescence-Activated Cell Sorting (FACS) is a technique used to multiparametrically 
analyze cells by suspending them in a liquid stream and passing them through a beam of 
laser light (Givan, 2004). In principle, detectors are placed such that one lies in line with 
the beam of laser light to measure forward scatter and another lies perpendicular to the 
beam to measure the side scatter. Additionally, one or more built-in fluorescent detectors 
are set to measure emitted fluorescence intensity from fluorescently-labeled cells. 
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Scattered and emitted light from cells are then converted to digital values. By analyzing 
these values, it is possible to measure and analyze the physical and chemical properties of 
the cells in addition to the intensity of fluorescence emitted from labeled cells (Basu et 
al., 2010). 
 
Here, the efficiency of the transduction process was analyzed according to the percentage 
of target cells expressing the reporter gene, enhanced green fluorescent protein (EGFP), 
encoded in the employed lentiviral transfer vectors (Figure  3-1 and Figure  3-2). Following 
72 hours of transduction, cells were harvested in non-sterile FACS tubes (i.e. 
polypropylene round-bottom tubes) at 1500 rpm for 5 minutes. The resulting supernatant 
was carefully discarded and cells were re-suspended in 200 µl FACS Buffer (PBS containing 
1 % (v/v) FCS). Cell suspensions were ultimately analyzed via the Becton Dickinson 
FACSCalibur™ Flow Cytometer (BD Biosciences, Heidelberg, Germany). Data were 
processed using the Becton Dickinson CellQuest™ Software (BD Biosciences, Heidelberg, 
Germany). During the data processing, EGFP-expressing cells were gated in Region (R2) to 
distinguish them from the flow of heterogeneous cell population.  
 
3.2.4. Luciferase Reporter Gene Assays 
The functional activity of both endogenous ERβ and transgenic human ERβ in the rat 
raphe nuclei-derived cell lines were assessed using standard reporter gene assays. The 
degree of estrogenicity (i.e. the transactivational activity) of the flavonoids was also 
examined. In principle, the assay basically tests for the initiation of a successful 
ligand-dependent activation of ERβ via the classical ERE pathway through the expression 
of a reporter plasmid (Figure  3-4). In this study, the 2x-ERE-tk-Luc plasmid, which contains 
the firefly luciferase reporter gene under the control of a double ERE-dependent 
promoter was utilized. The plasmid was kindly provided by Dr. Luisella Toschi (Schering 
AG, Berlin). 
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Figure  3-4: A simple schematic model of the reporter gene assay utilized in the present study. 
17β-Estradiol (presented in bright green) enters the cell and binds to respective hsp90-inactivated ERs, 
where a conformational change occurs. Free hsp90-activated bound ERs shuttle to the nucleus and binds to 
respective EREs, hence activating the transcriptional machinery of the firefly luciferase reporter gene. 
Alternatively, test substances (represented in orange) can enter the cell and either act as (A) estrogenic or 
(B) non-estrogenic substances, hence assessing their affinity for ERs and downstream estrogenicity. 
Abbreviations: E2, 17β-estradiol; hsp90, heat shock protein 90; ER, estrogen receptor; ERE, estrogen 
responsive elements; tk, thymidine kinase promoter; SV-40, Simian Virus-40; mRNA, messenger RNA. 
 
3.2.4.1. Day 1: Plating Target Cells 
RN46A-B14 cells (either untransduced or transduced with p6NST50) or RNDA cells (i.e. the 
RN46A-B14 cells transduced with p6NST50 + ERβ) were initially washed three times with 
PBS. In 24-well cell culture plates, cells were plated at a density of 1 x 105 cells per well in 
500 µl aliquots of medium. The medium was prepared as shown in Table  3-28.  As 
noticed, the 10 % FCS component in the original medium was replaced by 5 % DCC-FCS 
(FCS pre-treated with dextran-coated charcoal) to eliminate any steroid background 
generated from FCS. 
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Table  3-28: Phenol red-free DMEM / F12 medium containing 5 % DCC-FCS 
Cell Line Media Additives / Final Concentration 
(in phenol red-free DMEM / F12 medium) 
Temperature & 
5 % CO2 
Hygromycin B (50 mg/ml)                    100 µg/ml 
G418 (50 mg/ml)               250 µg/ml 
DCC-FCS                                                5 % (v/v) 
RN46A-B14 cells 
or  
RNDA cells 
Penicillin / Streptomycin 1 % (v/v) 
33 °C 
 
 
3.2.4.2. Day 2: Transient Transfection of Target Cells 
Initially, stock concentrations of reporter plasmid (2x-ERE-tk-Luc) were prepared using 
QIAGEN® Plasmid Midi-Preparation Kit (Section  3.2.2.3) and concentration was measured 
using the NanoDrop® ND-1000 UV-Vis Spectrophotometer (Tab: Nucleic Acid; Sample 
type: DNA-50). Transfection mixture was prepared using 1x Serum-Free Defined Medium 
(SFDM) (Table  3-29). Cells were transiently transfected with 0.6 µg reporter plasmid per 
well. 1,2-Dioleoyl-3-Trimethylammonium-Propane (DOTAP) was used as the standard 
liposomal transfection reagent, such that ratio of reporter plasmid to DOTAP was 
1 µg : 3 µl, respectively (Table  3-30). The transfection mixture was incubated for 12 
minutes at room temperature. Meanwhile, cells were washed twice with PBS. Finally, 
500 µl of the transfection mixture was added to each well and incubated at 33 °C and 5 % 
CO2 for 6 hours. Transfection medium was then aspirated and cells were incubated 
overnight in medium-containing 5 % DCC-FCS. 
 
Table  3-29: 10x SFDM per 500 ml DMEM / F12 medium 
Component Required Amount 
Insulin-Transferrin-Sodium Selenite Media Supplement 
solution 
- 
1 mM hydrocortisone solution (Final Concentration: 10-8 M) 
(prepared using deionized distilled water) 
50 µl 
Putrescine dihydrochloride (Final Concentration: 1 mg/l) 5 mg 
 
Filter sterilized and aliquots were stored at -20 °C 
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Table  3-30: Standardized reporter gene transfection mixture  
Component Required Amount / Volume 
(per well per 500 µl) 
Reporter Plasmid 0.6 µg 
DOTAP 1.8 µl 
1x SFDM added up to 150 µl 
Incubated for 12 minutes at room temperature 
Completed volume to 500 µl using 1x SFDM 
 
3.2.4.3. Day 3: Treatment of Target Cells 
Stock concentrations of all control and test substances (Table  3-31) were initially 
dissolved in DMSO. Final concentrations were prepared in medium containing 
5 % DCC-FCS ensuring that the final DMSO concentration used was 0.1 %. In all 
experiments, DMSO treatment served as the standard carrier control treatment. RNDA 
cells were initially treated with increasing concentrations of E2 (100 fM - 100 nM) to 
establish a sigmoidal E2-dose response relationship and determine the optimal E2 
concentration that shall be used as the positive control concentration in subsequent 
experiments. Accordingly, 10 nM E2 served as the standard positive control treatment in 
all experiments.  
 
Untransduced RN46A-B14 cells as well as RNDA cells were treated with 0.1 % DMSO or 
10 nM E2 to verify the expression levels of endogenous ERβ versus expression levels of 
transgenic ERβ. To further exclude non-specific transgenic ERβ effects, RN46A-B14 cells 
transduced with p6NST50 and RNDA cells were treated with 0.1 % DMSO or 10 nM E2. To 
further examine whether the observed effects were exclusively mediated by the activated 
transgenic ERβ, RNDA cells were treated with increasing concentrations (1 nM - 1 µM) of 
the ERα agonist (Propyl pyrazole triol) or the ERβ agonist (Diarylproprionitril).  
 
The transactivational activity of the flavonoids (i.e. the isoflavones and the 
naringenin-type flavanones) on the transgenic ERβ in RNDA cells was then scrutinized 
using an increasing range of concentrations (10 nM - 10 µM) to obtain dose-response 
relationships. Moreover, to determine whether the observed effects involve the 
interaction of the flavonoid with the transgenic ERβ, RNDA cells were co-treated with 
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1 µM of each flavonoid and 500 nM of the pure estrogen receptor antagonist, 
Fulvestrant. The Fulvestrant dose represented a 50-fold molar excess of 10 nM E2, which 
corresponded to 10x effective excess of antagonist (Wakeling and Bowler, 1987; Wakeling 
and Bowler, 1992). To further examine possible antiestrogenic properties, cells were 
co-treated with 10 nM E2 and 1 µM of each flavonoid. Total final volume of all reactions 
was 500 µl per well and cells were treated for 24 hours. 
 
Table  3-31: Substances used in luciferase reporter gene assays 
Substances Stock  
Concentration 
Final  
Concentration 
DMSO (Carrier Control Treatment) - 0.1 % 
17β-Estradiol Dose Response: 100 pM - 100 µM 
Positive Control: 10 µM 
100 fM - 100 nM 
10 nM 
Fulvestrant 1 mM 500 nM 
Propyl pyrazole triol 1 µM - 1 mM 1 nM - 1 µM 
Diarylproprionitril 1 µM - 1 mM 1 nM - 1 µM 
Genistein 10 µM - 10 mM 10 nM - 10 µM 
Daidzein 10 µM - 10 mM 10 nM - 10 µM 
Equol 10 µM - 10 mM 10 nM - 10 µM 
Naringenin 10 µM - 10 mM 10 nM - 10 µM 
8-Prenylnaringenin 10 µM - 10 mM 10 nM - 10 µM 
7-(O-prenyl)naringenin-4'-acetate 10 µM - 10 mM 10 nM - 10 µM 
6-(1,1-Dimethylallyl)naringenin 10 µM - 10 mM 10 nM - 10 µM 
 
3.2.4.4. Day 4: Measurement of Luciferase Activity 
Treated cells were washed twice with PBS then lysed by adding 100 µl 1x Promega 
reporter lysis buffer (diluted from a supplied 5x stock solution using deionized distilled 
water) (Promega, Mannheim, Germany). Plates were then incubated at -80 °C for 30 
minutes. Cells were allowed to thaw at room temperature and cell lysates were collected 
into Eppendorf tubes.  
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To normalize the data, protein concentration was determined using the bicinchoninic acid 
(BCA) standard assay (VWR, Darmstadt, Germany). For protein determination, BSA stock 
solution with 1 µg/µl BSA (dissolved in 0.15 M sodium chloride solution) was initially 
prepared and a BSA standard series was arranged as shown in Table  3-32. 10 µl of each 
standard (1 to 7) was pipetted horizontally and in triplicates into a clear 96 well 
flat-bottomed plate. 10 µl of the sample cell lysates and the 1x Promega reporter lysis 
buffer (negative control) were also pipetted in the same plate and in the same manner. 
Subsequently, 250 µl of the BCA mixture (supplied BCA solution and copper (II) sulphate 
solution used at a ratio of 50:1, respectively) was added to each well and incubated at 
37 °C for 30 minutes. BCA was then measured at an absorbance of 565 nm using the 
Infinite F200 spectrophotometer machine and the Magellan Software (TECAN, 
Männedorf, Switzerland).  
 
Table  3-32: BSA standard series used for luciferase reporter gene assays 
Tube # 0.15 M NaCl  1 µg/µl BSA solution 
(dissolved in 0.15 M NaCl) 
Final BSA Concentration per well 
1 - 10 µl 1 µg/µl 
2 2 µl 8 µl 0.8 µg/µl 
3 4 µl 6 µl 0.6 µg/µl 
4 6 µl 4 µl 0.4 µg/µl 
5 8 µl 2 µl 0.2 µg/µl 
6 9 µl 1 µl 0.1 µg/µl 
7 10 µl - 0 µg/µl 
 
To measure luciferase activity using the standard Luciferase Assay System (Promega, 
Mannheim, Germany), 10 µl of cell lysates were pipetted vertically and in duplicates into 
a white 96 well flat-bottomed plate. Subsequently, 50 µl of the supplied Promega 
Luciferase Assay Substrate (delyophilized using the supplied Promega Luciferase Assay 
Buffer) was added to each well and was measured immediately using the Infinite F200 
spectrophotometer machine; however no absorbance was specified in this case since the 
reaction is bioluminescent. Data analyses and statistical procedures were conducted as 
explained in Section  3.2.9.1. 
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3.2.5. Gene Expression Analysis 
Quantitative real-time PCR has proven to be a highly sensitive approach to amplify and 
simultaneously quantify the expression and regulation of target mRNA in cells or tissues. 
The general idea of quantitative real-time PCR is initiated by converting small amounts of 
RNA into cDNA by reverse transcription. The resulting cDNA is further amplified over a 
specified number of cycles. The newly synthesized PCR products are easily detected via 
the use of SYBR® Green I fluorescence dye that specifically binds double-stranded DNA. 
By plotting fluorescence against the cycle number on a logarithmic scale, relative 
concentrations of the amplified DNA are determined during the exponential phase of the 
reaction. A threshold is usually determined to detect fluorescence above background. The 
cycle at which the fluorescence from a sample crosses the threshold is usually determined 
by the Cycle Threshold Value (CT-value) [Reviewed in (VanGuilder et al., 2008)]. 
 
Quantitative real-time PCR also determines the melting temperature of the synthesized 
PCR products following the amplification reactions. The nucleotide composition as well as 
the length of the synthesized DNA product determines the melting temperature of the 
product. In principle, all PCR products for the same primer pair should show the same 
melting temperature. Since SYBR® Green I indiscriminately binds to double-stranded DNA 
including primer dimers, similar melting temperatures amongst all samples act as a 
reliable quality control (Nolan et al., 2006).  
 
For accurate quantification of gene expression, it is necessary to correct the expression of 
the gene of interest to a ubiquitously expressed gene, referred to as the internal 
reference gene. This correction allows for accurate comparison of gene expression 
amongst various samples, given that the expression of the internal reference gene is 
stable across all test samples, even under experimental conditions (Eisenberg and 
Levanon, 2003). In this study, the rat ribosomal protein S18 (Rps-18) (Chan et al., 1991) 
was used as the standard internal reference gene. 
  
3.2.5.1. RNA Isolation from Adherent Rat Raphe Nuclei-Derived Cells 
RNA isolation was carried out using peqGOLD TriFast™ standard protocol 
(http://www.peqlab.com/wcms/en/pdf/30-2010_m.pdf) (PEQLAB Biotechnologie GmbH, 
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Erlangen, Germany). Unless otherwise stated, all steps were carried out at room 
temperature and all working surfaces were sprayed with RNAse-Exitus Plus™ (Applichem, 
Darmstadt, Germany) to eliminate any RNase contaminations. 
 
• Homogenization: 
Adherent cells were trypsinized and harvested (Section  3.2.1.1). Cell pellet was 
re-suspended in 1 ml peqGOLD TriFast™ reagent and incubated for 5 minutes at room 
temperature to dissociate nucleoprotein complexes. 
 
• Phase separation: 
The re-suspended cell pellet was transferred to an appropriate Eppendorf tube and 200 µl 
of pure chloroform was added. The mixture was then vigorously shaken (by hand) for 15 
seconds at room temperature and left for a minimum of 10 minutes till a visual 
separation of phases was noticed. At this point, samples were centrifuged using the 
Biofuge fresco (Heraeus Instruments, Leipzig, Germany) at 12,000 x g for 5 minutes at 
4 °C. Centrifugation clearly separated the mixture into a lower red phase 
(phenol-chloroform phase), an interphase and a colourless upper aqueous phase. 
 
• Precipitation of RNA: 
Since the RNA is exclusively separated into the aqueous upper phase, the aqueous phase 
was collected into a new Eppendorf tube and the other two phases were kept at -80 °C. 
RNA was then precipitated with 500 µl 100 % isopropanol. Samples were briefly vortexed 
and kept at 4 °C for a minimum of 15 - 20 minutes. Samples were then centrifuged at 
12,000 x g for 10 minutes at 4 °C. The RNA pellet formed a white gel-like precipitate on 
the bottom and sides of the tube. 
 
• Washing of RNA: 
Supernatant was carefully removed and RNA pellet was washed twice with 1 ml 75 % 
ethanol and further centrifuged at 12,000 x g for 10 minutes at 4 °C. The 75 % ethanol in 
this step was prepared using diethylpyrocarbonate (DEPC)-treated water to inactivate 
possible RNase enzymes. 
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• Solubilization of RNA: 
RNA pellet was allowed to air-dry. Pellet was then re-suspended using 20 - 50 µl 
DEPC-treated water (depending on pellet size). Samples were stored at -80 °C until 
further use. 
 
• Measuring RNA concentration and RNA quality control: 
RNA concentration was measured using the NanoDrop® ND-1000 UV-Vis 
Spectrophotometer (Tab: Nucleic Acid; Sample type: RNA-40). To further assess the 
quality of the isolated RNA sample, 0.2 volumes of 6x loading buffer (Table  3-17) was 
added to 0.5 - 1 µg of each isolated RNA sample and the mixture was loaded onto a 1 % 
agarose gel (+ 0.004 % ethidium bromide). The gel was left to run at 100 volts for 30 
minutes in 1x TAE buffer (Table  3-18). Gel visualization took place under the UV-light 
(EpiChemi3 Benchtop Darkroom, UVP Ltd, Cambridge, UK) and gel image was captured 
using Labworks™ Image Acquisition and Analysis Software Version 4.6. 
 
3.2.5.2. DNase Digestion and Quantitative Real-Time PCR 
Genomic rat DNA was eliminated from the isolated RNA samples by incubating the 
sample with RQ1 RNase-Free DNase (Promega, Mannheim, Germany) for 30 minutes at 
37 °C in Primus 96 plus bench cycler (MWG-BIOTECH, Ebersberg, Germany). Reaction 
mixture was prepared as shown in Table  3-33. Following the incubation, the thermostable 
Taq DNA polymerase (Recombinant) (5 U / µl) (Invitrogen, Karlsruhe, Germany) was used 
in a quantitative real-time PCR (Table  3-34) to verify proper digestion of any genomic rat 
DNA via the cycling conditions described in Table  3-35. An independent positive control 
rat cDNA was included for quality control. A piece of the rat internal reference 
gene, Rps-18, was amplified as a test for the completeness of the digest. The reaction was 
carried out in low 96-well white un-skirted PCR plates (BIO-RAD, Munich, Germany). The 
plate was briefly centrifuged using the Megafuge 2.0R (Heraeus Instruments, Leipzig, 
Germany) and subsequently placed in the CFX96™ Real-Time System (BIO-RAD, Munich, 
Germany) and results were analyzed using the Bio-Rad CFX Manager Version 1.6. 
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Table  3-33: DNase digestion (10 µl total volume per reaction) 
Component Required Amount / Volume 
per reaction 
RNA sample 3 µg 
10x PCR Buffer (Sambrook et al., 1989) 1 µl  
RNaseOUT™ Recombinant Ribonuclease Inhibitor (40 U / µl) 0.5 µl 
RQ1 RNase-Free DNase (1 U / µl) 1 µl 
HPLC water added up to 10 µl 
Incubated at 37 °C for 30 minutes 
 
Table  3-34: Quantitative real-time PCR (20 µl total volume per reaction) 
Component Required Volume 
per reaction  
Quantitative real-time PCR Product 1 µl 
10x PCR Buffer (without Magnesium Chloride) (Invitrogen)  
including 2.4x SYBR® Green I (Sigma) 
2 µl 
50 mM Magnesium Chloride 0.8 µl 
dNTP mixture (Final Concentration: 2.5 mM each) 0.8 µl 
Rat Rps-18 primer mix (Final Concentration: 10 µM each) 
Fwd: CGT GAA GGA TGG GAA GTA TAG C 
Rev: TAT TAA CAG CAA AGG CCC AAA G 
0.6 µl 
Taq DNA Polymerase (Recombinant) (5 U / µl) 0.06 µl 
HPLC water added up to 20 µl 
 
Table  3-35: Cycling conditions for quantitative real-time PCR in CFX96™ Real-Time System 
Step Temperature [°C] Required Time Number  
of Cycles 
1. Initial Denaturation 95.0 3 minutes 1x 
2. Denaturation of dsDNA 95.0 10 seconds 
3. Annealing 60.0 10 seconds 
4. Extension 72.0 20 seconds 
 
40x 
5. Melting of dsDNA 95.0 10 seconds 1x 
6. Melt Curve 65.0 - 95.0 in 0.5 steps 5 seconds 1x 
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3.2.5.3. DNase Inactivation, cDNA Synthesis and Quantitative Real-Time PCR 
1 µl EDTA was added to the DNase digestion product to inactivate the RQ1 RNase-Free 
DNase. The samples were incubated at 80 °C for 3 - 5 minutes in Primus 96 plus bench 
cycler (MWG-BIOTECH, Ebersberg, Germany). Then, 10 µl of cDNA synthesis reaction 
mixture (Table  3-36) was added and samples were incubated at 42 °C for 1 hour in 
Primus 96 plus bench cycler (MWG-BIOTECH, Ebersberg, Germany). 
 
20 µl of HPLC water was finally added to each reaction and once again, the thermostable 
Taq DNA polymerase (Recombinant) (5 U / µl) was used in a quantitative real-time PCR 
(Table  3-34) to verify successful cDNA synthesis using the same cycling conditions 
described in Table  3-35. Again, an independent positive control rat cDNA was included for 
quality control. A piece of the rat internal reference gene, Rps-18, was also amplified as a 
test for the completeness of the synthesis. Prepared rat cDNA samples were then stored 
at -20 °C until further use. 
 
Table  3-36: cDNA synthesis reaction mixture (10 µl total volume per reaction) 
Component Required Volume 
Product of DNase digestion reaction 10 µl 
Oligo (dT)18-primers (Final Concentration: 100 µM) 1 µl 
dNTP mixture (Final Concentration: 10 mM each) 2 µl 
10x PCR Buffer (Sambrook et al., 1989) 1 µl 
50 mM Magnesium Chloride 1 µl 
RNaseOUT™ Recombinant Ribonuclease Inhibitor (40 U / µl) 0.5 µl 
MMLV-RT (200 U/µl) 1 µl 
HPLC water added up to 20 µl 
Incubated at 42 °C for 1 hour 
20 µl HPLC water was further added (i.e. final total volume per cDNA sample was 40 µl) 
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3.2.5.4. Primer Design 
Genomic DNA sequences of target genes (Table  3-37) were extracted from the UCSC 
Genome Browser Database (http://genome.ucsc.edu/) (Kent et al., 2002; Rhead et al., 
2010). The sequences were employed in Primer3 Version 2.2.3 
(http://frodo.wi.mit.edu/primer3/) (Rozen and Skaletsky, 2000) for primer design. Primers 
were designed to flank the last intron at the 3’ end of the sequence. The most prominent 
parameters for the primer design in the Primer3 program were: (1) melting temperature 
(59 °C - 61 °C), (2) amplicon size (150 - 220 bp), (3) primer length (18 - 20 bp) and (4) at 
least one GC-clamp at the 3’ end of the primer  
 
Using the Blat- and in silico PCR tools provided within the UCSC Genome Browser website, 
a primer sequence match search against the rat genome was performed to evaluate the 
specificity of the designed primers and their exact location on the genomic sequence. 
Finally, the primer pairs of each target gene (Table  3-37) were commercially synthesized 
by Biomers.net GmbH (Ulm, Germany). 
 
Table  3-37: Primer sequences utilized throughout the study 
Gene Symbol: Description Accession ID Primer Sequences (Fwd and Rev) 
ESR2: Human estrogen 
receptor-beta * 
NM_001040276 Fwd: GGC ATC TCC TCC CAG CAG CAA TCC     
Rev: TCA GCA TCT CCA GCA GCA GGT CAT A 
Esr2: Rat estrogen 
receptor-beta * 
NM_012754 Fwd: CTA CAG AGA GAT GGT CAA AAG TGG A  
Rev: GGG CAA GGA GAC AGA AAG TAA GT  
Rps-18: Rat ribosomal 
protein S18 * 
NM_213557 Fwd: CGT GAA GGA TGG GAA GTA TAG C 
Rev: TAT TAA CAG CAA AGG CCC AAA G 
Cml-5: Rat camello-like 5 NM_080884 Fwd: GGA TAG CGA AAG CAC TGG TC   
Rev: AGC AGA AGG GAA AGC ATA CG 
Sox-18: Rat sex determining 
region Y-box 18 
NM_001024781 Fwd: CTT TAT GGT GTG GGC GAA G 
Rev: AGG CCG GTA CTT GTA GTT GG 
Krt-19: Rat keratin, type I 
cytoskeletal 19 
NM_199498 Fwd: ATG AGC TGA ACA CCC AGG TC 
Rev: CAC CTT GGA TGT GTG ACA GC 
Nefm: Rat neurofilament, 
Medium polypeptide 
NM_017029 Fwd: ATC GAG ATC GCC GCA TAT AG 
Rev: TGT GTT GGA CCT TGA GCT TG 
Zdhhc-2: Rat zinc finger, 
DHHC-type containing 2 
NM_145096 Fwd: GCA ACC CTG CAT TAA CTA TGG 
Rev: TTG ATC CCC ATC ACT GAA GAC 
Slc6a4: Rat solute carrier 
family 6 member 4 
NM_013034 Fwd: TCT TGG GCT ACT GCA TAG GG 
Rev: CCT CTC CCA GGG TGT GTT AC 
* Previously designed primer pairs in the lab 
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3.2.5.5. PCR Optimization and PCR Efficiency 
As previously mentioned, the delivered lyophilized primers were re-suspended using a 
given volume of HPLC water such that stock concentrations were adjusted to 100 pmol/µl 
(100 µM) each. For each gene, a primer mix was prepared in which the final 
concentration of the forward and reverse primers was 10 pmol/µl (10 µM) each. For 
optimal PCR conditions, primer and magnesium chloride volumes were optimized such 
that 3.36 µl of the reaction mixture (Table  3-38) were pipetted into each well of a 96-well 
white un-skirted PCR plate (BIO-RAD, Munich, Germany) using a 4 x 4 matrix scheme 
Table  3-39. 
 
Table  3-38: Reaction mixture per well for the primer / magnesium chloride optimization 
Component Required Volume 
10x PCR Buffer (without Magnesium Chloride) (Invitrogen)  
including 2.4x SYBR® Green I (Sigma)  
2 µl 
dNTP mixture (Final Concentration: 2.5 mM each) 0.8 µl 
A rat cDNA sample 0.5 µl 
Taq DNA Polymerase (Recombinant) (5 U / µl) 0.06 µl 
Total Volume 3.36 µl 
 
 
 
Table  3-39: 4 x 4 matrix scheme for the primer / magnesium chloride optimization 
 
 
 0.8 1.2 1.6 2 
0.4 15.44 15.04 14.64 14.24 
0.6 15.24 14.84 14.44 14.04 
0.8 15.04 14.64 14.24 13.84 
1.2 14.64 14.24 13.84 13.44 
 
Primer Mix 
in µl 
(Fwd + Rev) 
(10 µM 
each) 
 [µl] 
HPLC water [µl] pipetted to 
complete 
total volume per well to 
20 µl 
Magnesium Chloride (50mM) in µl 
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The PCR reaction was carried out in the CFX96™ Real-Time System (BIO-RAD, Munich, 
Germany) using the cycling conditions described in Table  3-35. Via the Bio-Rad CFX 
Manager Version 1.6, the quantification and melting curve of each well was analyzed. 
First, the melting curve was analyzed such that a well-defined peak was observed at a 
specific melting temperature. Accordingly, conditions with primer and magnesium 
chloride concentrations were selected. Subsequently, the quantification curves were 
analyzed.  
 
Concentrations with the lowest CT-values were chosen and concentrations with the 
lowest primer consumption were finally selected. The appropriate size of PCR products 
was confirmed by agarose gel electrophoresis. 0.2 volumes of 6x loading buffer (Table 
 3-17) was added to 5 µl of the resulting PCR reaction and the mixture was loaded on a 2 % 
agarose gel (+ 0.004 % ethidium bromide) against a 50 bp DNA Ladder (1000 µg/ml) (NEW 
ENGLAND BioLabs GmbH, Frankfurt am Main, Germany). The gel was left to run at 
100 volts for 45 minutes in 1x TAE buffer (Table  3-18). 
 
The optimal primer and magnesium chloride concentrations were used for further 
determination of PCR efficiency. 1 µl of each of the standard dilution series (ranging from 
10-3 to 10-10) of the PCR product with the optimal conditions was pipetted in duplicates in 
low 96-well white un-skirted PCR plates (BIO-RAD, Munich, Germany) for evaluation of 
primer efficiency. The same abovementioned cycling conditions (Table  3-35) were used 
and efficiencies normally ranged from 85 – 110 % (i.e. indicating best PCR optimization). 
The primers and their PCR optimized conditions required for further mRNA expression 
analyses are presented in Table  3-40. 
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Table  3-40: PCR conditions required for mRNA expression analyses 
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3.2.5.6. mRNA Expression Analyses Using Quantitative Real-Time PCR 
Quantitative mRNA expression analyses were performed with all of the abovementioned 
genes. Since an optimal specificity and sensitivity of enzymatic action is required, each 
reaction was carried out using the Platinum® Taq DNA Polymerase (5 U / µl) (Invitrogen, 
Karlsruhe, Germany). Reaction mixtures were prepared as shown in Table  3-41. 
 
Table  3-41: Quantitative mRNA analyses reaction mixture (20 µl total volume per reaction) 
Component Required Volume per 
reaction  
Rat cDNA solution 0.5 µl 
10x PCR Buffer (without Magnesium Chloride) (Invitrogen)  
including 2.4x SYBR® Green I (Sigma) 
2 µl 
50 mM Magnesium Chloride Table  3-40 
dNTP mixture (Final Concentration: 2.5 mM each) 0.8 µl 
Gene’s primer mix (Fwd and Rev Final Concentration: 10 µM each) Table  3-40 
Platinum® Taq DNA Polymerase (5 U / µl) 0.06 µl 
HPLC water added up to 20 µl 
  
The quantitative real-time PCR reaction was carried out using the cycling conditions 
described in Table  3-35. As always mentioned, the rat Rps-18 was used as the standard 
internal reference gene. The reaction was carried out in low 96-well white un-skirted PCR 
plates (BIO-RAD, Munich, Germany). Each plate was briefly centrifuged using the 
Megafuge 2.0R (Heraeus Instruments, Leipzig, Germany) and subsequently placed in the 
CFX96™ Real-Time System (BIO-RAD, Munich, Germany) and results were analyzed via the 
Bio-Rad CFX Manager Version 1.6. Data analyses and statistical procedures were 
conducted as explained in Section  3.2.9.2. 
 
3.2.6. One-Colour Microarray-Based Gene Expression Analysis 
DNA microarray is a high throughput technology that is widely used to simultaneously 
measure changes in the expression of thousands of genes in any given biological sample. 
The core principle behind DNA microarrays is the binding of fluorescently-labelled copies 
of nucleic acids from target samples onto immobilized gene-specific probes fixed on a 
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solid state matrix, such as microscopic glass slides or ceramic chips. The amount of target 
sample binding to the probes defines the total strength of the generated signal from a 
spot or so-called feature (Freeman et al., 2000). 
 
There exist two general hybridization strategies in DNA microarray. The first and the most 
commonly known approach is the two-colour microarray where two different target 
samples are allowed to hybridize to the same microarray chip because they are both 
labeled with two different flourophores (usually Cyanine-3 and Cyanine-5) having two 
different emission wavelengths. The second recently used approach is the one-colour 
microarray where one single sample is labeled with one flourophore (usually Cyanine-3 
only) per array (Knapen et al., 2009). Both approaches have certain advantages and 
disadvantages. Yet, studies comparing one-colour and two-colour microarrays show that 
both approaches perform equally well regarding data quality and accuracy of measuring 
expression ratios (Patterson et al., 2006; Peixoto et al., 2006). Thus, the decision whether 
to use either approaches is mainly determined by experimental design considerations, 
costs and the researcher’s preference. In the present study, the one-colour microarray 
approach provided by Agilent Technologies (Waldbronn, Germany) was employed to 
globally assess E2-induced gene expression in RNDA cells due to two main reasons: 
(1) cost considerations and (2) avoiding the drawback of using Cyanine-5 as its 
susceptibility to environmental ozone levels leads to a decrease in quality of data (Fare et 
al., 2003). 
 
All microarray experiments were conducted under the guidance of the DNA Microarray 
Facility at the Max Planck Institute for Molecular Cell Biology and Genetics (Dresden, 
Germany). Cells were plated at a density of 1 x 106 cells per 75-cm2 cell culture flask. At 
approximately 70 % confluence, cells were treated with either 0.1 % DMSO (control 
carrier treatment) or 10 nM E2 (positive control treatment) for 24 hours. Cells were then 
trypsinized and harvested (Section  3.2.1.1) for RNA isolation using the peqGOLD TriFast™ 
standard protocol (Section  3.2.5.1). Three independent cell culture experiments were 
conducted.  
 
All isolated RNA samples were subjected to stringent quality control procedures using the 
Agilent 2100 bioanalyzer (http://www.chem.agilent.com/Library/applications/5989-
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1086EN.pdf) (Agilent Technologies, Waldbronn, Germany). By evaluating the resulting 
bioanalyzer electropherograms, a good RNA quality was indicated by well-defined peaks 
for 18s and 28s ribosomal RNA with an RNA Integrity Number of at least 7.00. 
 
Using the Agilent’s Quick Amp Labelling Kit (Agilent Technologies, Waldbronn, Germany) 
and following the standard Agilent’s One-Colour Microarray-Based 
Gene Expression Analysis Manual Version 5.7 (http://www.chem.agilent.com/Library/userma
nuals/Public/G4140-90041_One-Color_Tecan.pdf), 500 ng of total isolated RNA was used to 
pursue microarray experimental steps, as illustrated in Figure  3-5. 
 
 
Figure  3-5: Workflow of one-colour microarray approach for Cy3-labelled cRNA sample preparation and 
array processing. Abbreviations: mRNA, messenger RNA; cDNA, complementary DNA; cRNA, 
complementary RNA; Cy3, Cyanine-3.  
 
The resulting cyanine 3-labelled amplified and purified complementary RNA was further 
linearized and fragmented into smaller pieces to enhance the hybridization process onto 
probes on the Agilent microarray (4 x 44K) slide format of the whole rat transcriptome. 
The Agilent microarray slides were placed in an appropriate slide holder and loaded into 
the carousel of the Agilent DNA Microarray Scanner employing SureScan High Resolution 
Technology (Agilent Technologies, Waldbronn, Germany). Generated data were extracted 
using the Agilent Feature Extraction Software Version 9.5 (Agilent Technologies, 
Waldbronn, Germany). Following the manufacturer’s user 
guide (http://www.chem.agilent.com/Library/usermanuals/Public/UserGuide_050415.pdf), info-
rmation from probe features were extracted from the microarray scanned data in order 
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to measure gene expression of the given biological samples. Finally, the microarray raw 
data files (tab-delimited text format) were uploaded to the Agilent Technologies 
GeneSpring GX 9 Software (http://www.chem.agilent.com/cag/bsp/products/gsgx/manuals/Ge
neSpringGX9_QuickStartGuide.pdf). Probe sets that were undetectable in all treatment 
groups were eliminated. The remaining probe sets were first filtered on expression 
(20th-100th) percentile on normalized data. Finally, probe sets that exhibited at least 
two-fold change of expression in response to DMSO- and E2-treated samples were 
selected. 
 
3.2.7. Treatment of Raphe Nuclei-Derived Cells for Gene Expression Studies 
The regulation of mRNA expression of selected estrogen responsive genes (identified 
from the microarray-based analysis) was scrutinized in response to E2 or the flavonoids. 
Because RNDA cells encode a temperature-sensitive mutant of the SV40 large T-antigen, 
neuronal differentiation is constitutive upon shifting them to non-permissive temperature 
(White and Whittemore, 1992; Whittemore and White, 1993; White et al., 1994). Based 
on this property, the regulation of mRNA expression was investigated in RNDA cells 
grown under permissive temperature (proliferative conditions) or under non-permissive 
temperature (differentiation conditions) (i.e. denoted as D-RNDA cells). 
 
3.2.7.1. Treatment of RNDA Cells 
RNDA cells were plated at a density of 5 x 105 cells per 25-cm2 cell culture flask. At 
approximately 80 % confluence, cells were treated for 24 hours with the control or test 
substances (Table  3-42) prior to RNA isolation and gene expression analysis (Section 
 3.2.5). Three independent cell culture experiments were performed. 
 
Table  3-42: Treatment of RNDA cells for gene expression studies 
Substances Stock Concentration 
(dissolved in DMSO) 
Final Concentration 
(prepared in medium) 
DMSO (Carrier Control Treatment) - 0.1 % 
17β-Estradiol (Positive Control) 10 µM 10 nM 
8-Prenylnaringenin, Naringenin, 
6-(1,1-Dimethylallyl)naringenin, 
Genistein, Daidzein or Equol 
10 mM 10 µM 
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3.2.7.2. Treatment of D-RNDA Cells 
To treat D-RNDA cells, RNDA cells were first plated at a density of 2 x 106 cells per 75-cm2 
cell culture flask at 33 °C and 5 % CO2. At approximately 80 % confluence, one 75-cm
2 cell 
culture flask was treated for 24 hours with 0.1 % DMSO prior to RNA isolation and gene 
expression analysis (Section  3.2.5) (referred to as the day 0 sample). As depicted in Figure 
 3-6, the remaining 18 flasks were shifted to differentiation conditions at day 0 (i.e. day of 
initiation of differentiation).  
 
Media was changed every other day and cells were treated for 24 hours with the control 
or test substances (Table  3-43) prior to RNA isolation and gene expression analysis 
(Section  3.2.5). Two different collection time points were chosen: at day 1 and day 4 
following initiation of differentiation. Three independent cell culture experiments were 
performed. 
Shift remaining 18 flasks to 
differentiation conditions
(i.e. Day of Initiation 
of Differentiation)
Day -1 Day 0 Day 1 Day 2 Day 3 Day 4
Treat one flask of 
RNDA cells with 
0.1% DMSO
Collect treated RNDA 
cells (referred to as 
Day 0 sample) 
------------------
Meanwhile, treat first
set of D-RNDA cells 
with either:
0.1% DMSO,
10 nM E2,
10 nM E2 + 500 nM F
10 µM 8-PN,
10 µM NAR,
10 µM 6-DMAN,
10 µM GEN,
10 µM DAI or
10 µM EQ
Collect treated
D.RNDA cells 
(referred to as Day 1 
differentiated
samples)
Treat second set of 
D.RNDA cells with either:
0.1% DMSO,
10 nM E2,
10 nM E2 + 500 nM F,
10 µM 8-PN,
10 µM NAR,
10 µM 6-DMAN,
10 µM GEN,
10 µM DAI or
10 µM EQ
-
Collect treated
D.RNDA cells 
(referred to as Day 4 
differentiated
samples)
 
Figure  3-6: Time plan and experimental design pursued to treat D-RNDA cells for gene expression studies. 
Total number of flasks per experiment is 19 flasks. 
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Table  3-43: Treatment of D-RNDA cells for gene expression studies 
Substances Stock Concentration 
(dissolved in DMSO) 
Final Concentration 
(prepared in medium) 
DMSO (Carrier Control Treatment) - 0.1 % 
17β-Estradiol (Positive Control) 10 µM 10 nM 
Fulvestrant 1 mM 500 nM 
8-Prenylnaringenin, Naringenin, 
6-(1,1-Dimethylallyl)naringenin, 
Genistein, Daidzein or Equol 
10 mM 10 µM 
 
3.2.8. Protein Expression Analysis 
3.2.8.1. Western Blotting 
Western Blot analytical techniques were employed to detect and verify the successful 
expression of the transgenic human ERβ protein in RNDA cells. 
 
• Protein isolation: 
Protein fractions were initially isolated from RN46A-B14 cells (either untransduced or 
transduced with p6NST50) and RNDA cells. The rat raphe nuclei-derived cells were grown 
to 80 % confluence in 75-cm2 cell culture flasks. Using the NucleoSpin® RNA/Protein Kit 
(MACHEREY-NAGEL, Düren, Germany), cytosolic protein fractions were isolated as per 
manufacturer’s instructions.  
 
Briefly, cells were collected and lysed using 350 µl of the supplied Lysis Buffer RP1 and 
3.5 µl of β-mercaptoethanol (Sigma-Aldrich, Hamburg, Germany). Next, viscous cell 
lysates were vigorously vortexed and lysate viscosity was further reduced by filtration 
through the supplied NucleoSpin® Filter at 11,000 x g for 1 minute. Subsequently, RNA 
binding conditions were adjusted by adding 350 µl of 70 % ethanol to the homogenized 
lysate. For each preparation, the lysate was loaded onto the supplied NucleoSpin® 
RNA/Protein Column and centrifuged at 11,000 x g for 30 seconds. At this step, protein 
fractions were isolated by recovering the flow-through. 100 µl were transferred into a 
fresh supplied collection tube and the supplied Protein Precipitator was added at a ratio 
of 1:1. The mixture was vigorously shaken and kept at room temperature for 
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approximately 10 minutes and subsequently centrifuged at 11,000 x g for 5 minutes. The 
resulting protein pellet was then washed using 500 µl of 50 % ethanol and further 
centrifuged at 11,000 x g for 1 minute. Ultimately, protein pellet was air-dried for 5 - 10 
minutes and the pellet was dissolved by adding 100 µl of the supplied pre-warmed 
Protein Solving Buffer containing reducing agent (PSB-TCEP). Finally, protein samples 
were incubated at 95 °C - 98 °C for 3 minutes and eventually stored at -20 °C until protein 
quantification and further analysis. 
 
• Protein quantification: 
Following protein isolation, protein quantification is occasionally required prior to protein 
analysis. However, most protein quantification procedures are incompatible with sodium 
dodecyl sulphate (SDS), an anionic detergent that denatures secondary and tertiary 
protein structures and is commonly present in the sample buffer, as in the case with 
protein samples dissolved in PSB-TCEP. Hence, protein samples prepared using the 
NucleoSpin® RNA/Protein Kit (MACHEREY-NAGEL, Düren, Germany) were quantified as 
per manufacturer’s instructions based on the method described by Karlsson and 
colleagues (Karlsson et al., 1994). Briefly, BSA stock solution with 40 µg/µl BSA dissolved 
in deionized distilled water was initially prepared and a BSA standard series was arranged 
as shown in Table  3-44. 
 
Table  3-44: Standard BSA dilution series (adapted from the NucleoSpin® Kit) 
Tube # Supplied 
PSB-TCEP  
40 µg/µl BSA solution 
(dissolved in deionized distilled 
water) 
Final BSA Concentration in 
100 µl total volume per well 
1 75 µl 25 µl 10 µg/µl 
2 80 µl 20 µl 8 µg/µl 
3 85 µl 15 µl 6 µg/µl 
4 90 µl 10 µl 4 µg/µl 
5 95 µl 5 µl 2 µg/µl 
6 97.5 µl 2.5 µl 1 µg/µl 
7 50 µl - 0 µg/µl 
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20 µl of each standard (1 to 7) was pipetted in duplicates into a clear 96 well 
flat-bottomed plate. In addition, 20 µl of protein samples (each dissolved in PSB-TCEP) as 
well as PSB-TCEP buffer (serving as the negative control) were also pipetted in the same 
plate and in the same manner. Subsequently, 40 µl of the supplied PSB-TCEP buffer was 
added to all wells. Finally, 40 µl of 60 % trichloracetic acid was added to each well to end 
up with a final total volume of 100 µl per well. The plate was then mixed until color 
changed from blue (corresponds to color of PSB-TCEP) to bright yellow. Plate was left at 
room temperature for 30 minutes and eventually absorption was measured at a 
wavelength of 570 nm using the Infinite F200 spectrophotometer machine and the 
Magellan Software (TECAN, Männedorf, Switzerland). Protein concentrations were then 
calculated from the resulting standard curve. Accordingly, aliquots of 20 µg of protein 
were prepared and stored at -20 °C until further analysis. 
 
• Protein detection: 
Following protein isolation and quantification, target protein was detected using the 
Western blot analytical technique, which proceeded as follows: 
  
 1
st
 step: SDS-PolyAcrylamide Gel Electrophoresis (SDS-PAGE) 
Protein samples were first separated using SDS-PAGE, where the SDS component 
maintains polypeptides in their denatured state and applies a negative charge to the 
proteins in proportion to their mass, thus allowing the separation by their molecular 
weight (Weber and Osborn, 1969). Initially, all stock solutions of required buffers for 
SDS-PAGE were prepared as shown in Table  3-45 up to Table  3-48. 
 
Table  3-45: 4x Stacking gel buffer per 500 ml 
Component Required Amount 
Tris 30.25 g 
SDS 2 g 
Deionized distilled water added up to 500 ml 
pH adjusted to 6.8 and stored at room temperature 
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Table  3-46: 4x Separating gel buffer per 500 ml 
Component Required Amount 
Tris 90.75 g 
SDS 2 g 
Deionized distilled water added up to 500 ml 
pH adjusted to 8.8 and stored at room temperature 
 
Table  3-47: 10x Electrophoresis buffer per 1 Liter (Stock Solution) 
Component Required Amount 
Tris 30 g 
99 % Glycine 144 g 
Deionized distilled water added up to 1 Liter 
Stored at 4 °C 
 
Table  3-48: 1x Electrophoresis buffer per 1 Liter (Working Solution) 
Component Required Volume 
10x Electrophoresis Buffer stock solution 100 ml 
10 % SDS 10 ml 
Deionized distilled water added up to 1 Liter 
Stored at 4 °C 
 
At first, 10 % separating gel mixture was prepared (Table  3-49) and poured in a 1.5 mm 
thick gel chamber. The mixture was covered with a thin layer of 100 % isopropanol to 
ensure a very straight border between the two types of gels as well as facilitating fast 
polymerization by blocking oxygen contact. After approximately 30 minutes, the 
isopropanol was discarded and 4 % stacking gel mixture (Table  3-49) was poured on top 
of the polymerized separating gel. A 1.5 mm comb was then placed to spare for sample 
wells. After polymerization, the gel chamber was placed in its electrophoresis apparatus 
provided by Bio-Rad (BIO-RAD, Munich, Germany). The apparatus was filled with 1x 
electrophoresis buffer and sample wells were further rinsed and cleared by a thin needle 
using the 1x electrophoresis buffer. For sample loading, 20 µg of prepared protein 
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samples were heated up for 5 minutes at 95 °C and loaded into respective wells against 
7 µl of PageRuler™ Prestained Protein Ladder (Fermentas GmbH, St. Leon-Rot, Germany) 
to estimate protein size. The protein separation was carried out at 100 volts for 
approximately 2 hours. 
 
Table  3-49: SDS-PAGE composition (1.5 mm thickness) 
Component Required Volume 
(10 % Separating Gel) 
Required Volume 
(4 % Stacking Gel) 
4x Separating Gel Buffer 2.393 ml - 
4x Stacking Gel Buffer - 750 µl 
Rotiphorese® Gel 30 3.218 ml 450 µl 
4 % Ammonium Persulfate solution (APS) 154 µl 60 µl 
Tetramethylethylenediamine (TEMED) 8.25 µl 13 µl 
Deionized distilled water 3.850 ml 1.75 ml 
 
 2
nd
 step: Protein transfer 
In order to make the proteins accessible to antibody detection, they were transferred 
from within the gel onto a Polyvinylidene difluoride (PVDF) membrane (pore 
size = 0.45 µm) (Millipore GmbH, Schwalbach/Ts., Germany), which was initially activated 
by 100 % methanol for 10 minutes at room temperature and constant rotation. 
Meanwhile, stacks of blot paper (BIO-RAD, Munich, Germany) were pre-soaked in chilled 
transfer buffer (Table  3-50). The transfer was conducted in the Trans-Blot® SD Semi-Dry 
Transfer Cell (BIO-RAD, Munich, Germany) for 2 hours at a constant current of 
0.8 mA per cm2 of PVDF membrane. 
 
Table  3-50: Transfer buffer per 1 Liter 
Component Required Volume 
10x Electrophoresis Buffer 100 ml 
10 % SDS 10 ml 
100 % Methanol 100 ml 
Deionized distilled water added up to 1 Liter 
Stored at 4 °C 
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 3
rd
 step: Protein immunostaining and detection 
1x PBS-Tween 20 (1x PBST) (Table  3-51 and Table  3-52) was freshly prepared for all 
necessary washing steps. Following protein transfer, the PVDF membrane was incubated 
in 10 % non-fat dried milk powder (blocking buffer) (Table  3-53) for 1 hour at room 
temperature with constant shaking. The blocking buffer was used to avoid any unspecific 
antibody binding to the membrane. The membrane was then incubated with the primary 
antibody against ERβ (Table  3-54) overnight at 4 °C with constant shaking. The next day, 
the membrane was washed 3 times for 5 minutes each with 1x PBST and 
antibody-antigen complexes were detected by incubating the membrane with a 
horseradish peroxidase (HRPO)-conjugated secondary antibody (Table  3-54) for 1 hour at 
room temperature with constant shaking. Afterwards, the membrane was washed 3 
times for 5 minutes each with 1x PBST and the ERβ protein was visualized using the 
Amersham ECL Plus™ Western Blotting Detection System (GE Healthcare, Munich, 
Germany).  
 
All immunodetection steps were conducted in the dark room. First, the ECL solution 
(chemiluminescence reagent) was prepared by adding 25 µl of the supplied solution B to 
975 µl of the supplied solution A (dilution 1:40, respectively). The PVDF membrane was 
then incubated in the ECL solution for 5 minutes. Next, the reagent was slowly wiped off 
and an Amersham ECL Hyperfilm (GE Healthcare, Munich, Germany) was placed on the 
membrane for 30 minutes exposure time. The film was then (1) placed in developing 
solution (Kodak, La Hulpe, Belgium), (2) rinsed with deionized distilled water, (3) placed in 
fixing solution (Kodak, La Hulpe, Belgium) and finally (4) rinsed again with deionized 
distilled water.  
 
To allow for a second protein detection, the PVDF membrane was briefly rinsed with 
1x PBST and the antibody was stripped using a strip buffer (Table  3-55). The membrane 
was incubated in 20 ml strip solution for 30 minutes at 50 °C with constant rotation in the 
HB-1000 Hybridizer (UVP Ltd., Cambridge, United Kingdom). The membrane was then 
washed twice in 1x PBST for 10 minutes each with constant shaking, re-activated in 100 % 
methanol and re-blocked in 10 % blocking buffer for 1 hour at room temperature with 
constant shaking. The membrane was then incubated for 1 hour at 4 °C with a specific 
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antibody against the reference protein β-Actin (Table  3-54). Antibody-antigen complexes 
were detected by incubating the membrane with the same abovementioned 
HRPO-conjugated secondary antibody (Table  3-54) for 1 hour at room temperature with 
constant shaking. Afterwards, the membrane was washed 3 times for 5 minutes each with 
1x PBST and the β-Actin protein was visualized using the same aforementioned detection 
procedure. 
 
Resulting blots were left to dry and pictures were captured under the white light 
(EpiChemi3 Benchtop Darkroom, UVP Ltd, Cambridge, UK) and blot images were captured 
using Labworks™ Image Acquisition and Analysis Software Version 4.6. 
 
Table  3-51: 10x washing stock solution per 1 Liter 
Component Required Amount 
Disodium hydrogen phosphate dihydrated  142.4 g 
Sodium dihydrogen phosphate monohydrated 27.6 g 
Sodium Chloride 5.84 g 
Deionized distilled water added up to 1 Liter 
Stored at 4 °C 
 
Table  3-52: 1x washing working solution (1x PBST) per 1 Liter 
Component Required Volume 
10x washing stock solution (Table  3-51) 100 ml 
Tween® 20 1 ml 
Deionized distilled water added up to 1 Liter 
Stored at 4 °C 
 
Table  3-53: 10 % blocking buffer per 10 ml (Freshly Prepared) 
Component Required Amount 
Non-fat dried milk powder 1 g 
1x PBST added up to 10 ml 
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Table  3-54: Immunodetection antibodies (freshly prepared in 10 % blocking buffer) 
Primary Antibody Host 
 
Dilution Protein Size 
Polyclonal anti ERβ Rabbit 1:2,000 55 kDa 
Polyclonal anti β-Actin Rabbit 1:4,000 42 kDa 
Secondary Antibody Host Dilution 
HRPO-conjugated anti-rabbit IgG Goat 1:20,000 
 
Table  3-55: Strip buffer per 200 ml 
Component Required Amount / Volume 
Tris 1.51 g 
SDS 4 g 
Deionized distilled water 180 ml 
pH adjusted to 6.7 
β-Mercaptoethanol 1.4 ml 
Deionized distilled water added up to 200 ml 
Stored at room temperature 
 
3.2.8.2. Immunocytochemistry 
To confirm the switch of RNDA cellular status from proliferation to differentiation, a 
protein-based technique was sought to detect the expression of neuronal differentiation 
markers. By using standard ICC techniques, intracellular markers such as NF-L, NF-M, 
NF-H and NSE were labeled and visualized in RNDA cells and D-RNDA cells.  
 
RNDA cells were grown to 80 % confluence on autoclaved glass coverslips 18 x 18 mm 
(DIAGONAL GmbH, Münster, Germany) placed in 6-well cell culture plates. To initiate 
differentiation, RNDA cells were grown to 80 % confluence on autoclaved glass coverslips 
18 x 18 mm placed in 6-well cell culture plates. Cells were then shifted to differentiation 
conditions (Table  3-1). Cells were left to grow under differentiation conditions for four 
days followed by the addition of 10 µM dibutyryl cyclic AMP for an additional three days 
to enhance differentiation (White et al., 1994). 
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On the day of assessment, cells were rinsed twice with PBS (Table  3-10) and cell 
morphology was preserved in pre-warmed 4 % paraformaldehyde solution (Table  3-56) 
for 20 minutes at 37 °C. Following fixation, cells were rinsed twice with PBS and 
antigenicity was enhanced by incubating the cells in 50 mM ammonium chloride solution 
freshly prepared from a stock solution of 1 M (Table  3-57) for 10 minutes at room 
temperature. Subsequently, cells were rinsed twice with PBS and permeabilized in cold 
0.1 % Triton X-100 freshly prepared from a cold stock solution of 10 % (Table  3-58) for 5 
minutes at 4 °C to enhance antibody penetration during immunostaining. Prior to 
immunostaining, cells were rinsed twice with PBS and incubated in 3 % BSA solution 
(blocking buffer) (Table  3-59) for 1 hour at room temperature. For immunostaining, 
primary antibodies against NF-L, NF-M, NF-H and NSE were freshly prepared in cold 3 % 
BSA solution (Table  3-60). Cells were immunostained for 1 hour at room temperature in a 
dark humidified chamber. Cells were then rinsed twice with PBS for 5 minutes each and 
further incubated in 3 % BSA solution for 10 minutes at room temperature. Next, cells 
were incubated with a secondary antibody carrying the Alexa Flour® dye, a green 
fluorescent dye. The antibody was also freshly prepared in cold 3 % BSA (Table  3-61). 
Cells were incubated with the secondary antibody for 30 minutes at room temperature in 
a dark humidified chamber and ultimately rinsed three times with PBS for 5 minutes each 
and once with deionized distilled water to eliminate excess fluorescent phosphate 
crystals. Control samples were additionally included to test for antibody specificities by 
omitting incubation with either the primary or the flourochrome-coupled secondary 
antibody.  
 
Glass coverslips were inversely mounted on the anti-fade mounting mixture (Table  3-62) 
composed of the anti-fade medium, Mowiol 4-88 (Table  3-63) including DAPI 
(4',6-diamidino-2-phenylindole), which is a fluorescent stain that binds strongly to DNA, 
hence staining cell nucleus. Coverslips were mounted on DIAGONAL microscopic slides 
76 x 26 mm (DIAGONAL GmbH, Münster, Germany). Slides were left to dry in the dark at 
room temperature overnight. The next day, slides were kept at 4 °C until imaging.   
 
Imaging took place at the BIOTEC Microscope Facility (Biotechnology Centre, TU-Dresden, 
Dresden, Germany). Cell samples were viewed on a Carl Zeiss Axiovert 200 Imaging 
Microscopy via the Plan-Apochromat 63x / 1.40 Oil DIC objective. Control samples were 
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viewed on the same microscope but using the Plan-Apochromat 20x / 0.4 (Ph2). 
Photographs were captured using the Carl Zeiss Apotome camera (Carl Zeiss, Jena, 
Germany) and the AxioVert Software Release 4.8.1. 
 
Table  3-56: 4 % (w/v) paraformaldehyde per 50 ml (prepared under a fume hood) 
Component Required Amount / Volume 
Paraformaldehyde  2 g 
PBS 30 ml 
2 - 3 drops of 1 M NaOH was added with constant stirring  
and heating at 70 °C to clear suspension 
pH was adjusted to 7.4 
PBS added up to 50 ml 
Aliquots were stored at -20 °C  
 
Table  3-57: 1 M ammonium chloride solution per 50 ml (Stock Solution) 
Component Required Amount 
Ammonium Chloride 2.675 g 
PBS added up to 50 ml 
Filter sterilized and stored at room temperature 
 
Table  3-58: 10 % (v/v) Triton X-100 per 50 ml (Stock Solution) 
Component Required Volume 
Triton X-100 5 ml 
PBS added up to 50 ml  
Stored at 4 °C 
 
Table  3-59: Blocking buffer 3 % (w/v) BSA per 50 ml 
Component Required Amount 
BSA Fraction V 1.5 g 
PBS added up to 50 ml  
Filter sterilized and aliquots were stored at -20 °C  
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Table  3-60: Primary antibodies used in ICC (freshly prepared in cold 3 % BSA) 
Primary Antibodies Host Dilution 
Monoclonal anti NF-L Mouse 1:25 
Monoclonal anti NF-M Mouse 1:25 
Monoclonal anti NF-H Mouse 1:25 
Monoclonal anti NSE γγ Mouse 1:25 
 
Table  3-61: Secondary antibody used in ICC (freshly prepared in cold 3 % BSA) 
Secondary Antibody Host Dilution 
Alexa Flour 488 anti-mouse IgG (H + L) Goat 1:500 
 
Table  3-62: Anti-fade mounting mixture used in ICC per 1 ml 
Component Required Amount 
Mowiol 4-88 medium (Table  3-63) 996 µl 
DAPI added at a dilution of 1:250  
Hint: mixture was not vortexed to avoid bubbles  
Each coverslip required 35 - 40 µl mixture to ensure full coverage on microscopic 
slides 
 
Table  3-63: Mowiol 4-88 medium composition 
Component Required Amount / Volume 
Glycerol 6 g 
Mowiol 4-88 granules (yellow in colour) 2.4 g 
Stirred to mix 
Deionized distilled water 6 ml 
Stirred for 4 hours at room temperature 
0.2 M Tris (pH 8.5) 12 ml 
Heated in a water bath at 50 °C for 10 minutes 
After dissolving, centrifuged at 500 x g for 15 minutes 
Aliquots were stored at -20 °C 
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3.2.9. Data Analyses and Statistical Procedures 
Unless otherwise stated, all generated data were handled and plotted using Microsoft 
Office Excel 2003. Arithmetic mean and standard deviation values were calculated from 
three independent cell culture experiments with independent passage numbers. A paired 
two-sample t-test was applied when data from test groups with a defined standard 
deviation were compared to a control group bearing no standard deviation. Ultimately, 
an adapted Student’s t-test, Welch’s t-test, was applied when data with unequal 
variances were compared (Welch, 1938). 
 
3.2.9.1. Analysis of Data Generated from Luciferase Reporter Gene Assays 
Within the luciferase reporter gene assays, treatments were performed in triplicates. For 
each treatment, luciferase bioluminescent activity was calculated in relative luciferase 
units per amount of protein per well. Values were expressed as arithmetic 
mean ± standard deviation. Asterisks indicate values differing significantly from the DMSO 
carrier control treatment (which was always set to 100 %): 
 
*   : p ≤ 0.05 :  significant 
**   : p ≤ 0.01 :  very significant 
***   :  p ≤ 0.001 :  highly significant 
 
Hash signs indicate values differing significantly from the positive control treatment 
(E2 10 nM): 
 
#   : p ≤ 0.05 :  significant 
###   :  p ≤ 0.001 :  highly significant 
 
Plus signs indicate values differing significantly from the 1 µM single dose treatment of 
the flavonoids: 
 
++  :  p ≤ 0.01 :  very significant 
+++  : p ≤ 0.001 :  highly significant 
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• Measuring the value of the half maximal effective concentration (EC50): 
The value of EC50 refers to the concentration of a given substance that induces a half 
maximal response following specified exposure duration that finally reaches a plateau. It 
is commonly used to measure the substance’s estrogenic potency 
(http://www.graphpad.com/curvefit/introduction89.htm). 
 
In this study, the EC50 was calculated from the sigmoidal dose-response relationship curve 
using the statistical software Sigma Plot® Version 9.0. The following steps were conducted 
to calculate the EC50: 
(1) Right click on the curve of interest 
(2) Select “Fit Curve”. A “Regression Wizard” window will pop-up 
(3) For the “Equation Category”, select “ Standard Curve” from the drop-down menu 
(4) For the “Equation Name”, select “Four Parameter Logistic Curve”. The value of 
EC50 appears after clicking “Next” 
 
3.2.9.2. Analysis of Data Generated from Quantitative Real-Time PCRs 
Three independent rat cDNA samples were synthesized from three independent cell 
culture experiments. Relative gene expression levels of target genes were corrected with 
the expression of the rat internal reference gene, Rps-18. Relative quantification was 
performed using the ΔΔ cycle threshold (ΔΔCT) calculation method to describe the change 
of expression of a target gene relative to a reference group by using the CT-values (Winer 
et al., 1999; Pfaffl, 2001).  In this study and unless otherwise stated, data were either 
normalized against the DMSO carrier control treatment for RNDA cells or the day 0 
sample treated with DMSO for D-RNDA cells. A series of mathematical equations were 
exploited for data analysis. At first, the difference in average CT-values for the target gene 
of interest and the internal reference gene was calculated as follows: 
 
 Equation  3-1: ΔCT = CT average target gene – CT average rat Rps18 
 
Next, subtraction of the test treatment ΔCT from the control treatment ΔCT yielded the 
ΔΔCT. Since the reaction doubles the amount of product per cycle, the ΔΔCT value was 
used as the exponent of 2 as shown below: 
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 Equation  3-2: 2
ΔΔCT = 2 (ΔCT control treatment - ΔCT test treatment) 
 
2ΔΔCT values were expressed as arithmetic mean ± standard deviation of all PCR reactions. 
For RNDA cells, plus signs indicate values differing significantly from the DMSO carrier 
control treatment:  
 
+  : p ≤ 0.05 :  significant 
++   : p ≤ 0.01 :  very significant 
+++   :  p ≤ 0.001 :  highly significant 
 
For D-RNDA cells, asterisks indicate values differing significantly from the day 1 
differentiated sample treated with DMSO. In addition, hash sign indicates values differing 
significantly from the day 4 differentiated sample treated with DMSO: 
 
*   : p ≤ 0.05 :  significant 
**   :  p ≤ 0.01 :  very significant 
 
#   : p ≤ 0.05 :  significant 
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4. RESULTS 
 
4.1. Transduction Efficiency and Generation of RNDA Cells 
The efficiency of viral transduction was determined from the percentage of target cells 
expressing EGFP using standard flow cytometry techniques due to the fact that p6NST50 
and p6NST50 + ERβ lentiviral vectors encode EGFP as a reporter gene (Figure  3-1 and 
Figure  3-2). Two different viral stock dilutions (either UD or 1:10 diluted) were used to 
transduce RN46A-B14 cells as well as the reference control cell line HT-1080 (Section 
 3.2.3.3). As depicted in Figure  4-1, the resulting red dot density FACS charts represent 
percentage of either HT-1080 or RN46A-B14 cells expressing EGFP as compared to their 
untransduced counterparts. 
 
Region 2 (R2) of each FACS chart in Figure  4-1 was set to distinguish or “gate” the flow of 
the EGFP-expressing cells from the heterogeneous cell population. Hence, the efficiency 
of viral transduction was determined from the percentage of gated cells in Region 2 (R2) 
(signifying the percentage of cells expressing EGFP). After 72 hours of viral transduction, 
transduction of HT-1080 cells revealed that both lentiviral particles (i.e. p6NST50 and 
p6NST50 + ERβ) were infectious with efficacies reaching almost 93 % (Figure  4-1, 
Panel A). RN46A-B14 cells were generally transduced but with a relatively reduced 
efficacy if compared to HT-1080 cells (Figure  4-1, Panel B).  
 
There was no difference in the percentage of RN46A-B14 cells transduced with either the 
undiluted p6NST50 or 1:10 diluted p6NST50 viral particles (67.32 % vs. 68.12 %, 
respectively). An obvious difference was only noticed when RN46A-B14 cells were 
transduced with the viral vector encoding the ERβ, where the percentage of RN46A-B14 
cells transduced with 1:10 diluted p6NST50 + ERβ was 3.8-fold higher than the percentage 
of cells transduced with undiluted p6NST50 + ERβ (24.48 % vs. 6.39 %, respectively). 
Accordingly, RN46A-B14 cells transduced with the 1:10 diluted lentiviral particles were 
considered for this study. The cells were then propagated using the medium of 
untransduced RN46A-B14 cells but containing 60 µg/ml Zeocin™ (Table  3-1), as deduced 
from the Zeocin™ kill-curve (Section  3.2.3.1). 
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Figure  4-1: Red dot density FACS charts representing the efficiency of lentiviral transduction by 
determining the percentage of HT-1080 cells or RN46A-B14 cells expressing the reporter gene EGFP as 
compared to their untransduced counterparts. Cells were harvested 72 hours after transduction. EGFP is 
detected by the FL1 sensor (assigned to the x-axis). All other scattered light is detected by the FL2 sensor 
(assigned to the y-axis). Transduced cells expressing EGFP are gated in Region 2. The percentage of cells 
expressing EGFP is denoted by a coloured underline. (Panel A) transduction analysis of the reference 
control cell line HT-1080 cells incubated with undiluted or 1:10 diluted lentiviral particles and (Panel B) 
transduction analysis of RN46A-B14 cells incubated with undiluted or 1:10 diluted lentiviral particles.  
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Subsequently, supernatants of cultured transduced RN46A-B14 cells were tested for the 
absence of infectious viral particles. The purpose of this step was to ensure the safe 
transfer of the transduced cells from Biosafety Level 2 to Biosafety Level 1. Cell-free 
supernatants were harvested and checked for any EGFP expression using standard flow 
cytometry techniques (Section  3.2.3.3). As depicted in Figure  4-2, supernatants harvested 
from cultured RN46A-B14 cells transduced with 1:10 diluted p6NST50 (Figure  4-2 A) or 
1:10 diluted p6NST50 + ERβ (Figure  4-2 B) was devoid of any cells expressing EGFP 
(0.00 %) as compared to supernatants harvested from cultured untransduced RN46A-B14 
cells (0.01 %) (Figure  4-2 C). Therefore, this indicated that cultured transduced 
RN46A-B14 cells do not produce any further infectious lentiviral particles in their 
supernatants. Thus, cells were successfully and safely downgraded from Biosafety Level 2 
to Biosafety Level 1 and the newly generated RN46A-B14 cells transduced with 1:10 
diluted p6NST50 + ERβ were given the new notation, RNDA cells. 
 
Figure  4-2: Red dot density FACS charts representing the absence of infectious lentiviral particles in 
supernatants of cultured RN46A-B14 cells transduced with 1:10 diluted lentiviral vectors. EGFP is detected 
by the FL1 sensor (assigned to the x-axis). All other scattered light is detected by the FL2 sensor (assigned to 
the y-axis). Transduced cells expressing EGFP are gated in Region 2. Absence of infectious lentiviral particles 
in the supernatants were determined by the absence of cells expressing EGFP; values denoted by a green 
underline. (A) analysis of cell-free supernatants of cultured RN46A-B14 cells transduced with 1:10 diluted 
p6NST50, (B) analysis of cell-free supernatants of cultured RN46A-B14 cells transduced with 1:10 diluted 
p6NST50 + ERβ and (C) analysis of cell-free supernatants of cultured untransduced RN46A-B14 cells.  
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4.2. Successful Transcription and Translation of Transgenic Human ESR2 in 
RNDA Cells 
As previously mentioned, the reason for cloning and stably integrating human ESR2 
instead of a rat Esr2 in the studied rat cell model was due to two reasons: (1) availability 
of human ESR2 DNA fragment in the lab and (2) human ERβ shows approximately 89% 
identity in its translated region to the rat ERβ as compared to any other mammalian ERβ 
(Enmark and Gustafsson, 1999). Using the first passage number of the newly generated 
RNDA cells, successful transcription of the transgenic human ESR2 was verified by 
quantitative real-time PCR using its specified primer sequences and PCR conditions (Table 
 3-37 and Table  3-40). As depicted from the 1 % agarose gel in Figure  4-3 A, amplified 
human ESR2 cDNA with an amplicon size of 153 bp was successfully detected in RNDA 
cells (Figure  4-3 A, Lane 2) as opposed to RN46A-B14 cells transduced with p6NST50 
(Figure  4-3 A, Lane 1) or untransduced RN46A-B14 cells (Figure  4-3 A, Lane 3).  
 
Following the transcription analysis of the transgenic human ESR2, successful translation 
of human ERβ was verified using Western blot techniques. From RNDA cell protein 
extracts, an ERβ-immunoreactive band was detected at 55 kDa (Figure  4-3 B, Lane 3) as 
opposed to protein extracts from untransduced RN46A-B14 cells (Figure  4-3 B, Lane 1) or 
protein extracts from RN46A-B14 cells transduced with p6NST50 (Figure  4-3 B, Lane 2). 
 
(B)
ERβ: 55
1                          2                          3
β-Actin: 43
72
1                2 3
153 bp
(A)
 
 
Figure  4-3: Verification of successful transcription and translation of transgenic human ESR2 in RNDA 
cells. (A) A 1% agarose gel depicting the correct amplicon size of an amplified cDNA of transgenic human 
ESR2 in RNDA cells (Lane 2) as opposed to RN46A-B14 cells transduced with p6NST50 (Lane 1) or 
untransduced RN46A-B14 cells (Lane 3), (B) An immunoblot verifying protein expression of transgenic 
human ERβ against the reference protein (β-Actin) in RNDA cells (Lane 3) as opposed to untransduced 
RN46A-B14 cells (Lane 1) or RN46A-B14 cells transduced with p6NST50 (Lane 2). Molecular mass of protein 
ladder (Fermentas, St. Leon-Rot, Germany) are indicated in kDa. 
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4.3. Functional Characterization of Transgenic Human ERβ in RNDA Cells 
Following the validation of successful transcription and translation of the transgenic 
human ESR2 in RNDA cells, luciferase reporter gene assays (Section  3.2.4) were utilized to 
determine whether the transgenic human ERβ is functional for downstream 
investigations of estrogen-dependent activities. Accordingly, transient transfection assays 
with the firefly luciferase regulated by a double ERE as an estrogen-responsive reporter 
gene were employed in RNDA cells (Figure  3-4). 
 
The ability of increasing concentrations of E2 (100 fM - 100 nM) to evoke a specific 
response in RNDA cells was initially investigated. Results revealed a significant sigmoidal 
dose-response relationship in luciferase expression following E2 treatment (Figure  4-4 A). 
From this concentration-dependent regression curve and by using the statistical software 
Sigma Plot® Version 9.0, the EC50 of E2 was calculated to be 4.0 × 10
−10 M (Section 
 3.2.9.1). Moreover, the maximum response evoked by E2 was at a concentration of 
10 nM. This concentration was further used in all subsequent experiments as the 
standard positive control treatment.  
 
As depicted in Figure  4-4 B, a highly significant increase in luciferase output was noticed 
in RNDA cells as opposed to the untransduced RN46A-B14 cells in response to 10 nM E2 
treatment. Proof of excluding non-specific transgenic ERβ effects was further scrutinized 
where a highly significant increase in luciferase activity was observed in RNDA cells 
following 10 nM E2 treatment as opposed to the RN46A-B14 cells transduced with 
p6NST50 only (Figure  4-4 C). Additionally, the specific transcriptional activation of 
luciferase via the transgenic human ERβ was demonstrated by treating RNDA cells with 
increasing concentrations (1 nM - 1 µM) of Diarylproprionitril (the selective ERβ agonist) 
or Propyl pyrazole triol (the selective ERα agonist). RNDA cells significantly responded in a 
concentration-dependent manner to Diarylproprionitril (Figure  4-4 D) but not to Propyl 
pyrazole triol (Figure  4-4 E). 
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Figure  4-4: Transgenic human ERβ is functional in RNDA cells by inducing significant luciferase activity. 
Normalized luciferase output observed in RNDA cells in response to (A) increasing concentrations of E2 
(100 fM - 100 nM), (B) 10 nM E2 as opposed to untransduced RN46A-B14 cells, (C) 10 nM E2 as opposed to 
RN46A-B14 cells transduced with p6NST50, (D) increasing concentrations (1 nM - 1µM) of the selective ERβ 
agonist (Diarylproprionitril) and (E) increasing concentrations (1 nM - 1µM) of the selective ERα agonist 
(Propyl pyrazole triol). The luciferase output in response to DMSO treatment is represented by a black 
horizontal line set to 100 %. Effects differ significantly from DMSO treatment: ** p ≤ 0.01 and *** p ≤ 0.001. 
 
4.4. Transactivational Activity of Flavonoids in RNDA Cells 
Following the verification of stable integration of transgenic human ESR2 in RNDA cells 
and the significant functional activity of the transgenic human ERβ in RNDA cells, the 
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transactivational activity of the flavonoids on the transgenic ERβ was initially investigated 
in same studied cell line. These substances are sold as medicinal plant remedies or as 
dietary supplements and have reached quite remarkable market shares. Nevertheless, 
sufficient data regarding their activity as well as their efficacy and safety in different body 
organs, including the raphe nuclei region of the brain, remains to be unavailable. 
 
In this study, seven different flavonoids were tested for their transactivational activity on 
ERβ in the newly established RNDA cell model using the luciferase reporter gene assay. 
First, RNDA cells were treated with increasing concentrations of the three isoflavones: 
Genistein, Daidzein and Equol. RNDA cells were also treated with increasing 
concentrations of the second tested group of flavonoids, namely the naringenin-type 
flavanones. These include Naringenin, 8-Prenylnaringenin, 
7-(O-prenyl)naringenin-4'-acetate and 6-(1,1-Dimethylallyl)naringenin.   
 
4.4.1. Transactivational Activity of Isoflavones in RNDA Cells 
RNDA cells were treated with increasing concentrations of the isoflavones 
(10 nM - 10 µM). A co-treatment of 1 µM of each isoflavone with either 500 nM 
Fulvestrant or the effective dose of E2 (10 nM) was further tested in RNDA cells (Section 
 3.2.4.3). 
 
As depicted in all panels of Figure  4-5, a highly significant luciferase output was noticed in 
RNDA cells following 10 nM E2 treatment as compared to the DMSO treatment (black 
horizontal line set to 100 %). This high significant luciferase output was also noticed in a 
concentration-dependent manner starting at the lowest concentration of 10 nM when 
cells were treated with increasing concentrations of Genistein, Daidzein or Equol as 
compared to the DMSO treatment (Figure  4-5 A, B and C). Additionally, a co-treatment of 
Genistein, Daidzein or Equol with Fulvestrant completely antagonized effects elicited by 
1 µM of each isoflavone; indicating that all three substances act by binding to and 
activating the transgenic ERβ. Moreover, additional significant effects were observed in 
RNDA cells in response to a co-treatment of 10 nM 17β-Estradiol with 1 µM of either 
Genistein or Daidzein, but not Equol, if compared to the E2 single-dose treatment (Figure 
 4-5 A, B and C). Based on the tested doses of the isoflavones in this study 
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(i.e. 10 nM - 10 µM), calculation of the EC50 was not possible mathematically due to the 
fact that the data do not fit in sigmoidal dose-response relationship, where a plateau 
does not seem to be reached at 10 µM. 
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Figure  4-5: Effect of isoflavones on luciferase activity in RNDA cells. Normalized luciferase output observed 
in RNDA cells in response to (A) increasing concentrations of Genistein or co-treatment of 1 µM Genistein 
with either 500 nM Fulvestrant or 10 nM E2, (B) increasing concentrations of Daidzein or co-treatment of 
1 µM Daidzein with either 500 nM Fulvestrant or 10 nM E2 and (C) increasing concentrations of Equol or 
co-treatment of 1 µM Equol with either 500 nM Fulvestrant or 10 nM E2. The luciferase output in response 
to DMSO treatment is represented by a black horizontal line set to 100 %. Effects differ significantly from 
either DMSO treatment: *** p ≤ 0.001, E2 single-dose treatment: # p ≤ 0.05 or 1 µM single-dose treatment 
of the isoflavone: +++ p ≤ 0.001. 
 
4.4.2. Transactivational Activity of Naringenin-type Flavanones in RNDA Cells 
RNDA cells were treated with increasing concentrations of the naringenin-type flavanones 
(10 nM - 10 µM). A co-treatment of 1 µM of each with either 500 nM Fulvestrant or the 
effective dose of E2 (10 nM) was further tested (Section  3.2.4.3).  
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As illustrated in all panels of Figure  4-6, a highly significant luciferase output was noticed 
in RNDA cells following 10 nM E2 treatment as compared to the DMSO treatment (black 
horizontal line set to 100 %). This significant luciferase output was also noticed in a 
concentration-dependent manner starting at a concentration of 100 nM when cells were 
treated with increasing concentrations of Naringenin as compared to the DMSO 
treatment (Figure  4-6 A). Moreover, a co-treatment with Fulvestrant completely 
antagonized effects elicited by 1 µM Naringenin, indicating that Naringenin acts by 
binding to and activating the transgenic ERβ. However, no significant additional effects 
were noticed when RNDA cells were co-treated with 10 nM 17β-Estradiol and 1 µM 
Naringenin if compared to the E2 single-dose treatment. 
 
A similar pattern was noticed in response to 8-Prenylnaringenin (Figure  4-6 B), where a 
highly significant increase in luciferase output was displayed in a 
concentration-dependent manner starting at a concentration of 100 nM as compared to 
the DMSO treatment. As expected, co-treatment with Fulvestrant completely 
antagonized effects elicited by 1 µM 8-Prenylnaringenin, indicating that 
8-Prenylnaringenin also acts by binding to and activating the transgenic ERβ. In contrast 
to the parent molecule Naringenin, 1 µM 8-Prenylnaringenin was able to significantly 
antagonize effects elicited by 10 nM E2 if compared to the E2 single-dose treatment.  
 
As depicted in Figure  4-6 C, only the high concentrations of 
7-(O-prenyl)naringenin-4'-acetate (1 µM and 10 µM) caused a highly significant increase 
in luciferase output in RNDA cells as compared to the DMSO treatment. Co-treatment 
with Fulvestrant completely antagonized effects elicited by 1 µM 
7-(O-prenyl)naringenin-4'-acetate, which again indicates that 
7-(O-prenyl)naringenin-4'-acetate also acts by binding to and activating the transgenic 
ERβ. Similar to 8-Prenylnaringenin, 1 µM 7-(O-prenyl)naringenin-4'-acetate was also able 
to significantly antagonize effects elicited by 10 nM E2 if compared to the E2 single-dose 
treatment. 
 
In contrast to the abovementioned naringenin-type flavanones, no significant luciferase 
activity was detected in RNDA cells in response to increasing concentrations of 
6-(1,1-Dimethylallyl)naringenin (Figure  4-6 D). Moreover, co-treatment with either 
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500 nM Fulvestrant or 10 nM E2 did not reveal any significant change in luciferase output 
if compared to the single-dose treatment of either the substance or E2, respectively. 
Once again, based on the tested doses of the naringenin-type flavanones in this study 
(i.e. 10 nM – 10 µM), calculation of the EC50 was not possible mathematically due to the 
fact that the data do not fit in sigmoidal dose-response relationship, where a plateau 
does not seem to be reached at 10 µM. 
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Figure  4-6: Effect of naringenin-type flavanones on luciferase activity in RNDA cells. Normalized luciferase 
output observed in RNDA cells in response to (A) increasing concentrations of Naringenin or co-treatment 
of 1 µM Naringenin with either 500 nM Fulvestrant or 10 nM E2, (B) increasing concentrations of 
8-Prenylnaringenin or co-treatment of 1 µM 8-Prenylnaringenin with either 500 nM Fulvestrant or 10 nM 
E2, (C) increasing concentrations of 7-(O-prenyl)naringenin-4'-acetate or co-treatment of 1 µM 
7-(O-prenyl)naringenin-4'-acetate with either 500 nM Fulvestrant or 10 nM E2 and (D) increasing 
concentrations of 6-(1,1-Dimethylallyl)naringenin or co-treatment of 1 µM 6-(1,1-Dimethylallyl)naringenin 
with either 500 nM Fulvestrant or 10 nM E2. The luciferase output in response to DMSO treatment is 
represented by a black horizontal line set to 100 %. Effects differ significantly from either DMSO treatment: 
* p ≤ 0.05, ** p ≤ 0.01 and *** p ≤ 0.001, E2 single-dose treatment: # p ≤ 0.05 and ### p ≤ 0.001 or 1 µM 
single-dose treatment of the naringenin-type flavanone: ++ p ≤ 0.01 and +++ p ≤ 0.001.  
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4.5. Gene Expression Profiling Using Microarray Analysis 
Following the evaluation of the transactivational activity of the flavonoids on the 
transgenic ERβ in RNDA cells using luciferase reporter gene assays (Section  4.4), it was of 
interest to evaluate the potential of flavonoids to regulate endogenous gene expression 
of estrogen responsive genes in RNDA cells as compared to regulation patterns in 
response to 17β-Estradiol. Accordingly, a closer view on the E2-dependent changes in the 
expression of the whole rat transcriptome in RNDA cells was initially mapped using a DNA 
microarray technique (Section  3.2.6). A total of 40,000 transcripts were identified in 
RNDA cells following DMSO and E2 treatments. From this data set, the list of transcripts 
that showed at least two-fold change of expression in response to DMSO and E2 
treatment was selected. This list includes a total of 212 regulated transcripts; of which 64 
are down-regulated (Appendix  7-4) and 148 are up-regulated (Appendix  7-5) in response 
to E2 treatment.  
 
4.6. Gene Expression Validation Using Quantitative Real-Time PCR 
From a total of 212 estrogen regulated transcripts with at least two-fold change of 
expression, six genes were selected according to specific features of estrogenic regulation 
of expression. Camello-like 5 (Cml-5), sex determining region Y-box 18 (Sox-18) and 
keratin type I cytoskeletal 19 (Krt-19) were selected for their highest fold-change in 
response to E2 treatment. Neurofilament medium polypeptide (Nefm) and zinc finger, 
DHHC-type containing 2 (Zdhhc-2) were chosen because of their high basal expression in 
response to E2 treatment. Solute carrier family 6 member 4 (Slc6a4) was selected for its 
functional relevance in this serotonergic cell line as it encodes the serotonin re-uptake 
transporter. The DNA microarray outcome of all six genes was validated using 
quantitative real-time PCR. 
 
As depicted in Figure  4-7 A, Cml-5 (73.92 ± 71.95 fold), Sox-18 (16.04 ± 11.49 fold) and 
Krt-19 (7.56 ± 7.87 fold) were significantly and highly up-regulated in RNDA cells following 
E2 treatment. Nefm (0.30 ± 0.09 fold) and Zdhhc-2 (0.42 ± 0.14 fold) were significantly 
down-regulated in RNDA cells in response to E2 treatment (Figure  4-7 B). No significant 
regulation was observed for Slc6a4 mRNA following E2 treatment (Figure  4-7 B). 
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Figure  4-7: Validation of expression of six selected E2-regulated genes in RNDA cells using quantitative 
real-time PCR. Six genes were selected from the microarray according to specific features of estrogenic 
regulation of expression. Cells were treated with either 0.1 % DMSO (carrier control treatment) or 10 nM E2 
(positive control treatment) for 24 hours prior to RNA isolation. (A) up-regulated genes in response to E2 
treatment and (B) down-regulated genes in response to E2 treatment. Expression in response to DMSO 
treatment is represented by a black horizontal line set to 1. Data are normalized against the DMSO 
treatment. Plus signs indicate significance from DMSO treatment: ++ p ≤ 0.01 and +++ p ≤ 0.001. 
 
4.7. Effect of Flavonoids on the Regulation of mRNA Expression of 
Estrogen-Responsive Genes in RNDA Cells 
Following the identification and validation of expression of the six selected E2-regulated 
genes in RNDA cells (Section  4.5 and Section  4.6), the potential of flavonoids to regulate 
endogenous gene expression of the six selected estrogen responsive genes in RNDA cells 
was then investigated as compared to regulation patterns in response to 17β-Estradiol. 
Cells were treated for 24 hours prior to RNA isolation with 0.1 % DMSO, 10 nM E2 or 
10 µM of each of the flavonoids (Section  3.2.7.1). It is important to note that out of all 
the tested seven flavonoids in the present study, 7-(O-prenyl)naringenin-4’-acetate was 
excluded from these set of experiments regarding gene expression analyses because it 
exhibited low activity on downstream transactivational pathways in RNDA cells (Figure 
 4-6 C) and due to the fact that it is not yet known to be present in medicinal plant extracts 
and food items including dietary supplements with respective health claims. 
 
There was no basal Cml-5 mRNA expression detectable in these sets of experiments, 
hence expression in response to DMSO treatment is represented by a red horizontal line 
set to 0 (Figure  4-8 A). Cml-5 mRNA expression was clearly detectable following E2 
treatment. Thus, values of Cml-5 mRNA expression were normalized against the E2 
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treatment, yet significance of effects was calculated as compared to the DMSO 
treatment. Apart from the null regulation of Cml-5 mRNA expression in response to either 
Naringenin or 6-(1,1-Dimethylallyl)naringenin treatment in RNDA cells, Cml-5 mRNA was 
shown to be up-regulated in response to all the other tested substances, however 
significance of effects was only reached in response to E2, 8-Prenylnaringenin and 
Genistein as compared to the DMSO treatment (Figure  4-8 A).  
 
In all remaining panels of Figure  4-8 described hereafter, mRNA expression of the 
remaining genes was detectable in response to DMSO treatment. Thus, data were 
normalized against the DMSO treatment (black horizontal line set to 1). In Figure  4-8 B, a 
strong up-regulation of Sox-18 mRNA was observed in response to E2 (35.16 ± 20.96 fold) 
as compared to the DMSO treatment (black horizontal line set to 1), although this was 
statistically not significant. However, significant effects were measured in response to 
8-Prenylnaringenin (55.72 ± 12.04 fold), Genistein (48.21 ± 9.42 fold), Daidzein 
(29.11 ± 1.31 fold) and Equol (54.81 ± 18.50 fold) as compared to the DMSO treatment. 
Again, no change in regulation of Sox-18 mRNA was observed in response to either 
Naringenin or 6-(1,1-Dimethylallyl)naringenin treatment in RNDA cells. 
 
As represented in Figure  4-8 C, Krt-19 mRNA was significantly and highly up-regulated in 
response to E2 (11.82 ± 0.53 fold), 8-Prenylnaringenin (9.11 ± 1.42 fold), Genistein 
(13.18 ± 0.72 fold), Daidzein (8.02 ± 0.33 fold) and Equol (8.55 ± 0.54 fold) as compared to 
the DMSO treatment (black horizontal line set to 1). Yet, no change in mRNA regulation 
was detected in response to either Naringenin or 6-(1,1-Dimethylallyl)naringenin as 
compared to the DMSO treatment. 
 
As shown in Figure  4-8 D, Nefm mRNA was shown to be down-regulated in response to all 
tested substances, however significance of effects was only reached in response to E2 
(0.42 ± 0.19 fold), 8-Prenylnaringenin (0.57 ± 0.06 fold), Genistein (0.36 ± 0.05 fold), 
Daidzein (0.38 ± 0.14 fold) and Equol (0.52 ± 0.02 fold) as compared to the DMSO 
treatment (black horizontal line set to 1).  
 
Zdhhc-2 mRNA expression level (Figure  4-8 E) was significantly down-regulated in 
response to E2 (0.71 ± 0.09 fold), 8-Prenylnaringenin (0.68 ± 0.05 fold), Naringenin 
(0.74 ± 0.05 fold), Genistein (0.67 ± 0.03 fold), Daidzein (0.75 ± 0.01 fold) and Equol 
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(0.74 ± 0.02 fold) as compared to the DMSO treatment (black horizontal line set to 1). In 
contrast to the regulation of mRNA expression of the abovementioned genes in response 
to E2 or the flavonoids, Figure  4-8 F shows no significant regulation of Slc6a4 mRNA 
expression in RNDA cells in response to either E2 or the flavonoids as compared to the 
DMSO control treatment (black horizontal line set to 1). 
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Figure  4-8: Effect of flavonoids on the regulation of mRNA expression of the six selected estrogen 
responsive genes in RNDA cells. Cells were treated with either 0.1 % DMSO, 10 nM E2, 10 µM of the 
naringenin-type flavanones (grey bars) or 10 µM of the isoflavones (black bars) for 24 hours prior to RNA 
isolation. (A - C) regulation of mRNA expression of Cml-5, Sox-18 and Krt-19 in response to E2 and 
flavonoids and (D - F) regulation of mRNA expression of Nefm, Zdhhc-2 and Slc6a4 in response to E2 and 
flavonoids. For panel A, data are normalized against the E2 treatment and expression in response to DMSO 
treatment is represented by a red horizontal line set to 0. For panels B – F, expression in response to DMSO 
treatment is represented by a black horizontal line set to 1 and data are normalized against the DMSO 
treatment. Plus signs indicate significance from DMSO treatment: + p ≤ 0.05, ++ p ≤ 0.01 and +++ p ≤ 0.001. 
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4.8. Effect of Flavonoids on the Regulation of mRNA Expression of 
Estrogen-Responsive Genes in D-RNDA Cells 
Since RNDA cells encode a temperature-sensitive mutant of the SV40 large T-antigen, 
neuronal differentiation is constitutive upon shifting them from permissive (proliferative 
conditions) to non-permissive temperature (differentiating conditions) (White and 
Whittemore, 1992; Whittemore and White, 1993; White et al., 1994). Accordingly, it was 
not only of interest to evaluate the potential of flavonoids to regulate endogenous gene 
expression of the six selected estrogen responsive genes in RNDA cells grown under 
proliferative conditions (Section  4.7), but it was also of interest to look at their capacity to 
regulate endogenous gene expression in D-RNDA cells (i.e. RNDA cells grown under 
differentiation conditions); in which the cells are no longer under the mitotic drive of the 
temperature-sensitive mutant of SV40 large T-antigen. 
 
However, confirming the switch of RNDA cellular status from proliferation to 
differentiation was a prerequisite to these gene expression studies. As a result, 
intracellular markers of neuronal differentiation, namely NF-L, NF-M, NF-H and NSE were 
visualized using immunocytochemistry (Section  3.2.8.2). 
 
4.8.1. Cellular Differentiation of RNDA cells and Expression of Cell-Specific 
Antigens 
At 33 °C (i.e. permissive temperature), RNDA cells divide and show fibroblast-like 
morphology (Figure  4-9 A). When RNDA cells are shifted to 39 °C (i.e. non-permissive 
temperature), the cells cease division and exhibit phenotypic properties of neurons 
(Figure  4-9 B). RNDA cells and D-RNDA cells were highly immunoreactive for NF-L (Figure 
 4-9 C and D, respectively) and NF-M (Figure  4-9 E and F, respectively). Very low levels of 
NF-H and NSE were detected in RNDA cells (Figure  4-9 G and I, respectively). Yet, 
increased levels of NF-H and NSE immunoreactivities were observed following RNDA 
cellular differentiation (Figure  4-9 H and J, respectively). All immunoreactivities were 
cytoplasmic. No staining was observed if cells were only incubated with either the 
primary or secondary antibody (Appendix  7-6).   
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Figure  4-9: Phase contrast and fluorescence microscopy images of RNDA cells and D-RNDA cells. (A) a 
phase contrast microscopy image of RNDA cells at 33 °C, (B) a phase contrast microscopy image of RNDA 
cells at 39 °C (denoted as D-RNDA cells), (C and D) cells stained with NF-L monoclonal antibody (green 
channel), (E and F) cells stained with NF-M monoclonal antibody (green channel), (G and H) cells stained 
with NF-H monoclonal antibody (green channel) and (I and J) cells stained with NSE monoclonal antibody 
(green channel). Nuclei are stained with DAPI (blue channel). 
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4.8.2. Effect of Flavonoids on the Regulation of mRNA Expression Levels in 
D-RNDA Cells 
As illustrated in Figure  4-9, RNDA cells differentiate along the neuronal lineage upon 
shifting them to a non-permissive temperature (i.e. differentiation conditions); where the 
temperature-sensitive mutant of the SV40 large T-antigen is inactivated. Since they 
possess the ability to undergo differentiation, it was of interest to evaluate the effects of 
the flavonoids on the regulation of mRNA expression of the six selected estrogen 
responsive genes in D-RNDA cells (i.e. RNDA cells grown under differentiation conditions). 
In this study, the analysis time points were chosen to be day 1 and day 4 following 
initiation of differentiation (refer to Figure  3-6). Cells were treated for 24 hours prior to 
RNA isolation with 0.1 % DMSO, 10 nM E2, 10 nM E2 plus 500 nM Fulvestrant or 10 µM of 
each of the flavonoids (Section  3.2.7.2). 
 
Experiments described hereafter were evaluated based on two endpoints, namely (1) the 
impact of the process of cellular differentiation itself on the regulation of mRNA 
expression levels of the selected E2-regulated genes and (2) the responsiveness of the 
selected genes towards 17β-Estradiol or the flavonoids as RNDA cells undergo 
differentiation. 
 
In Figure  4-10 A, Cml-5 mRNA expression was not detectable in the day 0 sample treated 
with DMSO (green baseline set to 0) (also referred to as expression levels observed in the 
DMSO-treated RNDA cells grown under proliferative conditions). Cml-5 mRNA became 
measurable during cellular differentiation. Hence, gene expression data of Cml-5 were 
normalized in these set of experiments against the day 1 differentiated sample treated 
with DMSO. At day 1 following initiation of differentiation, Cml-5 mRNA expression was 
found to be significantly up-regulated in response to E2 (1.74 ± 0.26 fold) and Genistein 
(10.54 ± 1.79 fold) as compared to the day 1 differentiated sample treated with DMSO. 
The effect of E2 on the regulation of Cml-5 mRNA expression was completely antagonized 
by Fulvestrant (1.01 ± 0.21 fold); indicating the involvement of ERβ in this effect. There 
was a slight increase in Cml-5 mRNA expression from day 1 up to day 4 following initiation 
of differentiation, implying that the process of RNDA cellular differentiation had an effect 
on the regulation of mRNA expression of Cml-5, yet no significant additional effects on 
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mRNA expression levels were observed in response to E2 or the flavonoids as compared 
to the day 4 differentiated sample treated with DMSO. Nevertheless, an observable 
increase (2.61-fold) in Cml-5 mRNA expression was noticed in response to Genistein 
treatment only as compared to the day 4 differentiated sample treated with DMSO, 
although this was statistically not significant. 
 
In Figure  4-10 B, mRNA expression of Sox-18 was detectable in the day 0 sample treated 
with DMSO. Therefore, data were normalized against the day 0 sample treated with 
DMSO (black baseline set to 1). At day 1 following initiation of differentiation, an 
observable increase (8-fold) in Sox-18 mRNA expression was noticed in response to 
Genistein treatment only as compared to the day 1 differentiated sample treated with 
DMSO, although this was statistically not significant. At day 4 following initiation of 
differentiation, expression of Sox-18 mRNA remained at baseline levels with no significant 
additional effects on mRNA expression levels observed in response to E2 or the flavonoids 
as compared to the day 4 differentiated sample treated with DMSO. 
 
In Figure  4-10 C, mRNA expression of Krt-19 was also detectable in the day 0 sample 
treated with DMSO. Hence, data were normalized against the day 0 sample treated with 
DMSO (black baseline set to 1). At day 1 following initiation of differentiation, an 
up-regulation of Krt-19 mRNA was noticed as compared to expression levels observed in 
the DMSO-treated RNDA cells grown under proliferative conditions (i.e. the set baseline). 
Additionally, a 1.32-fold significant increase in Krt-19 mRNA expression was noticed in 
response to E2 treatment as compared to the day 1 differentiated sample treated with 
DMSO. This effect was shown to be completely antagonized by Fulvestrant. In addition, 
there was an observable increase in Krt-19 mRNA in response to the isoflavones: 
Genistein (1.93-fold), Daidzein (1.62-fold) and Equol (1.46-fold) as compared to the day 1 
differentiated sample treated with DMSO; however values did not reach statistical 
significance. At day 4 after initiation of differentiation, expression of Krt-19 mRNA was 
dramatically reduced to baseline levels, implying that the process of RNDA cellular 
differentiation had an effect on the regulation of mRNA expression of Krt-19, yet no 
significant additional effects on mRNA expression levels were observed in response to E2 
or the flavonoids as compared to the day 4 differentiated sample treated with DMSO. 
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Figure  4-10: Effect of flavonoids on the regulation of mRNA expression of Cml-5, Sox-18 and Krt-19 in 
D-RNDA cells at day 1 and day 4 following initiation of differentiation. D-RNDA cells were treated with 
0.1 % DMSO, 10 nM E2, 10 nM E2 plus 500 nM Fulvestrant, 10 µM of the naringenin-type flavanones (grey 
bars) or 10 µM of the isoflavones (black bars) for 24 hours prior to RNA isolation. In Panel A, data are 
normalized against the day 1 differentiated sample treated with DMSO and expression in response to 
DMSO treatment at the day 0 sample is represented by a green horizontal line set to 0. In Panels B and C, 
expression in response to DMSO treatment at the day 0 sample is represented by a black horizontal line set 
to 1. Data are normalized against the day 0 sample treated with DMSO. Asterisks indicate significance from 
the day 1 differentiated sample treated with DMSO: * p ≤ 0.05 and ** p ≤ 0.01. 
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In all panels of Figure  4-11 described hereafter, mRNA expression of the genes was 
detectable in the day 0 sample treated with DMSO (also referred to as expression levels 
observed in the DMSO-treated RNDA cells grown under proliferative conditions). Thus, 
data were normalized against the day 0 sample treated with DMSO (black baseline set to 
1). In contrast to the regulation of expression of Krt-19 mRNA, regulation of expression of 
Nefm mRNA was at baseline levels at day 1 following initiation of differentiation with no 
significant additional effects on mRNA expression levels observed in response to E2 or the 
flavonoids as compared to the day 1 differentiated sample treated with DMSO (Figure 
 4-11 A). However, an up-regulation of Nefm mRNA was noticed at day 4 following 
initiation of differentiation as compared to the set baseline, yet no significant additional 
effects on mRNA expression levels were observed in response to E2 or the flavonoids as 
compared to the day 4 differentiated sample treated with DMSO. 
 
In Figure  4-11 B, regulation of expression of Zdhhc-2 mRNA was at baseline levels at day 1 
following initiation of differentiation, however additional effects on mRNA expression 
levels were observed in response to E2 or the flavonoids as compared to the day 1 
differentiated sample treated with DMSO. In particular, decreased expression of Zdhhc-2 
mRNA was observed in response to E2 treatment (0.75-fold) at day 1 following initiation 
of differentiation as compared to the day 1 differentiated sample treated with DMSO, 
although values did not reach statistical significance. This effect was completely 
antagonized by Fulvestrant. Similar to E2, decreased expression of Zdhhc-2 mRNA was 
also observed in response to 8-Prenylnaringenin (0.75-fold), Naringenin (0.82-fold), 
Genistein (0.74-fold), Daidzein (0.83-fold) and Equol (0.80-fold) as compared to the day 1 
differentiated sample treated with DMSO, even though statistical significance was also 
not reached. At day 4 following initiation of differentiation, there was an up-regulation of 
Zdhhc-2 mRNA expression as compared to expression levels observed in the 
DMSO-treated RNDA cells grown under proliferative conditions (i.e. the set baseline), 
implying that the process of RNDA cellular differentiation had an effect on the regulation 
of mRNA expression of Zdhhc-2. A significant decrease in Zdhhc-2 mRNA expression was 
noticed in response to E2 (0.65-fold) as compared to the day 4 differentiated sample 
treated with DMSO. Once again, this effect was completely antagonized by Fulvestrant. 
Similar to E2, decreased expression of Zdhhc-2 mRNA was noticed in response to 
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8-Prenylnaringenin (0.73-fold), Naringenin (0.75-fold), 6-(1,1-Dimethylallyl)naringenin 
(0.76-fold) and Daidzein (0.67-fold), yet statistical significance was only reached in 
response to Genistein (0.66-fold) and Equol (0.65-fold) as compared to the day 4 
differentiated sample treated with DMSO (Figure  4-11 B). 
 
As shown in Figure  4-11 C, an up-regulation of Slc6a4 mRNA expression was observed at 
day 1 following initiation of differentiation as compared to the set baseline. Decreased 
expression of Slc6a4 mRNA was noticed in response to E2 treatment (0.70-fold) as 
compared to the day 1 differentiated sample treated with DMSO, even though values did 
not reach statistical significance. This effect was completely antagonized by Fulvestrant. 
Similar to E2, decreased expression of Slc6a4 mRNA was observed in response to 
8-Prenylnaringenin (0.71-fold), Naringenin (0.72-fold), Genistein (0.55-fold), Daidzein 
(0.80-fold) and Equol (0.80-fold) as compared to the day 1 differentiated sample treated 
with DMSO, nevertheless statistical significance was also not reached. At day 4 following 
initiation of differentiation, expression of Slc6a4 mRNA was reduced to baseline levels 
implying that the process of RNDA cellular differentiation had an effect on the regulation 
of mRNA expression of Slc6a4, yet no significant additional effects on mRNA expression 
levels were observed in response to E2 or the flavonoids as compared to the day 4 
differentiated sample treated with DMSO (Figure  4-11 C). 
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Figure  4-11: Effect of flavonoids on the regulation of mRNA expression of Nefm, Zdhhc-2 and Slc6a4 in 
D-RNDA cells at day 1 and day 4 following initiation of differentiation. D-RNDA cells were treated with 
0.1 % DMSO, 10 nM E2, 10 nM E2 plus 500 nM Fulvestrant, 10 µM of the naringenin-type flavanones (grey 
bars) or 10 µM of the isoflavones (black bars) for 24 hours prior to RNA isolation. Expression in response to 
DMSO treatment in the day 0 sample is represented by a black horizontal line set to 1. Data are normalized 
against the day 0 sample treated with DMSO. Hash signs indicate significance from the day 4 differentiated 
sample treated with DMSO: # p ≤ 0.05. 
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5. DISCUSSION 
 
Estrogens are known to exert many actions on different brain regions; amongst them are 
the raphe nuclei, where ERβ is the most abundantly expressed estrogen receptor subtype. 
Accumulating evidence suggests that estrogenic effects on the raphe nuclei are primarily 
important for regulating significant neuropsychological behaviors, including depression, 
mood swings, anxiety and panic behaviors, by releasing serotonin (Bethea et al., 2003; 
Nomura et al., 2005; Donner and Handa, 2009). Because of this connection, phases of 
intense hormone fluctuations, for instance during menopause, are often associated with 
several mood disturbances that often reduce the quality of life of menopausal women. 
Accordingly, long-term use of HRT appeared to be the method of choice for many 
menopausal women to help alleviate vasomotor symptoms, which may include 
neuropsychological changes such as depression. Irrespective of the beneficial effects of 
HRT to alleviate mood disorders (Klaiber et al., 1979; Schmidt et al., 2000; Rasgon et al., 
2002), a number of health risks attributed to HRT, such as breast and endometrial 
cancers, were arising (Dupont and Page, 1991; Steinberg et al., 1991; Beral et al., 1999; 
Chlebowski et al., 2003; Chlebowski et al., 2009). Hence, a recurrence of consumer 
interest in phytoestrogens, i.e. plant-derived secondary metabolites possessing 
estrogen-like bioactivity, has been noticed due to their occurrence in medicinal plant 
extracts and a wide variety of food items including dietary supplements with respective 
health claims (Henderson et al., 1994; Sullivan et al., 1997; Torgerson and Bell-Syer, 
2001). Even though these substances are sold as medicinal plant remedies or as dietary 
supplements and have reached quite remarkable market shares, sufficient data regarding 
their efficacy and safety remains to be unavailable. 
 
Isoflavones and naringenin-type flavanones, collectively known as the flavonoids, belong 
to a group of polyphenolic plant-derived secondary metabolites known to possess 
estrogen-like bioactivities as they structurally or functionally mimic mammalian 
estrogens, partial or in total, and therefore may have significant impact on women’s 
health (Cos et al., 2003; Ososki and Kennelly, 2003). Nevertheless, conclusive data on 
their activity, measured in this study by their transactivational activity on ERβ, as well as 
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their effects on the regulation of mRNA expression of estrogen responsive genes in the 
raphe nuclei region of the brain remained to be elusive due to the lack of suitable raphe 
nuclei-derived cellular models expressing sufficient amounts of functional estrogen 
receptor β. 
 
Hence, a raphe nuclei-derived cell line that expresses a functional ERβ was sought as a 
model to investigate effects of flavonoids in raphe nuclei in vitro. In this regard, 
RN46A-B14 cells derived from embryonic day 13 rat medullary raphe nuclei, were 
primarily used in this study as the main cellular source because previous reports indicate 
that those particular cells contain the same complement of nuclear estrogen receptors as 
the rat raphe serotonin neurons, hence providing a convenient in vitro cellular model for 
the study of estrogen action in raphe nuclei (Bethea et al., 2003). Nonetheless, expression 
of endogenous ERβ in these cells was not sufficient to pursue downstream investigations 
of estrogen-dependent activities (Appendix  7-1). Therefore, a rat raphe nuclei-derived in 
vitro model that expresses sufficient amounts of functional estrogen receptor β was 
established (termed RNDA cells) by stably transducing its parent cell line, RN46A-B14 
cells, with a suitable lentiviral expression vector encoding a human estrogen receptor β 
gene. The reason for stably integrating a human ESR2 instead of a rat Esr2 in the studied 
rat cell model was due to two reasons: (1) availability of human ESR2 DNA fragment in the 
lab and (2) human ERβ shows approximately 89% identity in its translated region to the 
rat ERβ as compared to any other mammalian ERβ (Enmark and Gustafsson, 1999). 
 
5.1. Stable Transduction, Expression and Functional Characterization of 
Transgenic ERβ in RNDA Cells 
The use of simple retroviruses, such as oncoretroviral-based vectors, is becoming 
substituted by more sophisticated and efficient lentiviral expression vector systems that 
have superior transduction efficiency in modifying cells in vitro and in vivo (Bukrinsky et 
al., 1993). Given that the provided RN46A-B14 cells in this study showed very low 
expression of endogenous ERβ, downstream in vitro investigations of effects of 
17β-Estradiol and the flavonoids on the raphe nuclei could not be pursued. To overcome 
this deficit, lentiviral-based expression vectors, namely p6NST50 and p6NST50 + ERβ, 
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were the method of choice to successfully integrate human ESR2 into the RN46A-B14 
cellular genome. Two different viral stock dilutions (either UD or 1:10 diluted) were used 
to transduce RN46A-B14 cells. Percentage of RN46A-B14 cells transduced with the 
undiluted p6NST50 + ERβ viral particles (6.39 %) was lower than the percentage of 
RN46A-B14 cells transduced with the 1:10 diluted p6NST50 + ERβ viral particles (24.48 %). 
The reason for the low transduction efficiencies observed with the undiluted viral 
particles was due to the high toxic viral effects that eventually led to death of infected 
RN46A-B14 cells. Accordingly, RN46A-B14 cells transduced with the 1:10 diluted lentiviral 
vectors were chosen for the present study. Specifically, the RN46A-B14 cells transduced 
with the 1:10 diluted p6NST50 + ERβ were denoted as RNDA cells. The successful 
transduction of RNDA cells with ESR2 was further verified in a two-step approach 
demonstrating first the expression of the transgenic human ERβ and subsequently its 
functional characterization. 
 
Using quantitative real-time PCR, transgenic human ESR2 mRNA expression was 
successfully confirmed in RNDA cells in contrast to the transduced RN46A-B14 cells with 
p6NST50 as well as the untransduced RN46A-B14 cells. Given that mRNA expression 
levels do not always directly correlate with protein expression levels (Hrabovszky et al., 
1998), Western blot analysis of RNDA whole-cell protein extracts confirmed the 
expression of the transgenic ERβ, as indicated at 55 kDa, as opposed to the transduced 
RN46A-B14 cells with p6NST50 and the untransduced RN46A-B14 cells. Functional activity 
of transgenic ERβ was later verified using luciferase reporter gene assays, where the 
newly generated RNDA cells were transiently transfected with the firefly luciferase 
reporter gene under the control of a double ERE-dependent promoter. Cell exposure to 
increasing concentrations of 17β-Estradiol resulted in a sigmoidal dose-response curve 
corresponding to an EC50
 of 4.0 × 10−10 M. The EC50 for 17β-Estradiol in the present study 
demonstrates higher sensitivity than the established and highly sensitive luciferase assay 
in MVLN cells (a derivative of an ERα-positive breast cancer cell line, MCF-7, stably 
transfected with a vitellogenin-A2-promoter / luciferase reporter construct) as well as the 
ERα-dependent human bone-derived U2OS cells; measuring a 17β-Estradiol response 
with an EC50 of 5 × 10
−12 M and 5 × 10−11 M, respectively (Zierau et al., 2006). 
Nevertheless, this minor difference in EC50 does not really affect the degree of affinity of 
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E2 to both ER subtypes as it is most probably cell-specific. A final step for the 
characterization of the transgenic ERβ was the treatment with the selective ERβ agonist 
(Diarylpropionitril) and the selective ERα agonist (Propyl pyrazole triol). The study has 
shown a concentration-dependent increase in luciferase output in response to 
Diarylpropionitril as opposed to the null effects observed when cells were exposed to 
Propyl pyrazole triol, which clearly validates the generated system and indicates that any 
observed estrogenic activity in RNDA cells is specifically mediated through the transgenic 
ERβ and not ERα. Those findings are highly consistent with previous findings from Bethea 
and colleagues (2003) who illustrated, using immunocytochemistry and quantitative 
real-time PCR, that RN46A-B14 cells are completely devoid of the ERα subtype (Bethea et 
al., 2003). 
 
5.2. Transactivational Activity of Flavonoids in RNDA Cells 
By establishing the functionality and sensitivity of the new cell model, the next aim of the 
present study was to evaluate the transactivational activity of three isoflavones and four 
naringenin-type flavanones on the transgenic ERβ in RNDA cells; as conclusive data on 
their transactivational activity and ultimately their estrogenic potency in the raphe nuclei 
region of the brain remain to be elusive.  
 
Using the same aforementioned luciferase reporter gene assay, it has been shown in this 
study that treatment with all three isoflavones resulted in a high expression of the firefly 
luciferase starting at the lowest dose of 10 nM (Figure  4-5). All three isoflavones are 
known to bind both estrogen receptor subtypes, yet with a higher relative binding affinity 
for ERβ than for ERα (Kuiper et al., 1998). Agonistic activities of the isoflavones via the 
estrogen receptors are particularly dependent on the position of the hydroxyl group at 
carbon-7 and carbon-4’ in the core structure of the isoflavones (Joung et al., 2003; 
Takeuchi et al., 2009). As clearly depicted in Figure  2-7, the chemical structures of all 
three isoflavones fulfill the above specific structural requirements for agonistic activity of 
isoflavones via ERβ. Accordingly, clear agonistic activities were demonstrated in RNDA 
cells in response to increasing concentrations of all three isoflavones. The high activity of 
the isoflavones in the ERβ-raphe nuclei cell-based system is in accordance to their high 
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activity in another reporter gene assay using Chinese Hamster Ovarian cells transiently 
transfected with an expression plasmid for human ERα or human ERβ (Takeuchi et al., 
2009). Nevertheless, the induction of the luciferase reporter gene in response to the 
isoflavones was shown to be substantially higher in the ERβ-dependent RNDA cells in this 
study as compared to the study of Takeuchi and colleagues (2009). The variation in 
luciferase induction in response to the isoflavones between different cell-based models 
could possibly be due to the recruitment of cell-type specific co-regulators following the 
differential nuclear receptor conformational changes in response to the isoflavones 
(Routledge et al., 2000). A slight additional effect was also observed in RNDA cells in 
response to a co-treatment of 10 nM 17β-Estradiol and 1 µM of either Genistein or 
Daidzein, but not Equol, if compared to the 17β-Estradiol single dose treatment (Figure 
 4-5). This slight additional effect is possibly due to the stabilization of the firefly luciferase 
reporter enzyme leading to an increase in the bioluminescent signal while conducting the 
experiment (Sotoca et al., 2010). Nonetheless, by reflecting this observation in whole 
animal models, this may probably alter the estrogenic potency of the three isoflavones 
according to the circulating endogenous 17β-Estradiol and therefore may ultimately show 
significant impacts on human health (Cos et al., 2003; Ososki and Kennelly, 2003). 
 
In the ERβ-dependent RNDA cells, a high transactivational activity on the transgenic ERβ 
has also been observed in response to Naringenin in a concentration-dependent manner 
starting at the lowest dose of 100 nM, albeit to a lesser extent than its structurally related 
compound, Genistein. Relative binding affinities of Naringenin versus Genistein for ERβ  is 
0.11 versus 87, respectively (Kuiper et al., 1998). Both dietary substances are structurally 
related by possessing hydroxyl groups at carbon-7 and carbon-4’ (Figure  2-8). However, 
the difference in the binding affinities is due to the fact that the aromatic B-ring is not in 
conjugation with the aromatic A-ring in Naringenin as compared to Genistein. This is due 
to the absence of the double bond between carbon-2 and carbon-3 in Naringenin on its 
C-ring (Vaya and Tamir, 2004). 
 
In this study, Naringenin showed high activity in the ERβ-raphe nuclei cell-based system 
as compared to its to weak activity in a different reporter gene assay using 293 human 
embryonal kidney cells transiently transfected with a luciferase reporter plasmid as well 
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as an expression plasmid for human ERβ, where Naringenin induced luciferase expression 
starting at the lowest dose of 1 µM (Kuiper et al., 1998). Additionally, Ruh and colleagues 
(1995) reported the weak activity of Naringenin in their tested micromolar range in an 
ERα-dependent MCF-7 cells transiently transfected with a luciferase reporter plasmid 
(Ruh et al., 1995). Furthermore, Kretzschmar and colleagues (2010) as well as Zierau and 
colleagues (2002) have also reported no transactivational activity for Naringenin in their 
ERα-dependent studied cell model, the MVLN breast cancer cells, at concentrations lower 
than 10 µM (Zierau et al., 2002; Kretzschmar et al., 2010). By comparing results from this 
study and results from the abovementioned studies, the present study clearly states that 
Naringenin is highly active in the ERβ-dependent raphe nuclei cell model as compared to 
other ER-dependent mammalian cell models. 
 
It has previously been reported that the addition of a prenyl group (i.e. prenylation) at 
carbon-8 on the A-ring of the Naringenin backbone results in 8-Prenylnaringenin, a 
compound with stronger estrogenic characteristics (Milligan et al., 2000; Zierau et al., 
2002; Kretzschmar et al., 2010). Numerous studies have pointed out the strong estrogenic 
potency of 8-Prenylnaringenin in various cellular models and organs expressing either ERα 
or ERβ (Milligan et al., 2000; Zierau et al., 2002; Effenberger et al., 2005; Overk et al., 
2008; Zierau et al., 2008). In this study, a high transactivational activity was also observed 
on the transgenic ERβ in RNDA cells in response to 8-Prenylnaringenin in a 
concentration-dependent manner. Nevertheless, prenylation did not result in an obvious 
difference between the transactivational activity of 8-Prenylnaringenin and its parent 
compound Naringenin on the transgenic ERβ in RNDA cells. In fact, the study pointed out 
a significant antagonistic effect of 8-Prenylnaringenin when co-added with 17β-Estradiol 
in RNDA cells as opposed to a co-treatment of 17β-Estradiol and Naringenin. Hence, one 
could hypothesize that the process of prenylation could serve as a possible structural 
modification that could lead to antagonistic effects of prenylflavonoids. By reflecting this 
observation in whole animal models, this may possibly alter the estrogenic potency of 
8-Prenylnaringenin according to the circulating endogenous 17β-Estradiol and therefore 
may ultimately show significant impacts on human health (Cos et al., 2003; Ososki and 
Kennelly, 2003). The antagonistic effect in response to the process of naringenin 
prenylation has also been observed in RNDA cells following a co-treatment of 
DISCUSSION 
_____________________________________________________________________ 
114 
7-(O-prenyl)naringenin-4’-acetate and 17β-Estradiol, therefore, substantiating the 
aforementioned proposed hypothesis. Additionally, 7-(O-prenyl)naringenin-4’-acetate, 
showed weak transactivational activity on ERβ in RNDA cells starting at the lowest 
concentration of 1 µM. This was also noticed in the ERα-dependent MVLN cells at the 
same tested concentration range (Kretzschmar et al., 2007). Hence, it may well be 
speculated that 7-(O-prenyl)naringenin-4’-acetate possesses considerable affinity for both 
estrogen receptor subtypes, yet may exhibit weak activity on downstream 
transactivational pathways. 
 
Surprisingly and in contrast to the above tested compounds, the current study did not 
pick-up any transactivational activity in RNDA cells in response to 
6-(1,1-Dimethylallyl)naringenin. These results are in contrast to studies reported by Zierau 
and colleagues, who reported a high measurable luciferase output in a 
concentration-dependent manner in other cell-based assays, such as the ERα-dependent 
MVLN cells, ERα-dependent human bone-derived U2OS cells and ERβ-dependent human 
bone-derived U2OS cells (Zierau et al., 2002; Zierau et al., 2008). Therefore, one could 
speculate that 6-(1,1-Dimethylallyl)naringenin could show selective estrogen receptor 
modulator-like properties (SERM) (Nilsson et al., 2001; Gruber et al., 2002; Shang and 
Brown, 2002). SERMs are defined as ligands that could mimic the action of E2 in some 
tissues, yet lack E2-like actions in others (Gruber et al., 2002). SERMs and phytoestrogens, 
in addition to the endogenous estradiol, may induce different nuclear receptor 
conformational changes in its tertiary structure due to discrepancies in both steric and 
electrostatic properties (Paige et al., 1999). Therefore, the assembly of the transcription 
machinery following the recruitment of cell-type specific co-regulators could vary 
(Routledge et al., 2000). Accordingly, altering the ability of ERβ to recruit co-repressors or 
co-activators may possibly be different in the studied RNDA cell model as opposed to 
other cell models, hence affecting downstream transcriptional events.       
 
Certainly, it is worth noting that identifying and pointing out the estrogenic potency (i.e. 
calculating the EC50) of all test flavonoids would have provided a better image for proper 
comparison. However, based on the tested doses of all flavonoids in this study 
(i.e. 10 nM – 10 µM), calculation of the EC50 was not possible mathematically due to the 
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fact that the data do not fit in a sigmoidal dose-response relationship, where a plateau 
does not seem to be reached at 10 µM. Higher concentrations were not possible as the 
substances are most likely to show toxic effects on RNDA cells. Nevertheless, this study 
indicates that the high transactivational activity on ERβ and ultimately the strong 
estrogenicity of Genistein, Daidzein, Equol, Naringenin and 8-Prenylnaringenin in RNDA 
cells could possibly manifest itself in the raphe nuclei region of the brain, provided it can 
cross the blood brain barrier in significant amounts. 
 
5.3. Identification of Estrogen Responsive Genes in RNDA Cells 
Following the evaluation of the transactivational activity of the flavonoids on the 
transgenic ERβ in RNDA cells using luciferase reporter gene assays, it was of interest to 
assess the potential of flavonoids to regulate endogenous gene expression of estrogen 
responsive genes in RNDA cells. This approach was considered essential in order to 
investigate whether their activity on a reporter gene level can be mirrored on the level of 
regulation of expression of estrogen responsive genes as compared to regulation patterns 
in response to 17β-Estradiol. As a result, it was initially necessary to identify genes 
undergoing estrogenic regulation of expression via ERβ in RNDA cells using a DNA 
microarray, which was one of the main aims of the study presented here. 
 
From a total of 40,000 transcripts, 212 regulated transcripts with at least two fold-change 
of expression were identified. This list is comparably big since it is approximately twice as 
large as compared to identified genes in other ER-based cell systems, such as the ERα- 
and ERβ-dependent human bone-derived U2OS cells, where only 80 and 76 transcripts 
with at least two fold-change of expression were E2 regulated, respectively (Monroe et 
al., 2003). However, due to the different microarray approaches utilized between this 
study and the study of Monroe and colleagues (2003), a conclusive comparison would not 
be possible, as each system should be taken as a separate entity. From 212 E2-regulated 
transcripts in RNDA cells, the E2-dependent regulation of three serotonin-related genes, 
namely Slc6a4, serotonin receptor 3b (Htr-3b) and serotonin receptor 6 (Htr-6) was 
identified. This finding supports the hypothesis that estrogens influence serotonin 
signaling in raphe nuclei. Unfortunately, due to the low copy number of Htr-3b and Htr-6 
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in these cells, it was not possible to validate their E2-dependent regulation using 
quantitative real-time PCR. Instead, the attention was focused on Slc6a4, a gene encoding 
serotonin re-uptake transporter in relation to the special functional relevance in this 
serotonergic cell line, in addition to five other E2-responsive genes, namely Cml-5, Sox-18, 
Krt-19, Nefm and Zdhhc-2, which were selected according to specific features of 
estrogenic regulation of expression (Section  4.6). Interestingly, a number of olfactory 
receptors and voltage-gated ion channels as well as organic anion transporters where also 
regulated in response to E2 in RNDA cells (Appendix  7-4 and Appendix  7-5). Nonetheless, 
investigations on the role of these genes and others in raphe nuclei were postponed for 
further studies due to time limitations. 
 
Microarray analysis has been well known to exhibit a lower dynamic range for detecting 
gene expression levels (Morey et al., 2006). Thus, to verify the microarray results with a 
more sensitive analysis of gene expression, the six selected E2-regulated genes were 
analyzed using quantitative real-time PCR. On one hand, the expression of Cml-5, Sox-18 
and Krt-19 was observed to be E2 up-regulated, whereas the expression of Nefm and 
Zdhhc-2 was observed to be E2 down-regulated on the microarray and this was 
successfully and significantly confirmed using quantitative real-time PCR. On the other 
hand, the expression of Slc6a4 was observed to be E2 down-regulated in RNDA cells using 
microarray analysis, unfortunately this could not be confirmed using quantitative 
real-time PCR. Nevertheless, the regulation of expression of Slc6a4 in response to test 
substances was still considered throughout the course of this study; in relation to its 
special functional relevance in RNDA cells. 
 
5.4. Effect of Flavonoids on the Regulation of mRNA Expression Levels in 
RNDA Cells 
To study the effects of dietary estrogen-like compounds in RNDA cells, it is necessary to 
go through different levels of complexity where investigations start with reporter gene 
assays followed by analyses of their capacity to regulate endogenous gene expression in 
the studied cell model. From Section  5.2, the transactivational activity of the flavonoids 
descended in the order shown in Table  5-1. 
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Table  5-1: Transactivational activity of flavonoids in RNDA cells. 
(+++) Very high Activity, +++ High Activity, + Low Activity  
Substance Transactivational activity deduced from the   
reporter gene assays in RNDA cells 
GEN (+++) 
DAI (+++) 
EQ (+++) 
NAR +++ 
8-PN +++ 
7-O-PN + 
6-DMAN No activity 
 
Based on these results, it was vital to scrutinize whether the effects of flavonoids on 
luciferase expression can be mirrored on the basis of regulation of expression of the 
aforementioned six selected genes undergoing estrogenic regulation. However, out of all 
seven tested flavonoids in this study, 7-(O-prenyl)naringenin-4’-acetate was excluded 
from these set of experiments regarding gene expression analyses because it exhibited 
low activity on downstream transactivational pathways in RNDA cells and due to the fact 
that it is not yet known to be present in medicinal plant extracts and food items including 
dietary supplements with respective health claims. All flavonoids were used at a 
concentration of 10 µM, as deduced from results of the reporter gene assays, to achieve 
the maximum level of regulation of target gene expression.  
 
Effects of flavonoids on the regulation of mRNA expression levels in RNDA cells (Figure 
 4-8) were in accordance with their transactivational activity. In particular, it was shown in 
the present study that gene regulation patterns in response to 8-Prenylnaringenin, 
Genistein, Daidzein and Equol on the mRNA up-regulation of Cml-5, Sox-18 and Krt-19 as 
well as the down-regulation of Nefm and Zdhhc-2 are in line with regulation patterns in 
response to 17β-Estradiol, as summarized in Table  5-2. Surprisingly, there was no 
regulation of mRNA expression of Cml-5, Sox-18 and Krt-19 in response to Naringenin as 
opposed to its high transactivational activity in RNDA cells. Interestingly, mRNA 
down-regulation of Nefm and Zdhhc-2 were noticed in response to Naringenin in line with 
regulation patterns in response to 17β-Estradiol (Table  5-2).   
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Table  5-2: Regulation of mRNA expression of estrogen responsive genes in response to the flavonoids in 
RNDA cells as compared to E2. ↔ No regulation, ↑ Up-regulation, ↓Down-regulation 
Substance / 
Gene Symbol 
DMSO E2 8-PN NAR 6-DMAN GEN DAI EQ 
Cml-5 ↔ ↑ ↑ ↔ ↔ ↑ ↑ ↑ 
Sox-18 ↔ ↑ ↑ ↔ ↔ ↑ ↑ ↑ 
Krt-19 ↔ ↑ ↑ ↔ ↔ ↑ ↑ ↑ 
Nefm ↔ ↓ ↓ ↓ ↔ ↓ ↓ ↓ 
Zdhhc-2 ↔ ↓ ↓ ↓ ↔ ↓ ↓ ↓ 
Slc6a4 ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ 
 
The classical pathway of estrogenic action is via ER dimerization followed by binding to 
estrogen responsive elements in the promoter region of target genes, hence leading to 
altered transcription and translation (Section  2.4.1). However, most of the target genes 
regulated by ERs lack ERE-like sequences (O'Lone et al., 2004). Hence, their regulation is 
modulated via alternative “non-classical” pathways. These may include regulation of 
target genes by ERs without directly binding to DNA, but rather via the formation of the 
pre-initiation complex through protein-protein interactions with transcription factors, 
such as the Activator Protein-1, Specificity Protein-1 or the Nuclear Factor-kappa B 
(Nilsson et al., 2001; Bjornstrom and Sjoberg, 2005; Cheskis et al., 2007). Since Naringenin 
was able to induce high luciferase expression (mediated by ERE regulatory element) but 
not expression of Cml-5, Sox-18 and Krt-19 in RNDA cells, one could argue that regulation 
of Cml-5, Sox-18 and Krt-19 in RNDA cells is possibly modulated via a “non-classical” 
pathway. In line with this thought, it can also be argued that the down-regulation of Nefm 
and Zdhhc-2 is possibly mediated either by an ERE regulatory element or by a different 
mechanism than the one employed for the regulation of Cml-5, Sox-18 and Krt-19 in 
RNDA cells due to the fact that the regulation of Nefm and Zdhhc-2 in response to 
Naringenin were in line with 17β-Estradiol. In addition, the results clearly indicate that 
8-Prenylnaringenin, Genistein, Daidzein and Equol act via the same mechanism as 
17β-Estradiol in RNDA cells in the regulation of expression of the selected estrogen 
responsive genes, irrespective of the employed regulatory element. 
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Furthermore, 6-(1,1-Dimethylallyl)naringenin did not regulate the mRNA expression level 
of Cml-5, Sox-18, Krt-19, Nefm and Zdhhc-2 in the present study (Table  5-2), in 
accordance to its missing transactivational activity on reporter gene expression through 
ERβ (Table  5-1). In contrast to the present study, Zierau and colleagues have previously 
reported that 6-(1,1-Dimethylallyl)naringenin seems to  exert estrogenic activity in vivo 
predominantly by influencing uterine mRNA expression of estrogen responsive genes 
containing ERE (Zierau et al., 2004; Zierau et al., 2008). It has also been reported that 
6-(1,1-Dimethylallyl)naringenin lacked any proliferative effect on the uterus due to the 
fact that uterine proliferation appears to be mediated by mechanisms other than 
ERE-mediated mechanisms (O'Brien et al., 2006). Taking these studies into consideration, 
6-(1,1-Dimethylallyl)naringenin still seems to show SERM-like properties, as it can 
influence mRNA expression of estrogen responsive genes in the uterus (Zierau et al., 
2004; Zierau et al., 2008), yet lacks the ability to regulate the expression of the six 
selected estrogen responsive genes in RNDA cells in the present study. Moreover, this 
study clearly reveals that 6-(1,1-Dimethylallyl)naringenin does not have any effects on the 
regulation of expression of estrogen responsive genes in the raphe nuclei-derived cell 
model neither via the classical ERE-dependent pathway nor via any other “non-classical” 
pathway. Nevertheless, further experimentations are required to support this 
assumption. 
 
Unfortunately, the study pointed out no regulation of mRNA expression of Slc6a4 in 
response to 17β-Estradiol and all flavonoids (Table  5-2). This is surprising because this 
contradicts results reported by Pecins-Thompson and colleagues (1998), where they 
clearly showed a down-regulation of Slc6a4 mRNA in rhesus macaques in response to 
17β-Estradiol, which is consistent with the therapeutic efficacy of 17β-Estradiol on mood 
in post-menopausal women (Pecins-Thompson et al., 1998). Nonetheless, the regulation 
of expression of Slc6a4 mRNA was still considered for further experimentations in this 
study; in relation to the final aim of the present study that is evaluating the effects of the 
flavonoids on the regulation of mRNA expression of the six selected E2-regulated genes in 
RNDA cells undergoing neuronal differentiation (denoted as D-RNDA cells). 
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5.5. Effect of Flavonoids on the Regulation of mRNA Expression Levels in 
D-RNDA Cells  
RNDA cells, a rat serotonergic neuronal cell line, encode a temperature-sensitive mutant 
of the SV40 large T-antigen just as their parent cell line RN46A-B14 cells. Accordingly, 
differentiation of this cell line along the neuronal lineage is initiated in response to 
shifting cells from their proliferative conditions (i.e. permissive temperatures) to 
differentiation conditions (i.e. non-permissive temperatures); in which the cells are no 
longer under the mitotic drive of the temperature-sensitive mutant of the SV40 large 
T-antigen (White and Whittemore, 1992; Whittemore and White, 1993; White et al., 
1994). The expression of intracellular neuronal differentiation markers was investigated in 
this study to primarily evaluate the switch of RNDA cells from their proliferative to 
differentiation cellular status using immunocytochemistry (Section  3.2.8.2). In this study, 
potential markers were represented by neurofilament proteins which are class IV 
intermediate 10 nm filamentous proteins composed of three subunits (low, medium and 
high). The names were designated according to their distinct molecular weights; where 
NF-L is 68-70 kDa, NF-M is 145-160 kDa and finally NF-H is 200-220 kDa.  Neurofilaments 
are found in neurons of vertebrates and are known to be formed in high concentrations 
during the development of neuronal axons (Cleverley et al., 1998; Lalonde and Strazielle, 
2003). NSE, an acid soluble protein of the glycolytic isoenzyme enolase that is composed 
of two gamma subunits, was additionally selected for this study. It is exclusively confined 
to neurons of the central and peripheral nervous systems as well as cells of 
neuroendocrine origin and is thought to serve as a growth factor in neurons (Schmechel 
et al., 1978; Schmechel et al., 1980; Kirino et al., 1983). 
 
Immunocytochemistry results presented in this study complement earlier work by White 
and colleagues (1994) (White et al., 1994), where RNDA cells expressed high levels of NF-L 
and NF-M in addition to low levels of NF-H and NSE. As cells differentiated (i.e. designated 
as D-RNDA cells), an enhanced NSE and neurofilament expression was noticed, indicating 
successful initiation of RNDA cellular differentiation. Unfortunately, RNDA cells do not 
proliferate as monolayer cultures. As a result, quantitation and comparative analysis of 
the presented immunostainings in this study could not be reported. 
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Following the proof of cellular differentiation, two main questions were addressed: (1) 
would the process of cellular differentiation itself regulate mRNA expression levels of the 
six selected E2-regulated genes? and (2) would the genes retain their responsiveness 
towards 17β-Estradiol or the flavonoids as RNDA cells differentiate? A prerequisite to the 
abovementioned questions was the proof of the stable expression of the ERβ as RNDA 
cells undergo differentiation. This is not considered trivial as retroviruses may in some 
cases possess an important drawback that is the inability to sustain expression of 
transgenes due to transcriptional silencing or self-inactivation (Swindle and Klug, 2002). In 
view of that, the present study pointed out sufficient mRNA expression of the transgenic 
ERβ in D-RNDA cells, which was highly maintained throughout the experimental period, as 
compared to expression levels in RNDA cells (Appendix  7-7). 
 
Initially, the impact of cellular differentiation on the regulation of mRNA expression levels 
of the six selected E2-regulated genes was evaluated. Apart from Sox-18, it was clearly 
shown that the process of cellular differentiation had either increased or decreased 
regulation of mRNA expression levels of the remaining genes as compared to levels 
during cellular proliferation (The set baseline in Figure  4-10 and Figure  4-11). In 
particular, an increase in mRNA expression levels of Nefm and Zdhhc-2 was observed 
throughout the process of cellular differentiation from day 1 up to day 4. The former gene 
encodes the NF-M protein. Thus, the up-regulation of Nefm in D-RNDA cells at day 4 
following initiation of differentiation substantiates the immunocytochemistry results 
presented in this study. In addition, Zdhhc-2 encodes a palmitolyation-related enzyme 
required for neuronal protein palmitolyation that are essential for neuronal development 
and cellular differentiation (Fukata and Fukata, 2010). Accordingly, increased regulation 
of Zdhhc-2 during cellular differentiation was to be expected. Based on these 
observations, one could argue that an up-regulation of Zdhhc-2 mRNA expression in 
RNDA cells undergoing differentiation may serve as an additional marker for neuronal 
differentiation in the raphe nuclei. Additionally, keratin-19 is a member of the keratin 
family, which are major protein components of the intermediate filaments responsible for 
the cell’s cytoarchitecture (Choi et al., 2000). Hence, a down-regulation of Krt-19 mRNA 
expression in RNDA cells undergoing differentiation could also serve as a further marker 
for neuronal differentiation in the raphe nuclei. Nonetheless, quantification of the 
respective gene products must be pursued to confirm the above observations. 
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Surprisingly, the regulation of Slc6a4 mRNA expression was reduced to baseline levels 
from day 1 up to day 4 following initiation of differentiation (Figure  4-11). As previously 
mentioned, Slc6a4 encodes a serotonin re-uptake transporter in this serotonergic cell 
line, a monoamine transporter protein which functions in all serotonergic neurons by 
means of transporting serotonin from synaptic spaces into presynaptic neurons (Murphy 
et al., 2008).  The reason why a down-regulation, instead of the expected up-regulation, 
was noticed at day 4 following initiation of differentiation is not yet clear. Furthermore, 
serotonin production was found to be extremely low in D-RNDA cells (Personal 
Communication; Annekathrin Schwabe, 2007). Thus, cell function analysis in relation to a 
serotonergic context was difficult to pursue during the time frame of the present study. 
 
Besides the change in regulation of mRNA expression levels in response to the process of 
cellular differentiation, a change in the responsiveness towards 17β-Estradiol and the test 
substances was also noticed in D-RNDA cells. For example, a down-regulation of Slc6a4 
mRNA expression in response to 17β-Estradiol and the flavonoids was observed in 
D-RNDA cells as opposed to no regulation in RNDA cells, which indicates that the process 
of RNDA cellular differentiation enhances the regulatory mechanism required for the 
suppression of Slc6a4 mRNA expression by 17β-Estradiol and the flavonoids. This clearly 
associates with the ongoing research stating that 17β-Estradiol treatment down-regulates 
Slc6a4 mRNA, which is consistent with the therapeutic efficacy of E2 on mood in 
post-menopausal women (Pecins-Thompson et al., 1998). In addition, regulation of mRNA 
expression of Cml-5 and Sox-18 was highly sensitive to Genistein treatment only in 
D-RNDA cells in a time point-dependent manner. The mechanism underlying this obvious 
sensitivity of Cml-5 and Sox-18 regulation in response to Genistein treatment and 
ultimately its biological relevance is not yet clear. Nonetheless, the present study clearly 
shows that the impact of the process of cellular differentiation itself on the regulation of 
expression of the six selected target genes seemed to be highly dominant over the effects 
caused in response to either 17β-Estradiol or any of the tested flavonoids at the studied 
time points. Results from D-RNDA cells are yet to be highly interpreted based on 
additional experiments. However, this is considered challenging given that insufficient cell 
quantities for larger experiments are currently obtainable; in other words, optimization of 
the differentiation protocol is a prerequisite to be able to perform further investigations 
on D-RNDA cells.  
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6. CONCLUSIONS AND FUTURE DIRECTIONS  
 
In the present study, the stable transduction of RN46A-B14 cells with the human ESR2 
following a lentiviral expression system was successfully achieved; thereby generating the 
new rat raphe nuclei-derived cell line, RNDA cells. The success of this transduction has 
been demonstrated biochemically by determining the ERβ expression on the mRNA as 
well as protein level and by characterizing its function using the firefly luciferase reporter 
gene under the control of a double ERE-dependent promoter. The reporter gene assay 
has also been used to demonstrate that target gene transcription in this cell line is solely 
and specifically mediated via the transgenic ERβ.  Hence, this study clearly presents the 
establishment of an in vitro raphe nuclei-derived model that overexpresses a functional 
ERβ to investigate downstream effects of dietary substances in the raphe nuclei.  
 
Accordingly, the transactivational activity of three isoflavones and four naringenin-type 
flavanones were clearly demonstrated in RNDA cells using the same aforementioned 
reporter gene assay. The study clearly illustrates the high transactivational activity of 
Genistein, Daidzein, Equol, Naringenin and 8-Prenylnaringenin in RNDA cells by 
stimulating luciferase expression in a concentration-dependent manner. However, no 
transactivational activity was noticed in response to 6-(1,1-Dimethylallyl)naringenin in the 
studied cell model. Results from the reporter gene assays were validated on the basis of 
regulation of mRNA expression of six estrogen responsive genes that were selected 
according to specific features of estrogenic regulation of expression from a DNA 
microarray. 
 
Apart from Slc6a4, the E2-dependent regulation of Cml-5, Sox-18, Krt-19, Nefm and 
Zdhhc-2 was successfully confirmed in RNDA cells using quantitative real-time PCR. The 
study reported that 17β-Estradiol up-regulated mRNA expression of Cml-5, Sox-18 and 
Krt-19. Similar effects were observed in response to 8-Prenylnaringenin, Genistein, 
Daidzein and Equol. This was consistent with earlier findings obtained with an ERE-driven 
reporter gene assay in the same cell line. In addition, 17β-Estradiol down-regulated mRNA 
expression of Nefm and Zdhhc-2. Similar effects were observed in response to 
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8-Prenylnaringenin, Naringenin, Genistein, Daidzein and Equol. This clearly demonstrates 
that 17β-Estradiol and Naringenin induce different estrogen receptor β-mediated 
responses in RNDA cells. In addition, the study clearly indicates that 8-Prenylnaringenin, 
Genistein, Daidzein and Equol act via the same mechanism as 17β-Estradiol in the 
regulation of expression of those estrogen responsive genes in RNDA cells, irrespective of 
the employed regulatory element. Nevertheless, further experimentations such as 
co-immunoprecipitation experiments should be pursued to further identify which 
transcription factors are being involved.  
 
It was additionally proven that RNDA cells could differentiate under non-permissive 
conditions (denoted as D-RNDA cells) by expressing potential markers for cellular 
differentiation of neuronal cells. It was clearly shown from the present study that under 
these differentiation conditions, changes in cell morphology, in mRNA expression levels 
and in responsiveness towards 17β-Estradiol or the flavonoids were observed. Most 
importantly, the study pointed out that the down-regulation of Krt-19 as well as the 
up-regulation of Nefm and Zdhhc-2 serve as indicators for RNDA cellular differentiation 
and that the responsiveness of the six selected genes towards 17β-Estradiol treatment as 
well as treatment with all tested flavonoids is almost lost in D-RNDA cells. 
 
Despite all these findings, it is crucial to further investigate the regulation of expression of 
these newly identified E2-regulated genes in rat brain tissue sections using, for instance, 
in situ hybridization to investigate whether the observed in vitro regulation of gene 
expression is also present in vivo. It would also be of interest to track whether the 
regulation of these genes is only restricted to the raphe nuclei region or to other brain 
regions. Nevertheless, this in vitro-based study provides the basis to shed light on the 
complex molecular and cellular events following the interplay of phytoestrogens, 
particularly the flavonoids, with neural cell populations in the raphe nuclei. 
 
At this point of the study, RNDA cells are still not conclusively proven useful as a good 
model to study effects of estrogen on serotonin production and signaling, because these 
processes do not seem to take place yet in the cellular phenotype of RNDA cells 
established so far. Therefore, future studies may include: (1) clustering the DNA 
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microarray data to help infer the functional role of other genes, besides the main 
serotonergic-related genes, that may be involved in the serotonergic pathway; hence 
enhancing the neuronal serotonergic phenotype of RNDA cells and (2) investigating 
whether 17β-Estradiol in addition to 8-Prenylnaringenin, Naringenin, Genistein, Daidzein 
and Equol could possibly regulate the process of serotonin production and signaling in 
RNDA cells. Such findings may possibly provide new avenues for the pharmacotherapeutic 
intervention in mood disorders related to periods of intense hormone fluctuations during 
menopause. 
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7. APPENDICES 
 
Appendix  7-1: Proof of insufficient endogenous expression of ERβ in RN46A-B14 cells in 
response to 10 nM 17β-Estradiol treatment as compared to the carrier control treatment 
DMSO (set to 100 %). 
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Appendix  7-2: Human ESR2 isoform 1 genomic sequence 
 
atggatataa aaaactcacc atctagcctt aattctcctt cctcctacaa ctgcagtcaa 
tccatcttac ccctggagca cggctccata tacatacctt cctcctatgt agacagccac 
catgaatatc cagccatgac attctatagc cctgctgtga tgaattacag cattcccagc 
aatgtcacta acttggaagg tgggcctggt cggcagacca caagcccaaa tgtgttgtgg 
ccaacacctg ggcacctttc tcctttagtg gtccatcgcc agttatcaca tctgtatgcg 
gaacctcaaa agagtccctg gtgtgaagca agatcgctag aacacacctt acctgtaaac 
agagagacac tgaaaaggaa ggttagtggg aaccgttgcg ccagccctgt tactggtcca 
ggttcaaaga gggatgctca cttctgcgct gtctgcagcg attacgcatc gggatatcac 
tatggagtct ggtcgtgtga aggatgtaag gcctttttta aaagaagcat tcaaggacat 
aatgattata tttgtccagc tacaaatcag tgtacaatcg ataaaaaccg gcgcaagagc 
tgccaggcct gccgacttcg gaagtgttac gaagtgggaa tggtgaagtg tggctcccgg 
agagagagat gtgggtaccg ccttgtgcgg agacagagaa gtgccgacga gcagctgcac 
tgtgccggca aggccaagag aagtggcggc cacgcgcccc gagtgcggga gctgctgctg 
gacgccctga gccccgagca gctagtgctc accctcctgg aggctgagcc gccccatgtg 
ctgatcagcc gccccagtgc gcccttcacc gaggcctcca tgatgatgtc cctgaccaag 
ttggccgaca aggagttggt acacatgatc agctgggcca agaagattcc cggctttgtg 
gagctcagcc tgttcgacca agtgcggctc ttggagagct gttggatgga ggtgttaatg 
atggggctga tgtggcgctc aattgaccac cccggcaagc tcatctttgc tccagatctt 
gttctggaca gggatgaggg gaaatgcgta gaaggaattc tggaaatctt tgacatgctc 
ctggcaacta cttcaaggtt tcgagagtta aaactccaac acaaagaata tctctgtgtc 
aaggccatga tcctgctcaa ttccagtatg taccctctgg tcacagcgac ccaggatgct 
gacagcagcc ggaagctggc tcacttgctg aacgccgtga ccgatgcttt ggtttgggtg 
attgccaaga gcggcatctc ctcccagcag caatccatgc gcctggctaa cctcctgatg 
ctcctgtccc acgtcaggca tgcgagtaac aagggcatgg aacatctgct caacatgaag 
tgcaaaaatg tggtcccagt gtatgacctg ctgctggaga tgctgaatgc ccacgtgctt 
cgcgggtgca agtcctccat cacggggtcc gagtgcagcc cggcagagga cagtaaaagc 
aaagagggct cccagaaccc acagtctcag tga 
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Appendix  7-3: Lentiviral transfer vector map 
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Appendix  7-4: List of down-regulated transcripts in response to E2 treatment in RNDA 
cells (Total: 64) 
 
Genes 
Symbol Description (Rattus norvegicus …) Accession ID 
Ednrb Endothelin Receptor type B NM_017333 
Mgc-114464 Similar to expressed sequence AI836003 NM_001024909 
Tcte-3 T-complex-associated testis expressed 3 XM_344846 
Enpp-1 Ectonucleotide pyrophosphatase / phosphodiesterase 1 NM_053535 
Fam161a Family with sequence similarity 161, member A NM_001013876 
Akap-11 A kinase (PRKA) anchor protein 11 AW533317 
Glod-5 Glyoxalase domain containing 5 NM_001106957 
Sema-3e Sema domain, immunoglobulin domain (Ig), short basic 
domain, secreted, (semaphorin) 3E 
NM_001106579 
Olfml-2A Olfactomedin-like 2A NM_001106572 
Hopx HOP homeobox NM_133621 
Tgfbi Transforming growth factor, beta induced NM_053802 
Rxrg Retinoid X receptor gamma NM_031765 
Fmo-4 Flavin containing monooxygenase 4, transcript variant 1 NM_144562 
Mgat4a Mannosyl (alpha-1,3-)-glycoprotein 
beta-1,4-N-acetylglucosaminyltransferase, isozyme A, 
transcript variant 2 
NM_001012225 
Atp8a1 ATPase, aminophospholipid transporter (APLT), class I, 
type 8A, member 1 
XM_223390 
Slc6a4 Solute carrier family 6 member 4 NM_013034 
Loc-363337 Similar to RIKEN cDNA 1700081O22 NM_001014221 
Olr-631 olfactory receptor 631 NM_001000339 
Hook-1 Hook homolog 1 (Drosophila) NM_001107946 
Rgd-1563978 Similar to mKIAA1387 protein XM_228611 
Trim-71 Tripartite motif-containing 71 XM_236676 
Scn-1a Sodium channel, voltage-gated, type I, alpha NM_030875 
Mpz Myelin protein zero NM_017027 
Gpr-132 G protein-coupled receptor 132 NM_001170595 
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Ppp2r2b Protein phosphatase 2 (formerly 2A), regulatory subunit 
B (PR 52), beta isoform (Ppp2r2b) 
NM_022209 
Loc-365528 Similar to tripartite motif-containing 40; ring finger 
RNF35 
XM_345077 
Olr-303 Olfactory receptor 303 NM_001000239 
Mbl-1 Mannose-binding lectin (protein A) 1 NM_012599 
Rgd-1311103 Similar to RIKEN cDNA 2410146L05 XR_007793 
Htra-3 HtrA serine peptidase 3 XM_341237 
Aytl-1b Acyltransferase like 1B (Aytl1b) NM_001025631 
Cdx-2 Caudal type homeo box 2 NM_023963 
Rgd-1564894 Similar to glycine-N-acyltransferase isoform a NM_001126278 
Zdhhc-2 Zinc finger, DHHC-type containing 2 NM_145096 
Cpa-6 Carboxypeptidase A6 NM_001107900 
Loc-296723 Similar to Fatty acid-binding protein, epidermal (E-FABP) 
(Cutaneous fatty acid-binding protein) (C-FABP) (DA11) 
XR_005499 
Bche Butyrylcholinesterase NM_022942 
Nefm Neurofilament, medium polypeptide NM_017029 
Slc7a11 Solute carrier family 7 (cationic amino acid transporter, 
y+ system), member 11 
NM_001107673 
G0s2 G0/G1switch 2 NM_001009632 
Aldh1a3 Aldehyde dehydrogenase 1 family, member A3 NM_153300 
Reln Reelin NM_080394 
Tlr-2 Toll-like receptor 2 NM_198769 
Fam101a Family with sequence similarity 101, member A NM_001109547 
Mat-1a Methionine adenosyltransferase I, alpha NM_012860 
Epb4.1l3 Erythrocyte protein band 4.1-like 3 NM_053927 
Expressed Sequence Tags 
Description (Rattus norvegicus …) Accession ID 
UI-R-CN0 cDNA clone UI-R-CN0-bky-b-03-0-UI 3' end BF417274 
NIH_MGC_255 cDNA clone IMAGE:7318127 5' end  CO394414 
Normalised rat muscle, Bento Soares cDNA clone RMUCN59 3' end AI175447 
Wackym-Soares normalised rat vestibular cDNA library DV716578 
UI-R-E1 cDNA clone UI-R-E1-fi-e-08-0-UI 3'end AA956109 
UI-R-CN1 cDNA clone UI-R-CN1-cmn-b-09-0-UI 3' end BQ196019 
APPENDICES 
_____________________________________________________________________ 
130 
UI-R-A0 cDNA clone UI-R-A0-ax-e-11-0-UI 3' similar to gb AA818298 
UI-R-AE1 cDNA clone UI-R-AE1-zj-h-05-0-UI 3' end CK839132 
UI-R-C4 cDNA clone UI-R-C4-ald-b-11-0-UI 5' end BF564082 
Wackym-Soares normalised rat vestibular cDNA library DV713600 
UI-R-EP0 cDNA clone UI-R-EP0-cnx-o-18-0-UI 3' end BQ209143 
UI-R-C3 cDNA clone UI-R-C3-sz-d-06-0-UI 3' end AI547622 
UI-R-EP0 cDNA clone UI-R-EP0-cnx-l-14-0-UI 3' end BQ209488 
Normalised rat embryo, Bento Soares cDNA clone RGICV38 5' end AW915435 
Normalised rat heart, Bento Soares cDNA clone RHEAB83 3' end AA799505 
UI-R-E1 cDNA clone UI-R-E1-gc-d-03-0-UI 5’ end BF557223 
UI-R-CA0 cDNA clone UI-R-CA0-bgm-c-12-0-UI 3' end BF401583 
Normalised rat lung, Bento Soares cDNA clone RLUCS36 3' end AI233887 
 
 
Appendix  7-5: List of up-regulated transcripts in response to E2 treatment in RNDA cells 
(Total: 148) 
 
Genes 
Symbol Description (Rattus norvegicus …) Accession ID 
Ckb Creatine kinase, brain NM_012529 
Prl6a1 Prolactin family 6, subfamily a, member 1 NM_022176 
Sox-9 SRY-box containing gene 9 XM_343981 
Agt Angiotensinogen (serpin peptidase inhibitor, clade A, 
member 8) 
NM_134432 
Tas2r143 Taste receptor, type 2, member 143 NM_001025061 
Slco2b1 Solute carrier organic anion transporter family, member 
2b1 
NM_080786 
Prkcz Protein kinase C, zeta NM_022507 
Olr-264 Olfactory receptor 264 NM_001000999 
Idi-2 Isopentenyl-diphosphate delta isomerase 2 XM_577595 
Rgd-1306091 Similar to mixed lineage kinase 4 XM_226572 
Inmt Indolethylamine N-methyltransferase NM_001109022 
Esrrb Estrogen-related receptor beta NM_001008516 
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Tnfrsf-14 Tumor necrosis factor receptor superfamily, member 14 
(herpesvirus entry mediator) 
NM_001015034 
Cybb Cytochrome b-245, beta polypeptide NM_023965 
Cldn-22 Claudin 22 NM_001110143 
Olr-185 Olfactory receptor 185 NM_001000183 
Pnpla-5 Patatin-like phospholipase domain containing 5 NM_001130497 
Tusc-5 Tumour suppressor candidate 5 NM_001039163 
Loc-307938 Similar to tripartite motif-containing 9 (TRIM9)-like 
protein 
XM_226563 
Loc-363326 Hypothetical LOC363326 NM_001126289 
Olr-1633 Olfactory receptor 1633 NM_001000835 
Loc-292493 Similar to necdin XM_218132 
Cbln-1  Cerebellin 1 precursor NM_001109127 
Mfsd6l Major facilitator superfamily domain containing 6-like NM_001105787 
CfI Complement factor I NM_024157 
Ocln Occludin NM_031329 
Rgd-1310773 Similar to hypothetical protein FLJ31810 NM_001107926 
Rgd-1310495 Similar to KIAA1919 protein XM_228270 
Rgd-1563150 Similar to B-cell translocation gene 1 XM_233323 
Krt-19 Keratin, type I cytoskeletal 19 NM_199498 
Loc-301128 Similar to jumonji domain containing 2B BC098860 
Vgll-1 Vestigial like 1 (Drosophila) XM_343832 
Otp Orthopedia homeobox AY169319 
Gpcr-12 G protein-coupled receptor 12 NM_030831 
Olr-307 Olfactory receptor 307 NM_001000241 
Rgd-1303271 similar to chromosome 1 open reading frame 172 NM_001004268 
Loc-367313 Similar to alpha 3 type VI collagen isoform 1 precursor; 
collagen VI, alpha-3 polypeptide 
XM_346073 
Dchs-2    Dachsous 2 (Drosophila) XR_008777 
Htr-3b 5-hydroxytryptamine (serotonin) receptor 3b NM_022189 
Rbm-4b  RNA binding motif protein 4B AA901213 
Dppa-1 Developmental pluripotency associated 1 NM_001105905 
Dmp-1 Dentin matrix acidic phosphoprotein 1 NM_203493 
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Gas-6 Growth arrest specific 6 NM_057100 
Ermap Erythroblast membrane-associated protein XM_233453 
Olr-1733 Olfactory receptor 1733 NM_001000510 
Olr-736 Olfactory receptor 736 NM_001001384 
Prss-34 Protease, serine, 34 NM_001105772 
Loc-246267 Resection-induced TPI (rs11) NM_144751 
Pla2g5 Phospholipase A2, group V NM_017174 
Rgd-1562546 Similar to trophinin isoform 1 XM_344729 
Sstr-3 Somatostatin receptor 3  NM_133522 
Pkd2l1 Polycystic kidney disease 2-like 1 NM_001106352 
Olr-482 Olfactory receptor 482 NM_001000561 
Slc34a1 Solute carrier family 34 (sodium phosphate), member 1  NM_013030 
Tmigd-1 Transmembrane and immunoglobulin domain 
containing 1  
NM_001135029 
Mbp Myelin basic protein, transcript variant 3 NM_001025293 
Nr5a2 Nuclear receptor subfamily 5, group A, member 2 NM_021742 
Havcr-2 Hepatitis A virus cellular receptor 2 NM_001100762 
Gpr-35 G protein-coupled receptor 35 NM_001037359 
Ckmt-2 Creatine kinase, mitochondrial 2, sarcomeric, nuclear 
gene encoding mitochondrial protein 
NM_001127652 
Sstr-2 Somatostatin receptor 2 NM_019348 
Tex-19.2 Testis expressed gene 19.2 NM_001109622 
Olr-851 Olfactory receptor 851 NM_001000400 
Klk-10 Kallikrein related-peptidase 10 NM_001004100 
Olr-1346 Olfactory receptor 1346 NM_001000520 
Olr-1639 Olfactory receptor 1639 NM_001000833 
Stac-2 SH3 and cysteine rich domain 2 NM_001108834 
Loc-301133 Similar to tumour necrosis factor ligand superfamily 
member 14 (CD258 antigen) 
XM_236794 
Rgd-1560565 Similar to tumour protein p53 inducible protein 5 XM_574586 
Olr-837 Olfactory receptor 837 NM_001000897 
Loc-291014 Similar to serine/threonine kinase XM_225194 
Olr-441 Olfactory receptor 441 NM_001000283 
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Loc-307974 Similar to pecanex-like 2 isoform 1 XM_226603 
Cacna2d2 Calcium channel, voltage-dependent, alpha 2/delta 
subunit 2 
NM_175592 
Olr-461 Olfactory receptor 461 NM_001000294 
Sox-18 Sex determining region Y-box 18 NM_001024781 
Rnase1l2 Ribonuclease, RNase A family, 1-like 2 (pancreatic) NM_001025116 
Wfdc-5 WAP four-disulfide core domain 5 NM_001106538 
Nos1ap Nitric oxide synthase 1 (neuronal) adaptor protein NM_138922 
Ptprt Protein tyrosine phosphatase, receptor type, T NM_001108603 
Taar7e Trace-amine-associated receptor 7e NM_175590 
Olr-841 Olfactory receptor 841 NM_001000405 
Masp-1 Mannan-binding lectin serine peptidase 1 NM_022257 
Trim-58 Tripartite motif-containing 58 XM_001075898 
Il13ra1 Interleukin 13 receptor, alpha 1 NM_145789 
Olr-1538 Olfactory receptor 1538 NM_001000530 
Cpxm-2 Carboxypeptidase X (M14 family), member 2 NM_001106306 
Cadps Ca++-dependent secretion activator NM_013219 
Olr-91 Olfactory receptor 91 NM_001000139 
Bai-3 Brain-specific angiogenesis inhibitor 3 NM_001106898 
Lrfn-2 Leucine rich repeat and fibronectin type III domain 
containing 2 
NM_001039699 
Igsf-1 Immunoglobulin superfamily, member 1 NM_175763 
Olr-1016 Olfactory receptor 1016 NM_001000070 
Cnrip-1 Cannabinoid receptor interacting protein 1 NM_001014232 
Olr-252 Olfactory receptor 252 NM_001000219 
Haao 3-hydroxyanthranilate 3,4-dioxygenase NM_020076 
Loc-691700 Similar to heparan sulfate D-glucosaminyl 
3-O-sulfotransferase 4 
XM_001079317 
Olr-141 Olfactory receptor 141 NM_001001274 
Olr-1428 Olfactory receptor 1428 NM_001000011 
Loc-307084 Similar to heat shock protein 8 XR_006798 
Olr-1598 Olfactory receptor 1598 NM_001000910 
Ccdc-114 Coiled-coil domain containing 114 NM_001126277 
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Tcfap2d Transcription factor AP-2, delta NM_001106895 
Htr-6 5-hydroxytryptamine (serotonin) receptor 6 NM_024365 
Srebf-1 Sterol regulatory element binding factor 1 XM_213329 
Loc-295811 Similar to Transcription factor DP-1 (E2F dimerization 
partner 1) (DRTF1-polypeptide-1) 
XM_230157 
Kcna-5 Potassium voltage-gated channel, shaker-related 
subfamily, member 5 
NM_012972 
Mgat5b Mannosyl (alpha-1,6-)-glycoprotein beta-1,6-N-acetyl-
glucosaminyltransferase, isozyme B 
NM_001107068 
Lrp-2 Low density lipoprotein-related protein 2 NM_030827 
Olr-35 Olfactory receptor 35 NM_001000121 
Loc-362932 Similar to cytochrome P-450-11beta XM_343261 
Alx-3 Aristaless-like homeobox 3 NM_001007012 
Hhatl Hedgehog acyltransferase-like NM_001106868 
Loc-302508 Similar to Putative deoxyribonuclease KIAA0218 XM_228696 
Cora2a Coronin, actin binding protein 2A NM_001012101 
Loc-689103 Similar to vitelliform macular dystrophy 2-like 2, 
transcript variant 2 
XM_001066317 
Gpbar-1 G protein-coupled bile acid receptor 1 NM_177936 
Rgd-1565213 Similar to channel, sperm associated 4 XM_342941 
Pcdhb-6 Protocadherin beta 6 NM_001014780 
Cml-5 Camello-like 5 NM_080884 
Olr-1309 Olfactory receptor 1309 NM_001000466 
Clec11a C-type lectin domain family 11, member a NM_001012459 
Olr-826 Olfactory receptor 826 NM_001000903 
Expressed Sequence Tags 
Description (Rattus norvegicus …) Accession ID 
UI-R-E1 cDNA clone UI-R-E1-fe-h-04-0-UI 3' end AA956265 
UI-R-E0 cDNA clone UI-R-E0-dd-h-10-0-UI 3' end AA900238 
UI-R-CX0 cDNA clone UI-R-CX0-bxl-b-12-0-UI 3' end BI276762 
UI-R-C1 cDNA clone UI-R-C1-ks-e-10-0-UI 3' end AI059063 
NCI_CGAP_DZ1 cDNA clone IMAGE:7348303 3' end BQ209739 
UI-R-A0 cDNA clone UI-R-A0-am-e-04-0-UI 3' end AA818093 
Normalised rat lung, Bento Soares Rattus sp. cDNA clone RLUCS03 3' end AI233855 
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UI-R-CA1 cDNA clone UI-R-CA1-biy-e-22-0-UI 3' end BF403327 
Normalised rat heart, Bento Soares Rattus sp. cDNA clone RHEAD03 3' end AA799601 
UI-R-BJ0 Rattus norvegicus cDNA clone UI-R-BJ0-aee-d-04-0-UI 3' end AW252115 
UI-R-E1 cDNA clone UI-R-E1-fv-c-11-0-UI 3' end AA963043 
UI-R-A1 cDNA clone UI-R-A1-eq-f-07-0-UI 5' end BF556330 
UI-R-CA1 cDNA clone UI-R-CA1-bip-a-10-0-UI 3' end BF405054 
UI-R-BS1 cDNA clone UI-R-BS1-ayx-a-08-0-UI 3' end BE108243 
UI-R-BT1 cDNA clone UI-R-BT1-bmy-b-09-0-UI 3' end BF412064 
UI-R-DQ0 cDNA clone UI-R-DQ0-cja-a-09-0-UI 3' end BI303371 
UI-R-E0 cDNA clone UI-R-E0-cl-a-08-0-UI 3' end AA859335 
UI-R-C2p cDNA clone UI-R-C2p-ro-c-01-0-UI 3' end AI556829 
UI-R-DK0 cDNA clone UI-R-DK0-cgk-g-07-0-UI 3' end BI297059 
UI-R-A1 cDNA clone UI-R-A1-ex-e-09-0-UI 3' end AA955473 
UI-R-C0 cDNA clone UI-R-C0-he-b-07-0-UI 3' end AA996504 
UI-R-CA0 cDNA clone UI-R-CA0-bfe-e-06-0-UI 3' end BF392124 
UI-R-C0 cDNA clone UI-R-C0-jn-c-07-0-UI 3' end AI030133 
UI-R-BJ1 cDNA clone UI-R-BJ1-awd-g-11-0-UI 3' end BE113335 
UI-R-Y0 cDNA clone UI-R-Y0-mk-b-12-0-UI 3' end AI111559 
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Appendix  7-6: Proof of specificity of antibodies utilized in immunocytochemistry 
 
 
 
 
 
 
 
 
 
Appendix  7-7: Human ERβ mRNA expression in RNDA cells under conditions promoting 
proliferation (set to 1) and differentiation at either day 1 or day 4 following initiation of 
differentiation. Cells are treated with 0.1 % DMSO. 
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